Datasets:

ChatDOC
/

OCRFlux-pubtabnet-single

Dataset card Data Studio Files Files and versions Community

Split (1)

train · 9.06k rows

image_name stringlengths 68 68	type stringclasses 2 values	gt_table stringlengths 116 12.6k
df3630f9788fa5702a70626f7b4a50740154bc54c191e50d952c345b31a0db20.png	simple	<table><tr><td>First author</td><td>Year</td><td>Skin condition</td></tr><tr><td>Praveenkumar et al. [29]</td><td>2016</td><td>Psoriasis</td></tr><tr><td>Kokpol et al. [30]</td><td>2014</td><td>Psoriasis</td></tr><tr><td>Henseler et al. [31]</td><td>1995</td><td>Psoriasis</td></tr><tr><td>Owczarczyk-Saczonek et al. [34]</td><td>2015</td><td>Psoriasis</td></tr><tr><td>Gisondi et al. [26]</td><td>2007</td><td>Psoriasis</td></tr><tr><td>Nagpal et al. [51]</td><td>2016</td><td>Acne</td></tr><tr><td>Del Prete et al. [52]</td><td>2012</td><td>Acne</td></tr><tr><td>Akin Belli et al. [54]</td><td>2016</td><td>Rosacea</td></tr><tr><td>Shlyankevich et al. [56]</td><td>2014</td><td>Hidradenitis suppurativa</td></tr><tr><td>Banger et al. [61]</td><td>2015</td><td>Androgenic alopecia</td></tr><tr><td>El Sayed et al. [62]</td><td>2016</td><td>Androgenic alopecia</td></tr><tr><td>Saleh et al. [66]</td><td>2014</td><td>Lichen planus</td></tr><tr><td>Arias-Santiago et al. [65]</td><td>2011</td><td>Lichen planus</td></tr><tr><td>Lee et al. [68]</td><td>2017</td><td>Atopic dermatitis</td></tr><tr><td>Ambiel et al. [71]</td><td>2014</td><td>Pemphigus</td></tr><tr><td>Saylam Kurtipek et al. [83]</td><td>2015</td><td>Holoderma</td></tr><tr><td>Wali et al. [84]</td><td>2016</td><td>Striae</td></tr><tr><td>Chen et al. [85]</td><td>2016</td><td>Acanthosis nigricans</td></tr><tr><td>Puttegowda et al. [75]</td><td>2015</td><td>Tendon xanthomas</td></tr><tr><td>Nagase et al. [76]</td><td>2013</td><td>Skin aging</td></tr><tr><td>Penington et al. [86]</td><td>2007</td><td>Wound healing</td></tr></table>
6e9bfacd730265b2a009132e6662ec63339bcd81bb45fdf418bedfe660d57a50.png	simple	<table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td></td><td>Domain <i>Bacteria</i></td><td>TAS [13]</td></tr><tr><td></td><td></td><td>Phylum <i>Bacteroidetes</i></td><td>TAS [14,15]</td></tr><tr><td></td><td></td><td>Class <i>Bacteroidia</i></td><td>TAS [14,16]</td></tr><tr><td></td><td>Current classification</td><td>Order <i>Bacteroidales</i></td><td>TAS [14,17]</td></tr><tr><td></td><td></td><td>Family <i>Rikenellaceae</i></td><td>TAS [14,18]</td></tr><tr><td></td><td></td><td>Genus <i>Alistipes</i></td><td>TAS [5,19]</td></tr><tr><td></td><td></td><td>Species <i>Alistipes timonensis</i></td><td>IDA</td></tr><tr><td></td><td></td><td>Type strain JC136<sup>T</sup></td><td>IDA</td></tr><tr><td></td><td>Gram stain</td><td>Negative</td><td>IDA</td></tr><tr><td></td><td>Cell shape</td><td>Bacilli</td><td>IDA</td></tr><tr><td></td><td>Motility</td><td>Nonmotile</td><td>IDA</td></tr><tr><td></td><td>Sporulation</td><td>Nonsporulating</td><td>IDA</td></tr><tr><td></td><td>Temperature range</td><td>Mesophile</td><td>IDA</td></tr><tr><td></td><td>Optimum temperature</td><td>37°C</td><td>IDA</td></tr><tr><td>MIGS-6.3</td><td>Salinity</td><td>Growth in BHI medium + 1% NaCl</td><td>IDA</td></tr><tr><td>MIGS-22</td><td>Oxygen requirement</td><td>Anaerobic</td><td>IDA</td></tr><tr><td></td><td>Carbon source</td><td>Unknown</td><td>NAS</td></tr><tr><td></td><td>Energy source</td><td>Unknown</td><td>NAS</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Human gut</td><td>IDA</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free living</td><td>IDA</td></tr><tr><td>MIGS-14</td><td>PathogenicityBiosafety levelIsolation</td><td>Unknown2Human feces</td><td>NAS</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Senegal</td><td>IDA</td></tr><tr><td>MIGS-5</td><td>Sample collection time</td><td>September 2010</td><td>IDA</td></tr><tr><td>MIGS-4.1</td><td>Latitude</td><td>13.7167</td><td>IDA</td></tr><tr><td>MIGS-4.1</td><td>Longitude</td><td>16.4167</td><td>IDA</td></tr><tr><td>MIGS-4.3</td><td>Depth</td><td>Surface</td><td>IDA</td></tr><tr><td>MIGS-4.4</td><td>Altitude</td><td>51 m above sea level</td><td>IDA</td></tr></table>
0d0bc9de6c6c29ae5507a5362d45889429184a8828acde20cc00d8244c7b007d.png	complex	<table><tr><td> </td><td>Correct reactions</td><td>Correct</td></tr><tr><td> </td><td>(ignoring enzyme)</td><td>(including enzyme)</td></tr><tr><td colspan="3"><i>Pantothenate and coenzyme A biosynthesis pathway</i></td></tr><tr><td>Recall(P) (%)</td><td>78 (7/9)</td><td>56 (5/9)</td></tr><tr><td>Precision (%)</td><td>59 (24/41)</td><td>41 (17/41)</td></tr><tr><td colspan="3"><i>Tetrahydrofolate biosynthesis pathway</i></td></tr><tr><td>Recall(P) (%)</td><td>90 (9/10)</td><td>70 (7/10)</td></tr><tr><td>Precision (%)</td><td>60 (39/65)</td><td>38 (25/65)</td></tr><tr><td colspan="3"><i>Aerobic fatty acid β-oxidation I pathway</i></td></tr><tr><td>Recall(P) (%)</td><td>29 (2/7)</td><td>29 (2/7)</td></tr><tr><td>Precision (%)</td><td>30 (11/37)</td><td>14 (5/37)</td></tr></table>
88df28ea23405e43bd18e8d4352dd8b2eaa24079d0e7c8c31b0f4827be5034ed.png	complex	<table><tr><td rowspan="2">Prognosis</td><td rowspan="2">Wald</td><td rowspan="2"><i>P</i></td><td rowspan="2">Exp(B)</td><td colspan="2">95% CI for Exp(B)</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td colspan="6">OS</td></tr><tr><td> Age(year) ≥50 vs.<50</td><td>1.577</td><td>0.215</td><td>1.643</td><td>0.788</td><td>3.319</td></tr><tr><td> Gender Female vs. Male</td><td>3.298</td><td>0.081</td><td>2.506</td><td>0.907</td><td>6.387</td></tr><tr><td> Histological type U vs. D</td><td>0.441</td><td>0.526</td><td>0.745</td><td>0.253</td><td>2.479</td></tr><tr><td> T classification T2–4 vs. T1</td><td>9.309</td><td>0.003<sup>a</sup></td><td>3.568</td><td>1.521</td><td>6.517</td></tr><tr><td> N classification N1-3vs. N0</td><td>12.505</td><td>0.001<sup>a</sup></td><td>2.389</td><td>1.543</td><td>4.228</td></tr><tr><td> Clinical classification II-IVb vs. I</td><td>6.218</td><td>0.014<sup>a</sup></td><td>0.487</td><td>0.119</td><td>0.668</td></tr><tr><td> CXCL5 expression High vs. Low</td><td>4.885</td><td>0.027</td><td>1.960</td><td>1.079</td><td>3.560</td></tr><tr><td> CXCR2 expression High vs. Low</td><td>1.295</td><td>0.255</td><td>0.691</td><td>0.365</td><td>1.307</td></tr><tr><td colspan="6">DMFS</td></tr><tr><td> Age(year) ≥50 vs.<50</td><td>1.267</td><td>0.234</td><td>2.137</td><td>0.802</td><td>4.304</td></tr><tr><td> Gender Female vs. Male</td><td>3.137</td><td>0.091</td><td>3.267</td><td>0.798</td><td>13.223</td></tr><tr><td> Histological type U vs. D</td><td>0.702</td><td>0.564</td><td>0.523</td><td>0.158</td><td>2.694</td></tr><tr><td> T classification T2–4 vs. T1</td><td>3.236</td><td>0.079<sup>a</sup></td><td>2.413</td><td>0.903</td><td>6.446</td></tr><tr><td> N classification N1-3vs. N0</td><td>6.533</td><td>0.004<sup>a</sup></td><td>2.578</td><td>1.131</td><td>6.327</td></tr><tr><td> Clinical classification II-IVb vs. I</td><td>2.786</td><td>0.095<sup>a</sup></td><td>0.413</td><td>0.251</td><td>1.099</td></tr><tr><td> CXCL5 expression High vs. Low</td><td>5.169</td><td>0.023</td><td>2.740</td><td>1.149</td><td>6.532</td></tr><tr><td> CXCR2 expression High vs. Low</td><td>1.700</td><td>0.192</td><td>1.879</td><td>0.728</td><td>4.849</td></tr></table>
0f5091127833f44ca93627013095fc334613017b7618ad4b4dc901ee9aed6717.png	simple	<table><tr><td>Year</td><td>Zonal Population</td><td>New PTB+ cases Reported (n = 8558)</td><td>Case Notification/ 10<sup>5 </sup>persons/year</td><td>Proportion of estimated PTB+ incident cases notified, %*</td></tr><tr><td>1994</td><td>1004000</td><td>512</td><td>49</td><td>45.2</td></tr><tr><td>1995</td><td>1070160</td><td>1025</td><td>96</td><td>87.9</td></tr><tr><td>1996</td><td>1101195</td><td>1162</td><td>106</td><td>96.8</td></tr><tr><td>1997</td><td>1133129</td><td>946</td><td>84</td><td>76.6</td></tr><tr><td>1998</td><td>1165990</td><td>1277</td><td>110</td><td>100.5</td></tr><tr><td>1999</td><td>1199804</td><td>1510</td><td>126</td><td>115.5</td></tr><tr><td>2000</td><td>1234598</td><td>1267</td><td>103</td><td>94.2</td></tr><tr><td>2001<sup>§</sup></td><td>1174118</td><td>858</td><td>73</td><td>67.0</td></tr></table>
ba6ce94cca53afd61e5255004343c6fc9b0c8923923d61d5057e7c9eb315a8dd.png	complex	<table><tr><td rowspan="3"></td><td colspan="2">Intervention (n=5297)</td><td colspan="2">Control (n=5246)</td><td rowspan="2">Incidence rate ratio (95% CI)</td><td rowspan="2">p value</td></tr><tr><td>Number of events</td><td>Incidence rate (cases per 100 child-years, 95% CI)</td><td>Number of events</td><td>Incidence rate (cases per 100 child-years, 95% CI)</td></tr><tr><td>Malaria</td><td> 175</td><td>2·19 (1·87–2·52)</td><td> 134</td><td>1·66 (1·38–1·95)</td><td>1·32 (1·03–1·69)</td><td>0·03</td></tr><tr><td>Sepsis</td><td>51</td><td>0·64 (0·46–0·82)</td><td>54</td><td>0·67 (0·49–0·85)</td><td>0·95 (0·64–1·41)</td><td>0·81</td></tr><tr><td>Gastroenteritis</td><td>24</td><td>0·30 (0·18–0·42)</td><td>28</td><td>0·35 (0·22–0·48)</td><td>0·86 (0·49–1·53)</td><td>0·62</td></tr><tr><td>Burns</td><td>9</td><td>0·11 (0·04–0·19)</td><td>10</td><td>0·12 (0·05–0·20)</td><td>0·91 (0·37–2·23)</td><td>0·83</td></tr><tr><td>Accidental injury</td><td>12</td><td>0·15 (0·07–0·24)</td><td>9</td><td>0·11 (0·04–0·18)</td><td>1·42 (0·58–3·45)</td><td>0·44</td></tr><tr><td>Malnutrition</td><td>5</td><td>0·06 (0·01–0·12)</td><td>5</td><td>0·06 (0·01–0·12)</td><td>1·01 (0·29–3·48)</td><td>0·99</td></tr><tr><td>Asthma</td><td>6</td><td>0·08 (0·02–0·14)</td><td>2</td><td>0·02 (0·01–0·06)</td><td>3·03 (0·51–18·11)</td><td>0·22</td></tr><tr><td>Other</td><td>36</td><td>0·45 (0·30–0·60)</td><td>36</td><td>0·45 (0·30–0·59)</td><td>1·02 (0·62–1·66)</td><td>0·94</td></tr><tr><td>Total</td><td> 318</td><td>3·99 (3·55–4·43)</td><td> 278</td><td>3·45 (3·05–3·86)</td><td>1·15 (0·95–1·38)</td><td>0·15</td></tr></table>
458232217823a6db4067442756c5dc85ccd69749b8029868d5f80b6e0dd01371.png	simple	<table><tr><td>Folates</td><td>Methionine cycle</td><td>Transsulfuration</td><td>Other</td></tr><tr><td>THF = 4.61</td><td>Met = 49.2</td><td>Cysta = 36.9</td><td>Ser = 563</td></tr><tr><td>510CH = 0.28</td><td>SAM = 81.1</td><td>Cys = 195</td><td>Gly = 924</td></tr><tr><td>510CH2 = 0.51</td><td>SAH = 19.1</td><td>GluCys = 9.8</td><td>Sarc = 9.16</td></tr><tr><td>10fTHF = 3.41</td><td>Hcy = 1.12</td><td>GSH = 6591</td><td>DMG = 0.71</td></tr><tr><td>5mTHF = 4.50</td><td></td><td>GSSG = 61.3</td><td>Aicart = 0.94</td></tr><tr><td>DHF = 0.039</td><td></td><td>Glut = 3219</td><td>HCOOH = 13.1</td></tr></table>
b8505365dcd6616aad320fa968c7e4b472e0bf87654c47eeedab4c06969847d5.png	complex	<table><tr><td>Physical symptoms</td><td colspan="4">GSF group</td><td colspan="4">Non-GSF group</td><td> </td></tr><tr><td>Subscale and item</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td><td>Missing</td></tr><tr><td> </td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td><td>n(%)</td></tr><tr><td>Distressed or bothered by pain</td><td>56 (31.1)</td><td>37 (20.6)</td><td>38 (21.1)</td><td>49 (27.2)</td><td>114 (36.2)</td><td>84 (26.7)</td><td>57 (18.1)</td><td>60 (19)</td><td>19 (3.7)</td></tr><tr><td>Loss of memory</td><td>25 (13.9)</td><td>17 (9.4)</td><td>45 (25)</td><td>93 (51.3)</td><td>15 (4.9)</td><td>19 (6.2)</td><td>72 (23.4)</td><td>202 (65.6)</td><td>26 (5.1)</td></tr><tr><td>Headache</td><td>7 (3.9)</td><td>14 (7.8)</td><td>45 (25.1)</td><td>113 (63.1)</td><td>16 (5.2)</td><td>37 (12)</td><td>60 (19.5)</td><td>195 (63.3)</td><td>27 (5.3)</td></tr><tr><td>Dry mouth</td><td>31 (17.1)</td><td>56 (30.9)</td><td>51 (28.2)</td><td>43 (23.8)</td><td>56 (17.9)</td><td>53 (17)</td><td>88 (28.2)</td><td>115 (36.9)</td><td>21 (4.1)</td></tr><tr><td>Sore mouth</td><td>9 (5)</td><td>16 (8.8)</td><td>29 (16)</td><td>127 (70.2)</td><td>10 (3.3)</td><td>19 (6.3)</td><td>41 (13.5)</td><td>233 (76.9)</td><td>30 (5.8)</td></tr><tr><td>Shortness of breath</td><td>42 (23.1)</td><td>41(22.5)</td><td>43 (23.6)</td><td>56 (30.8)</td><td>42 (13.3)</td><td>36 (11.4)</td><td>71 (22.5)</td><td>166 (52.7)</td><td>17 (3.3)</td></tr><tr><td>Cough</td><td>19 (10.5)</td><td>37 (20.4)</td><td>39 (21.5)</td><td>86 (47.5)</td><td>15 (4.9)</td><td>34 (11.1)</td><td>81 (26.5)</td><td>176 (57.5)</td><td>27 (5.3)</td></tr><tr><td>Feeling sick (nausea)</td><td>16 (8.8)</td><td>24 (13.3)</td><td>40 (22.1)</td><td>101 (55.8)</td><td>30 (9.6)</td><td>41 (13.2)</td><td>73 (23.5)</td><td>167 (53.7)</td><td>22 (4.3)</td></tr><tr><td>Being sick (vomiting)</td><td>11 (6.1)</td><td>14 (7.8)</td><td>24 (13.4)</td><td>130 (72.6)</td><td>29 (9.4)</td><td>21 (6.8)</td><td>43 (14)</td><td>214 (69.7)</td><td>28 (5.4)</td></tr><tr><td>Bowel problems</td><td>35 (19.2)</td><td>35 (19.2)</td><td>32 (17.6)</td><td>80 (44)</td><td>48 (15)</td><td>48 (15)</td><td>66 (20.7)</td><td>157 (49.2)</td><td>13 (2.5)</td></tr><tr><td>Bladder problems</td><td>24 (13.3)</td><td>21 (11.6)</td><td>25 (13.8)</td><td>111 (61.3)</td><td>31 (10)</td><td>31 (10</td><td>47 (15.1)</td><td>202 (65)</td><td>22 (4.3)</td></tr><tr><td>Feeling weak</td><td>53 (28.8)</td><td>54 (29.3)</td><td>40 (21.7)</td><td>37 (20.1)</td><td>40 (12.7)</td><td>85 (27.1)</td><td>86 (27.4)</td><td>103 (32.8)</td><td>16 (3.1)</td></tr><tr><td>Feeling tired</td><td>63 (34.6)</td><td>57 (31.3)</td><td>43 (23.6)</td><td>19 (10.4)</td><td>85 (26.7)</td><td>92 (28.9)</td><td>76 (23.9)</td><td>65 (20.4)</td><td>14 (2.7)</td></tr><tr><td>Problems sleeping at night</td><td>34 (18.9)</td><td>31 (17.2)</td><td>33 (18.3)</td><td>82 (45.6)</td><td>73 (23.2)</td><td>70 (22.2)</td><td>51 (16.2)</td><td>121 (38.4)</td><td>19 (3.7)</td></tr><tr><td>Feeling sleepy during the day</td><td>33 (17.9)</td><td>69 (37.5)</td><td>54 (29.3)</td><td>28 (15.2)</td><td>56 (17.7)</td><td>77 (24.4)</td><td>112 (35.4)</td><td>71 (22.5)</td><td>14 (2.7)</td></tr><tr><td>Loss of appetite</td><td>33 (18)</td><td>34 (18.6)</td><td>45 (24.6)</td><td>71 (38.8)</td><td>45 (14.2)</td><td>59 (18.6)</td><td>67 (21.1)</td><td>147 (46.2)</td><td>13 (2.5)</td></tr><tr><td>Changes in your weight</td><td>32 (17.7)</td><td>41(22.7)</td><td>40 (22.1)</td><td>68 (37.6)</td><td>37 (11.9)</td><td>38 (12.2)</td><td>77 (24.7)</td><td>160 (51.3)</td><td>21 (4.1)</td></tr><tr><td>Swallowing</td><td>12 (6.7)</td><td>6 (3.4)</td><td>25 (13.4)</td><td>135 (75.8)</td><td>12 (3.8)</td><td>12 (3.8)</td><td>29 (9.2)</td><td>261 (83.1)</td><td>22 (4.3)</td></tr><tr><td>Changes in your appearance</td><td>13 (7.2)</td><td>24 (13.3)</td><td>25 (13.9)</td><td>118 (65.6)</td><td>10 (3.2)</td><td>22 (7)</td><td>41 (13.1)</td><td>240 (76.7)</td><td>21 (4.1)</td></tr><tr><td>Restless and agitated</td><td>22 (12.2)</td><td>34 (18.9)</td><td>55 (30.6)</td><td>69 (38.3)</td><td>28 (8.8)</td><td>47 (14.8)</td><td>76 (23.9)</td><td>167 (52.5)</td><td>16 (3.1)</td></tr><tr><td>Symptoms not being under control</td><td>19 (10.4)</td><td>29 (15.8)</td><td>46 (25.1)</td><td>81 (44.3)</td><td>34 (10.8)</td><td>26 (8.2)</td><td>72 (22.8)</td><td>184 (58.2)</td><td>30 (5.8)</td></tr></table>
05feba05bb227e047605f3b26b40651b7461c5d710aaf9650732123fdbc220a1.png	complex	<table><tr><td>Experimental phase</td><td>Correlation</td><td>Brain regions</td><td>x</td><td>y</td><td>z</td><td>Cluster size</td><td>t value</td><td><i>p</i> value FWE</td></tr><tr><td rowspan="7">Fear conditioning</td><td rowspan="5">Positive</td><td>Posterior cingulate cortex</td><td>12</td><td>−34</td><td>46</td><td>70</td><td>3.10</td><td>0.033</td></tr><tr><td>Posterior insular cortex</td><td>44</td><td>−38</td><td>24</td><td>116</td><td>3.22</td><td>0.034</td></tr><tr><td>Amygdala</td><td>16</td><td>2</td><td>12</td><td>140</td><td>3.32</td><td>0.037</td></tr><tr><td>Hypothalamus</td><td>−12</td><td>0</td><td>−8</td><td>33</td><td>2.71</td><td>0.039</td></tr><tr><td>Anterior insular cortex</td><td>36</td><td>28</td><td>6</td><td>138</td><td>3.09</td><td>0.051</td></tr><tr><td rowspan="2">Negative</td><td>Orbitofrontal cortex</td><td>−16</td><td>34</td><td>−24</td><td>21</td><td>3.21</td><td>0.038</td></tr><tr><td>Subgenual anterior cingulate cortex</td><td>−6</td><td>18</td><td>−18</td><td>48</td><td>3.00</td><td>0.039</td></tr><tr><td rowspan="3">Shock delivery (unconditioned responses)</td><td rowspan="2">Positive</td><td>Hypothalamus</td><td>8</td><td>4</td><td>−32</td><td>357</td><td>4.11</td><td>0.015</td></tr><tr><td>Middle insular cortex</td><td>−40</td><td>2</td><td>8</td><td>311</td><td>3.53</td><td>0.040</td></tr><tr><td>Negative</td><td>Orbitofrontal cortex</td><td>−14</td><td>34</td><td>−18</td><td>44</td><td>3.40</td><td>0.011</td></tr><tr><td rowspan="2">Late extinction learning</td><td>Positive</td><td>Subgenual anterior cingulate cortex</td><td>−14</td><td>26</td><td>−14</td><td>30</td><td>2.88</td><td>0.028</td></tr><tr><td>Negative</td><td>Middle insular cortex</td><td>−36</td><td>4</td><td>16</td><td>62</td><td>3.27</td><td>0.024</td></tr><tr><td rowspan="8">Early extinction recall</td><td rowspan="8">Positive</td><td>Parahippocampus</td><td>−30</td><td>2</td><td>−20</td><td>183</td><td>5.35</td><td>0.001</td></tr><tr><td>Subgenual anterior cingulate cortex</td><td>10</td><td>12</td><td>−18</td><td>64</td><td>4.39</td><td>0.002</td></tr><tr><td>Anterior insular cortex</td><td>32</td><td>18</td><td>12</td><td>82</td><td>4.35</td><td>0.003</td></tr><tr><td>Anterior insular cortex</td><td>−62</td><td>10</td><td>0</td><td>1595</td><td>5.34</td><td>0.005</td></tr><tr><td>Dorsal anterior cingulate cortex</td><td>10</td><td>24</td><td>40</td><td>91</td><td>4.13</td><td>0.005</td></tr><tr><td>Ventromedial prefrontal cortex</td><td>−14</td><td>40</td><td>−26</td><td>572</td><td>4.37</td><td>0.014</td></tr><tr><td>Middle cingulate cortex</td><td>−4</td><td>0</td><td>36</td><td>76</td><td>3.33</td><td>0.024</td></tr><tr><td>Orbitofrontal cortex</td><td>−16</td><td>52</td><td>−18</td><td>572</td><td>3.94</td><td>0.034</td></tr></table>
801fe1688b500378cb8341cf0b13ed479c9d1a602cd5099184a82d62816ca4fb.png	complex	<table><tr><td> </td><td colspan="2">ANXA1-SER</td><td> </td><td colspan="2">ANXA1-TYR</td><td> </td></tr><tr><td> </td><td>HPV+</td><td>HPV-</td><td>Controls</td><td>HPV+</td><td>HPV-</td><td>Controls</td></tr><tr><td>Cancer</td><td>13.5 ± 1.6</td><td>14.6 ± 0.4</td><td>-</td><td>15.3 ± 0.6*</td><td>13.6 ± 1.6</td><td>-</td></tr><tr><td>Epithelium</td><td>23.2 ± 1.7*</td><td>16.0 ± 1.0</td><td>15.3 ± 0.3</td><td>22.2 ± 0.7</td><td>18.5 ± 1.5</td><td>26.7 ± 0.9</td></tr></table>
884c7598b284831c458f06c075822de9857cd2c245c98bf00e13e004d0e8010e.png	complex	<table><tr><td>Variations</td><td></td><td>1<sup>st</sup> Day</td><td>2<sup>nd</sup> Day</td><td>3<sup>rd</sup> Day </td><td>P value</td></tr><tr><td rowspan="2">Number of bolusesrequired</td><td>Group B</td><td>31.47±24.39</td><td>24.07±20.25</td><td>19.20±14.59</td><td rowspan="2">0.084</td></tr><tr><td>Group L</td><td>38.87±28.27</td><td>21.13±16.82</td><td>17.77±12.38</td></tr><tr><td rowspan="2">Number of bolusesdelivered</td><td>Group B</td><td>15.87±6.66</td><td>9.97±4.79</td><td>8.93±3.95</td><td rowspan="2">0.348</td></tr><tr><td>Group L</td><td>16.37±8.39</td><td>9.70±5.42</td><td>8.50±4.20</td></tr><tr><td rowspan="2">Total Consumption(ml)</td><td>Group B</td><td>79.17±33.45</td><td>49.67±23.81</td><td>44.67±19.78</td><td rowspan="2">0.371</td></tr><tr><td>Group L</td><td>81.67±41.65</td><td>48.5±27.13</td><td>42.5±20.99</td></tr></table>
4079a9ac9a773f44129f423cb6c776a35d8986edf46a3ef19853543bc82e7179.png	complex	<table><tr><td>Components</td><td>Mean IOP (±SD)</td><td>P Value</td><td>Mean CCT (±SD)</td><td>P Value</td></tr><tr><td colspan="5">Abdominal Obesity</td></tr><tr><td>Yes</td><td>26.23±4.17</td><td>0.126</td><td>591.12±56.15</td><td>0.317</td></tr><tr><td>No </td><td>25.34±3.76</td><td> </td><td>596.34±91.77</td><td> </td></tr><tr><td colspan="5">Elevated Fasting Glucose</td></tr><tr><td>Yes</td><td>26.12±3.69</td><td>0.033</td><td>584.59±76.28</td><td>0.462</td></tr><tr><td>No </td><td>24.59±2.45</td><td> </td><td>597.72±92.65</td><td> </td></tr><tr><td colspan="5">High Blood Pressure</td></tr><tr><td>Yes</td><td>27.24±2.62</td><td><0.0001</td><td>601.38±74.67</td><td>0.002</td></tr><tr><td>No </td><td>23.83±4.47</td><td> </td><td>576.23±93.79</td><td> </td></tr><tr><td colspan="5">Low HDL</td></tr><tr><td>Yes</td><td>25.37±3.23</td><td>0.234</td><td>585.53±97.28</td><td>0.538</td></tr><tr><td>No </td><td>26.29±2.72</td><td> </td><td>598.09±64.92</td><td> </td></tr><tr><td colspan="5">Elevated Triglyceride</td></tr><tr><td>Yes</td><td>27.51±2.39</td><td>0.004</td><td>589.57±46.45</td><td>0.317</td></tr><tr><td>No </td><td>23.74±3.34</td><td> </td><td>597.52±73.73</td><td> </td></tr></table>
baa49a5311ba1cb99c1d125d90f87bcc0100a0efff00f382f0eb2127e9b7d9c8.png	simple	<table><tr><td>Reference</td><td>Measurement of PAH-RPF/true RPF (<i>n</i>/<i>n</i>)</td><td>PAH-RPF (ml/min)</td><td>True RPF (ml/min)</td></tr><tr><td>[17]</td><td>6 (0)</td><td>-</td><td>690</td></tr><tr><td>[18]</td><td>40 (11)</td><td>475</td><td>1116</td></tr><tr><td>[19]</td><td>22 (6)</td><td>474</td><td>1238</td></tr></table>
0a4ad1a9056f7b176cf2ea7fe8eb0917b9be54c51f13024f6daa7e8e677d95f5.png	simple	<table><tr><td>SNP</td><td>MAF (% [<i>n</i>/<i>N</i>])</td><td>OR (95% CI)</td><td><i>P</i></td></tr><tr><td>rs600144</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>25.9 (850/3278)</td><td>0.96 (0.9 to 1.1)</td><td>NS</td></tr><tr><td> Controls</td><td>26.8 (857/3202)</td><td></td><td></td></tr><tr><td>rs11970361</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>5.7 (187/3300)</td><td>0.94 (0.8 to 1.2)</td><td>NS</td></tr><tr><td> Controls</td><td>6.0 (194/3238)</td><td></td><td></td></tr><tr><td>rs11970411</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>10.2 (338/3300)</td><td>1.01 (0.9 to 1.2)</td><td>NS</td></tr><tr><td> Controls</td><td>10.1 (328/3238)</td><td></td><td></td></tr><tr><td>rs582757</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>24.8 (816/3286)</td><td>0.89 (0.8 to 0.99)</td><td>0.041</td></tr><tr><td> Controls</td><td>27.0 (871/3220)</td><td></td><td></td></tr><tr><td>rs17780429</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>12.7 (418/3300)</td><td>0.91 (0.8 to 1.0)</td><td>NS</td></tr><tr><td> Controls</td><td>13.8 (446/3236)</td><td></td><td></td></tr></table>
317ae5f6077fa3828d0080382e0125a678cabee0ab909c72fc73826c4ff3c14f.png	simple	<table><tr><td></td><td>accepted marine species in WORMS</td><td>18S V9 OTUs in plankton<sup>a</sup></td></tr><tr><td>Acanthocephala</td><td>468</td><td>0</td></tr><tr><td>Annelida</td><td>12 862</td><td>404 (48)</td></tr><tr><td>Arthropoda</td><td>57 871</td><td>9497 (205)</td></tr><tr><td>Brachiopoda</td><td>396</td><td>8 (4)</td></tr><tr><td>Bryozoa</td><td>6167</td><td>15 (5)</td></tr><tr><td>Cephalorhyncha</td><td>238</td><td>13</td></tr><tr><td>Chaetognatha</td><td>131</td><td>531 (7)</td></tr><tr><td>Chordata</td><td>22 248</td><td>6972 (32)</td></tr><tr><td>Cnidaria</td><td>11 407</td><td>842 (82)</td></tr><tr><td>Ctenophora</td><td>192</td><td>33 (9)</td></tr><tr><td>Cycliophora</td><td>2</td><td>0</td></tr><tr><td>Dicyemida</td><td>122</td><td>1</td></tr><tr><td>Echinodermata</td><td>7252</td><td>74 (19)</td></tr><tr><td>Entoprocta</td><td>180</td><td>12</td></tr><tr><td>Gastrotricha</td><td>497</td><td>2</td></tr><tr><td>Gnathostomulida</td><td>98</td><td>0</td></tr><tr><td>Hemichordata</td><td>130</td><td>12 (3)</td></tr><tr><td>Mollusca</td><td>45 219</td><td>560 (89)</td></tr><tr><td>Nematoda</td><td>7152</td><td>30 (6)</td></tr><tr><td>Nemertea</td><td>1359</td><td>81 (4)</td></tr><tr><td>Orthonectida</td><td>25</td><td>0</td></tr><tr><td>Phoronida</td><td>19</td><td>0</td></tr><tr><td>Placozoa</td><td>1</td><td>0</td></tr><tr><td>Platyhelminthes</td><td>12 230</td><td>148 (12)</td></tr><tr><td>Porifera</td><td>8476</td><td>25 (4)</td></tr><tr><td>Rotifera</td><td>187</td><td>7 (2)</td></tr><tr><td>Sipuncula</td><td>147</td><td>0</td></tr><tr><td>Tardigrada</td><td>193</td><td>2</td></tr><tr><td>Xenacoelomorpha</td><td>433</td><td>0</td></tr><tr><td>unassigned metazoan</td><td>n.a.</td><td>402</td></tr><tr><td>total</td><td>195 702</td><td>19 671 (531)</td></tr></table>
c6fcb27ef2020c9eaaab7056b2b755a00ca4d33e23a7371d480b443571e665d2.png	complex	<table><tr><td></td><td>CON</td><td>HSD2BKO</td></tr><tr><td>Adrenal size: body weight (adult)</td><td>5.9 ± 0.9 × 10<sup>−4</sup> (15)</td><td>4.9 ± 0.9 × 10<sup>−4</sup> (18)</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">Brain gene expression (<i>n</i> = 5–8)</td></tr><tr><td><i>Crh</i> (E15.5; PVN)(ROD)</td><td>0.336 ± 0.01</td><td>0.320 ± 0.026</td></tr><tr><td><i>Crh</i> (E17.5; PVN)(ROD)</td><td>0.274 ± 0.0181</td><td>0.252 ± 0.016</td></tr><tr><td>Nr3c2 (E15.5; HC)(ROD)</td><td>ND</td><td>ND</td></tr><tr><td><i>Nr3c2</i> (E17.5; HC)(ROD)</td><td>0.26 ± 0.02</td><td>0.26 ± 0.01</td></tr><tr><td><i>Nr3c2</i> (Adult; HC) (norm to HPRT)</td><td>0.868 ± 0.077</td><td>0.818 ± 0.061</td></tr><tr><td><i>Nr3c1</i> (Adult; HC)(norm to HPRT)</td><td>0.733 ± 0.170</td><td>0.744 ± 0.055</td></tr><tr><td><i>Hsd11b1</i> (E12.5; norm to HPRT)</td><td>0.172 ± 0.033</td><td>0.155 ± 0.021</td></tr><tr><td><i>Hsd11b1</i> (E17.5; norm to HPRT)</td><td>0.188 ± 0.028</td><td>0.148 ± 0.022</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">Plasma corticosterone (nmol/l)</td></tr><tr><td>Fetal (E17.5)</td><td>31.2 ± 2.1</td><td>28.1 ± 2.0</td></tr><tr><td colspan="3">  </td></tr><tr><td>Adult</td><td>(10)</td><td>(9)</td></tr><tr><td>AM</td><td>35.3 ± 4.8</td><td>34.3 ± 6.7</td></tr><tr><td>PM</td><td>196.5 ± 16.6</td><td>179.9 ± 22.9</td></tr><tr><td colspan="3">  </td></tr><tr><td>Restraint stress corticosterone levels (nmol/l)</td><td>(12)</td><td>(12)</td></tr><tr><td>0 min restraint stress</td><td>33.8 ± 4.7</td><td>35.9 ± 5.3</td></tr><tr><td>30 min restraint stress</td><td>622.9 ± 87.4</td><td>661.0 ± 98.1</td></tr><tr><td>1 h post restraint stress</td><td>155.7 ± 27.8</td><td>181.9 ± 26.8</td></tr></table>
7f0741322e631626567490dd7a75914c89ac6054c5612e7db1f01f4ed0599bde.png	simple	<table><tr><td>Level of lesion</td><td>Number of patients</td><td>Percentage</td></tr><tr><td>Thoracic</td><td>3</td><td>3.49</td></tr><tr><td>Thoracolumbar</td><td>6</td><td>6.98</td></tr><tr><td>Lumbar</td><td>23</td><td>26.74</td></tr><tr><td>Lumbosacral</td><td>18</td><td>20.93</td></tr><tr><td>Sacral</td><td>16</td><td>18.60</td></tr><tr><td>Sacrococcygeal</td><td>1</td><td>1.16</td></tr><tr><td>Not available</td><td>19</td><td>22.09</td></tr><tr><td>Total</td><td>86</td><td>100</td></tr></table>
29e3d19141535c8870d89fe5d5883b9fba65d69a3564ac1d58de736b3db11598.png	simple	<table><tr><td></td><td>β</td><td>t</td><td><i>p</i></td></tr><tr><td>Maternal age (per year)</td><td>−0.008</td><td>−0.45</td><td>0.65</td></tr><tr><td>Maternal weight (per kg)</td><td>0.211</td><td>11.77</td><td><0.001</td></tr><tr><td>Frozen thawed embryo (versus fresh embryo)</td><td>0.079</td><td>4.25</td><td><0.001</td></tr><tr><td>ICSI (versus IVF)</td><td>0.009</td><td>0.48</td><td>0.63</td></tr><tr><td>SAGE (versus Vitrolife)</td><td>−0.004</td><td>−0.24</td><td>0.81</td></tr><tr><td>Gestational age</td><td>0.490</td><td>27.38</td><td><0.001</td></tr><tr><td>Gender (male versus female)</td><td>0.110</td><td>6.33</td><td><0.001</td></tr></table>
175c447ec27452a109ec215e0f35c41bded47e6e5a834ad07a136e599349660d.png	complex	<table><tr><td></td><td colspan="2">Secretory uric acid transporter</td></tr><tr><td>Compound</td><td>OAT1</td><td>ABCG2</td></tr><tr><td>Lesinurad</td><td>3.90 ± 0.94</td><td>>100</td></tr></table>
01f004ad9f9d538f28dc1edd0dcc1844e8dae3b548d82f22bd77188fab23aede.png	simple	<table><tr><td>Pathway</td><td>Description</td></tr><tr><td>G protein-coupled receptor (GPCR) signaling</td><td>There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. Sixteen of these receptors were deregulated in our tumor series (available upon request).</td></tr><tr><td>EGFR signaling</td><td>This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway.</td></tr><tr><td>ErbB2 signaling</td><td>The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 interacting protein (<i>ERBB2IP</i>) was also upregulated. However, the ErbB4 signaling pathway was not deregulated.</td></tr><tr><td>Integrin cell surface interactions</td><td>Integrin αIIb β3 signaling presented four upregulated elements. The amyloid β (A4) precursor protein-binding family B member 1-interacting protein (<i>APBB1IP</i>) and downstream effector Talin-1 (<i>TLN1</i>) were upregulated. This upregulation provoked the activation of integrin αIIb β3 and the subsequent activation of tyrosine-protein kinase SYK (<i>SYK</i>), which was also upregulated, by Src.</td></tr></table>
076d9395afbeb921187a0c14965a1c07165ee3f25d19b3466bf129cc2f651928.png	complex	<table><tr><td>Characteristic</td><td>Case (<i>n</i> = 82)</td></tr><tr><td colspan="2">Age in years</td></tr><tr><td>> 45</td><td>21</td></tr><tr><td>≤ 45</td><td>61</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>33</td></tr><tr><td> Female</td><td>49</td></tr><tr><td>Tumour size, cm</td><td>5.94 ± 2.65</td></tr><tr><td colspan="2">Location</td></tr><tr><td> Left</td><td>31</td></tr><tr><td> Right</td><td>51</td></tr><tr><td colspan="2">Symptoms</td></tr><tr><td> Asymptomatic</td><td>48</td></tr><tr><td> Symptomatic</td><td>34</td></tr><tr><td colspan="2">Fuhrman grade</td></tr><tr><td> 1 to 2</td><td>32</td></tr><tr><td> 3 to 4</td><td>50</td></tr><tr><td colspan="2">TNM stage</td></tr><tr><td> I to II</td><td>49</td></tr><tr><td> III to IV</td><td>33</td></tr><tr><td colspan="2">pT status</td></tr><tr><td> T1 to T2</td><td>64</td></tr><tr><td> T3 to T4</td><td>18</td></tr><tr><td colspan="2">pN status</td></tr><tr><td> N0</td><td>59</td></tr><tr><td> N1</td><td>23</td></tr><tr><td colspan="2">pM status</td></tr><tr><td> M0</td><td>78</td></tr><tr><td> M1</td><td>4</td></tr><tr><td colspan="2">Surgical treatment</td></tr><tr><td> Radical</td><td>55</td></tr><tr><td> Partial</td><td>27</td></tr><tr><td colspan="2">Tumour thrombus</td></tr><tr><td> Negative</td><td>72</td></tr><tr><td> Positive</td><td>10</td></tr></table>
338d39e857491843816fd7d7f24cdff0d7763acf4e6edd505b8fe1d939c03caa.png	complex	<table><tr><td>Annual Report Year</td><td>Case Number</td><td>Clinical Summary</td></tr><tr><td colspan="3">Patients Treated with FabAV</td></tr><tr><td>2001</td><td>55</td><td>A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minutes, she was hypotensive, profoundly hypoxic, developed pulmonary edema, and had a seizure. Treatment included intubation with ventilator support, dopamine, and FabAV (dose not reported). She never developed local tissue effects or coagulopathy. Despite maximal therapy, she died five days after envenomation.</td></tr><tr><td>2002</td><td>69</td><td>A 43-year-old man presented with severe hypotension after a rattlesnake bite. He remained hypotensive despite fluids, dopamine, epinephrine, diphenhydramine, steroids, and 26 vials of whole-IgG antivenom. Disseminated intravascular coagulopathy developed. He then received six vials of FabAV, after which his blood pressure improved such that vasopressors were discontinued. He developed epistaxis and oral mucosal bleeding that was treated with 7 additional vials of whole-IgG antivenom and transfusions of platelets, fresh frozen plasma, and cryoprecipitate (response not reported). He developed renal failure, and ultimately died of multi-system organ failure.</td></tr><tr><td>2003</td><td>424</td><td>A 33-year-old man received FabAV for an apparently uncomplicated rattlesnake envenomation. He was discharged from the hospital 24 hours later with only minimal symptoms, and was given a prescription for oxycodone with acetaminophen. He died of an apparent overdose of oxycodone that night.</td></tr><tr><td>2004</td><td>52</td><td>A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol, and fentanyl, which led to respiratory arrest, aspiration, and acute respiratory distress syndrome. Medical care was withdrawn, and the patient died.</td></tr><tr><td>2004</td><td>53</td><td>A 55-year-old man presented with severe hypotension and coma from apparent intravascular envenomation from a rattlesnake. FabAV therapy and aggressive resuscitation were not initiated for several hours. The patient developed renal failure, disseminated intravascular coagulopathy, and circulatory collapse, and died seven hours after envenomation.</td></tr><tr><td colspan="3">Patients Treated with Unspecified Antivenom</td></tr><tr><td>2001</td><td>56</td><td>A 30-year-old man presented comatose after rattlesnake envenomation. On presentation, he was found to have coagulopathy, thrombocytopenia, and a subarachnoid hemorrhage. He received "10 to 20 vials" of unspecified antivenom, but died after withdrawal of life support.</td></tr><tr><td>2005</td><td>57</td><td>A 32-year-old man presented to the emergency department in respiratory arrest due to anaphylaxis from a rattlesnake bite. He received unspecified antivenom, and subsequently died of anoxic encephalopathy.</td></tr></table>
14a3a99918799915737ddf9a6f917de9730463928db42646c88c84893e764c73.png	complex	<table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (mg/Kg bw)</td><td colspan="3">Blood antioxidant enzymes</td></tr><tr><td>SOD (U/g Hb)</td><td>GPX (U/g Hb)</td><td>CAT (K/g Hb)</td></tr><tr><td>NC</td><td>-</td><td>2943 ± 104.4 <sup>a</sup></td><td>51.31±4.2<sup>a</sup></td><td>1.57 ± 0.6<sup>a</sup></td></tr><tr><td>DC</td><td>-</td><td>1945.8 ± 21.6</td><td>33.11 ± 3.74</td><td>0.541 ± 0.011</td></tr><tr><td>ASE+D</td><td>500</td><td>3125.4 ± 54.2 <sup>a</sup></td><td>42.2 ± 5.21<sup>b</sup></td><td>0.882 ± 0.12 <sup>c</sup></td></tr><tr><td>AAE+D</td><td>500</td><td>3214.3 ± 83.2 <sup>a</sup></td><td>47.5 ± 4.2 <sup>a</sup></td><td>0.839 ± 0.09 <sup>c</sup></td></tr><tr><td>SOE+D</td><td>250</td><td>2591 ± 9.13 <sup>a</sup></td><td>41.33 ± 2.08 <sup>b</sup></td><td>0.598 ± 0.04 <sup>e</sup></td></tr><tr><td>Met+D</td><td>100</td><td>2118.1 ± 29.7 <sup>c</sup></td><td>37.31 ± 5.51 <sup>e</sup></td><td>0.551 ± 0.07 <sup>e</sup></td></tr></table>
7f5ca12fa38da089aaaab93823e53eed1b6debb727b0f7186139f2381ccf1e8a.png	simple	<table><tr><td></td><td>NanoString FROZ vs FFPE</td><td>ScriptSeq FROZ vs FFPE</td></tr><tr><td>BRB123</td><td>0.926 (0.950)</td><td>0.790 (0.943)</td></tr><tr><td>BRB144</td><td>0.955 (0.965)</td><td>0.807 (0.957)</td></tr><tr><td>BRB147</td><td>0.728 (0.917)</td><td>0.802 (0.945)</td></tr><tr><td>BRB157</td><td>0.807 (0.930)</td><td>0.793 (0.932)</td></tr><tr><td>BRB212</td><td>0.972 (0.962)</td><td>0.830 (0.963)</td></tr><tr><td>BRB215</td><td>0.818 (0.976)</td><td>0.598 (0.961)</td></tr><tr><td>BRB248</td><td>0.942 (0.976)</td><td>0.830 (0.972)</td></tr><tr><td>BRB277</td><td>0.973 (0.970)</td><td>0.825 (0.971)</td></tr><tr><td>MCJBCR028</td><td>0.747 (0.941)</td><td>0.773 (0.933)</td></tr><tr><td>mean</td><td>0.874 (0.954)</td><td>0.783 (0.953)</td></tr></table>
7418a5ef129f99c2c13ec6b242cb021bac9417cc512af7d76118ccd232011728.png	simple	<table><tr><td></td><td><i>N</i></td><td>Drug</td><td>Duration</td><td>Subcutaneous adipose tissue</td><td>Visceral adipose tissue</td><td>Body mass index (kg/m<sup>2</sup>)</td><td>Reference</td></tr><tr><td>No change in SAT</td><td>30</td><td>Rosi versus placebo</td><td>24 weeks</td><td>MRI: NS</td><td>MRI: NS</td><td>NS</td><td>Sutinen et al. [55]</td></tr><tr><td></td><td>108</td><td>Rosi versus placebo</td><td>48 weeks</td><td>DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS</td><td>CT: NS</td><td>NS</td><td>Carr et al. [56]</td></tr><tr><td></td><td>14</td><td>Pio versus feno versus pio + feno versus placebo</td><td>12 months</td><td>DEXA upper limb fat: NS DEXA lower limb fat: NS CT s.c. abdomen: NS</td><td>CT: NS</td><td>NS</td><td>Gavrila et al. [65]</td></tr><tr><td></td><td>96</td><td>Rosi versus placebo</td><td>24 weeks</td><td>DEXA limb fat: NSDEXA arm fat: NS DEXA leg fat: NS</td><td>ND</td><td>NS</td><td>Cavalcanti et al. [62]</td></tr><tr><td>Increase in SAT</td><td>28</td><td>Rosi versusplacebo</td><td>3 months</td><td>CT thigh (cm<sup>2</sup>): rosi: + 2.3 versus pla −0.9, Δ rosi versus pla, <i>P</i> = .002CT s.c. abdomen: NS DEXA leg: NS (rosi +50 g versus pla −80 g,Δ rosi versus pla <i>P</i> = .08)</td><td>CT: NS</td><td>NS</td><td>Hadigan et al. [57]</td></tr><tr><td></td><td>105</td><td>Rosi versus metformin versus rosi + met versus placebo</td><td>16 weeks</td><td>DEXA leg fat (%): rosi: +4.8,NS; met: −3.6,NS; rosi + met: −0.5,NS; pla: −8.3%,NS Δ rosi vs pla <i>P</i> = .03, other groups versus pla, NSDEXA arm fat: NS DEXA limb fat: NS CT s.c. abdomen: NS</td><td>CT (%): rosi: 0.0,NS; met: −0.6,NS; rosi + met:−7.9,NS; pla: −7.2,NS Δ rosi versus pla, <i>P</i> = .08, other groups versus pla, NS</td><td>Body mass index ND, body weight (kg): rosi: 0.0,NS; met: −2.0,<i>P</i> < .001; rosi + met: −1.5,<i>P</i> < .01; pla:−0.05,NS Δ met versuspla, <i>P</i> = .03; Δ met + rosi versuspla, <i>P</i> = .06</td><td>Mulligan et al. [60]</td></tr><tr><td></td><td>130</td><td>Pio versus placebo</td><td>48 weeks</td><td>DEXA limb fat (g): pio: +380 g; pla: +50 gΔ pio versus pla <i>P</i> = .051 CT s.c. abdomen: NS</td><td>CT: NS</td><td>Pio: +0.9; pla: +0.3Δ pio versus pla <i>P</i> = .07</td><td>Slama et al. [66]</td></tr><tr><td></td><td>39</td><td>Rosi versus metformin</td><td>26 weeks</td><td>CT s.c. abdomen (cm<sup>2</sup>) rosi: +16,<i>P</i> < .05; met: −11,<i>P</i> < .05 Δ rosi versus met 27cm<sup>2</sup> (95% CI, 7 to 46)</td><td>CT (cm<sup>2</sup>)rosi: −1,NS; met: −25,<i>P</i> < .05 Δ rosi versus met 24 cm<sup>2</sup> (95% CI, 6 to 51)</td><td>Rosi: +0.4,<i>P</i> < .05; met: −0.4,<i>P</i> < .05 Δ rosi versusmet 0.7 (95% CI, 0.5 to 1.6)</td><td>van Wijk et al. [58]</td></tr></table>
68acf21e48a4a9bd740a99e2894dc1cd4e4e5753735d9bd770b91563ff1be016.png	simple	<table><tr><td></td><td>Group A (non-GBA)</td><td>Group B (GBA)</td><td><i>P</i> value</td></tr><tr><td>Neck lymphadenopathy</td><td>26/60 (43%)</td><td>7/14 (50%)</td><td>NS</td></tr><tr><td>Fissured lips</td><td>53/60 (88%)</td><td>12/14 (86%)</td><td>NS</td></tr><tr><td>Strawberry tongue</td><td>47/61 (77%)</td><td>11/14 (79%)</td><td>NS</td></tr><tr><td>Conjunctivitis</td><td>55/60 (92%)</td><td>12/14 (86%)</td><td>NS</td></tr><tr><td>Skin rash</td><td>51/58 (88%)</td><td>15/15 (100%)</td><td>NS</td></tr><tr><td>BCG erythema change</td><td>25/58 (43%)</td><td>6/13 (46%)</td><td>NS</td></tr><tr><td>Induration of extremities</td><td>39/56 (70%)</td><td>3/12 (25%)</td><td>NS</td></tr></table>
6a796850c3dc37e6814a39cd01cf390a059c3db7f356896f9fc0917a603de84b.png	simple	<table><tr><td>Heuristic</td><td>Network load (No. of groups)</td><td>Channel Constraint (<i>ω</i>)</td><td>Radio Constraint</td><td>Network Size</td><td>Communication Radius</td></tr><tr><td>SPT</td><td>(200%, 200%)*</td><td>(175%, 150%)</td><td>(400%, 350%)</td><td>(300%, 142%)</td><td>(180%, 175%)</td></tr><tr><td>GIT</td><td>(200%, 125%)</td><td>(175%, 100%)</td><td>(400%, 250%)</td><td>(16%, 96%)</td><td>(180%, 83%)</td></tr><tr><td>CAGIT</td><td>(50%, 125%)</td><td>(125%, 100%)</td><td>(300%, 250%)</td><td>(16%, 142%)</td><td>(100%, 175%)</td></tr><tr><td>ICADCR</td><td>(31%, 13%)</td><td>(17%, 25%)</td><td>(50%, 100%)</td><td>(7%, 7%)</td><td>(61.4%, 92%)</td></tr></table>
0c1dae09fa84325b6cc5035911318cd56cb654eede2b5e664787a77f9fbd295c.png	simple	<table><tr><td>AMPLICON</td><td>SSCP ANALYSIS</td><td>HRMA/SEQUENCING<sup>1</sup></td><td>N. OF CASES</td></tr><tr><td>EXON 1</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 2</td><td>WT</td><td>WT</td><td>23</td></tr><tr><td></td><td>WT</td><td>c.[64G > A]+[=]</td><td>1</td></tr><tr><td></td><td>c.[64G > A]+[64G > A]</td><td>c.[64G > A]+[64G > A]</td><td>2</td></tr><tr><td>EXON 3</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 4</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 5</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 6</td><td>WT</td><td>WT</td><td>18</td></tr><tr><td></td><td>c.[504+35G > A]+[=]</td><td>c.[504+35G > A]+[=]</td><td>7</td></tr><tr><td></td><td>c.[481G > C]+[=]</td><td>c.[481G > C]+[=]</td><td>1</td></tr><tr><td>EXON 7</td><td>WT</td><td>WT</td><td>19</td></tr><tr><td></td><td>c.[536A > G]+[536A > G]</td><td>c.[536A > G]+[536A > G]</td><td>2</td></tr><tr><td></td><td>c.[536A > G]+[=]</td><td>c.[536A > G]+[=]</td><td>5</td></tr><tr><td>EXON 8</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 9</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 10</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 11</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 12</td><td>WT</td><td>WT</td><td>16</td></tr><tr><td></td><td>c.[1014G > C]+[=]</td><td>c.[1014G > C]+[=]</td><td>6</td></tr><tr><td></td><td>WT</td><td>c.[1014G > C]+[1014G > C]</td><td>1</td></tr><tr><td></td><td>c.[1147delC]+[=]</td><td>c.[1147delC]+[=]</td><td>1</td></tr><tr><td></td><td>c.[1023_1024insGA]<sup>2</sup>+[=]</td><td>c.[1023_1024insGA]<sup>2</sup>+[=]</td><td>1</td></tr><tr><td></td><td>c.[1163T > C]+[=]</td><td>c.[1163T > C]+[=]</td><td>1</td></tr><tr><td>EXON 13</td><td>WT</td><td>WT</td><td>19</td></tr><tr><td></td><td>c.[1187G > A]+[1187G > A]</td><td>c.[1187G > A]+[1187G > A]</td><td>1</td></tr><tr><td></td><td>c.[1187G > A]+[=]</td><td>c.[1187G > A]+[=]</td><td>4</td></tr><tr><td></td><td>c.[1227_1228dupGG]+[1227_1228dupGG]</td><td>c.[1227_1228dupGG]+[1227_1228dupGG]</td><td>1</td></tr><tr><td></td><td>c.[1187-27C > T(+)1258C > A]<sup>3</sup></td><td>c.[1187-27C > T(+)1258C > A]<sup>3</sup></td><td>1</td></tr><tr><td>EXON 14</td><td>WT</td><td>WT</td><td>24</td></tr><tr><td></td><td>c.[1437_1439delGGA]+[=]</td><td>c.[1437_1439delGGA]+[=]</td><td>1</td></tr><tr><td></td><td>c.[1437_1439delGGA]+[1437_1439delGGA]</td><td>c.[1437_1439delGGA]+[1437_1439delGGA]</td><td>1</td></tr><tr><td>EXON 15</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 16</td><td>WT</td><td>WT</td><td>26</td></tr></table>
7a07100dc01ffa72363bee3236284c23e2fa089621777cc8eecc2fd65dba7bd1.png	complex	<table><tr><td rowspan="2">Essential oil</td><td colspan="2"><i>S. pyogenes</i></td><td colspan="2"><i>S. pneumoniae</i></td><td colspan="2"><i>S. mutans</i></td></tr><tr><td>MIC</td><td>MBC</td><td>MIC</td><td>MBC</td><td>MIC</td><td>MBC</td></tr><tr><td>Cinnamon bark</td><td>0.41</td><td>0.81</td><td>0.06</td><td>0.13</td><td>0.20</td><td>0.41</td></tr><tr><td>Thyme</td><td>0.43</td><td>0.87</td><td>0.11</td><td>0.22</td><td>0.04</td><td>0.09</td></tr><tr><td>Clove</td><td>0.10</td><td>0.20</td><td>0.25</td><td>0.50</td><td>0.41</td><td>0.81</td></tr><tr><td>Peppermint</td><td>0.35</td><td>0.70</td><td>0.35</td><td>0.70</td><td>0.70</td><td>1.39</td></tr><tr><td>Citronella</td><td>0.17</td><td>0.34</td><td>0.09</td><td>0.17</td><td>0.17</td><td>0.34</td></tr><tr><td>Eucalyptus</td><td>2.82</td><td>5.64</td><td>1.41</td><td>2.81</td><td>0.70</td><td>1.41</td></tr><tr><td>Scots pine</td><td>1.35</td><td>2.71</td><td>0.68</td><td>1.35</td><td>1.35</td><td>2.71</td></tr></table>
d575b9521bced00a961c16b37711c323310fa047d6d094c1818bad359f25e0da.png	complex	<table><tr><td>Stimulus 1</td><td>Stimulus 2</td><td>95% CI Lower bound</td><td>Difference of Means (1–2)</td><td>95% CI Upper bound</td><td><i>P</i></td></tr><tr><td colspan="6">TOTALLY ENGAGED (<i>N</i> = 27)</td></tr><tr><td>Audio only</td><td>Multimodal</td><td>–39.72</td><td>–28.33</td><td>–16.95</td><td><0.001</td></tr><tr><td>Music: FAV</td><td>Audio only</td><td>27.69</td><td>39.07</td><td>50.46</td><td><0.001</td></tr><tr><td>Music: FAV</td><td>Multimodal</td><td>–0.64</td><td>10.74</td><td>22.12</td><td>0.0682</td></tr><tr><td colspan="6">FRUSTRATED (<i>N</i> = 27)</td></tr><tr><td>Audio only</td><td>Multimodal</td><td>–3.81</td><td>6.19</td><td>16.18</td><td>0.3023</td></tr><tr><td>Music: FAV</td><td>Audio only</td><td>–27.47</td><td>–17.48</td><td>–7.49</td><td><0.001</td></tr><tr><td>Music: FAV</td><td>Multimodal</td><td>–21.29</td><td>–11.30</td><td>–1.31</td><td>0.0232</td></tr></table>
b0b035e9477fe547dabe265625779fea7f815c3f699367cd88de4c1769d6fa7c.png	complex	<table><tr><td>Activities Related to HAI Prevention</td><td>Professional Groups</td><td><i>N</i></td><td>Average Values in Groups</td><td>Median</td><td>Standard Deviation</td><td>95% CI</td></tr><tr><td rowspan="3">Hand-hygiene</td><td>Medical student</td><td>28</td><td>5.6</td><td>6.0</td><td>2.71</td><td>4.649, 6.494</td></tr><tr><td>Medical intern</td><td>18</td><td>6.2</td><td>7.0</td><td>2.71</td><td>4.873, 7.571</td></tr><tr><td>Physician</td><td>54</td><td>6.0</td><td>7.0</td><td>2.78</td><td>5.241, 6.759</td></tr><tr><td rowspan="3">Use of disposable gloves</td><td>Medical student</td><td>28</td><td>6.6</td><td>7.0</td><td>1.52</td><td>6.016, 7.198</td></tr><tr><td>Medical intern</td><td>18</td><td>5.0</td><td>5.5</td><td>2.57</td><td>3.724, 6.276</td></tr><tr><td>Physician</td><td>54</td><td>4.9</td><td>5.0</td><td>2.41</td><td>4.229, 5.548</td></tr><tr><td rowspan="3">Adherence to aseptic technique</td><td>Medical student</td><td>28</td><td>5.2</td><td>5.0</td><td>1.97</td><td>4.451, 5.978</td></tr><tr><td>Medical intern</td><td>18</td><td>5.5</td><td>6.0</td><td>2.50</td><td>4.255, 6.745</td></tr><tr><td>Physician</td><td>54</td><td>5.3</td><td>6.0</td><td>2.63</td><td>4.616, 6.051</td></tr></table>
95f6d32a67381cacef7883fdcd3f5a3fb0a8b351a80504a1d3699a99125cc178.png	complex	<table><tr><td></td><td colspan="4">urine pH > 5.5 (idRTA)</td><td colspan="4">urine pH < 5.5</td><td>p</td></tr><tr><td></td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td></td></tr><tr><td>serum alkaline phosphate (U/L)mean (SD)</td><td>798 (82.84)</td><td>617 (55.67)</td><td>533 (55.02)</td><td>375 (53.21)</td><td>679 (64.60)</td><td>489 (51.40)</td><td>447 (60.00)</td><td>299 (46.82)</td><td>P < 0.01</td></tr><tr><td>serum calcium (mmol/L)mean (SD)</td><td>1.92 (0.08)</td><td>2.01 (0.06)</td><td>2.12 (0.03)</td><td>2.25 (0.5)</td><td>1.98 (0.07)</td><td>2.13 (0.08)</td><td>2.20 (0.080</td><td>2.28 (0.08)</td><td>P < 0.01</td></tr><tr><td>serum phosphate (mmol/L)mean (SD)</td><td>1.13 (0.08)</td><td>1.26 (0.07)</td><td>1.47 (0.06)</td><td>1.50 (0.06)</td><td>1.10 (0.09)</td><td>1.24 (0.08)</td><td>1.54 (0.07)</td><td>1.59 (0.05)</td><td>P < 0.01</td></tr><tr><td>Mean Height range (cm)</td><td>72.00 to 83.00</td><td></td><td></td><td></td><td>74.00 to 91.00</td><td></td><td></td><td></td><td></td></tr><tr><td>Mean height velocity range (cm)</td><td>4.50 -8.00</td><td></td><td></td><td></td><td>4.00 - 8.40</td><td></td><td></td><td></td><td></td></tr></table>
2d976160d34a7172258c2f1601cba7e853d9348280261b9cdd380b7c34106038.png	simple	<table><tr><td>Identified Motif Sequence</td><td># Seqs withMotif</td><td>Motif E-Value</td><td>TRANS FAC Hit ID</td><td>TRANS AC Binding Site Sequence</td><td>TRANS FAC annotation</td></tr><tr><td>CATCCAACGGC</td><td>29</td><td>1.2E-1</td><td>M00227</td><td>TCCAACGGC</td><td>Myb</td></tr><tr><td>CCCGCCACGCGCCAC</td><td>48</td><td>5.1E-26</td><td>M00187</td><td>GCCACG<underline>T</underline>GCC</td><td>Helix Loop Helix</td></tr><tr><td>TGGCGGGA</td><td>50</td><td>5.8E-13</td><td>M00024</td><td>TGGCG<underline>C</underline>GA</td><td>Elongation Factor 2</td></tr><tr><td>CCAAACCC</td><td>50</td><td>2.7E-5</td><td>No Hit</td><td></td><td></td></tr><tr><td>CCACCACCACC</td><td>48</td><td>3.8E-16</td><td>No Hit</td><td></td><td></td></tr><tr><td>ACACAACACAC</td><td>45</td><td>2.2E-10</td><td>No Hit</td><td></td><td></td></tr><tr><td>AAAATAAAAATAAAA</td><td>9</td><td>2.27E-7</td><td>No Hit</td><td></td><td></td></tr><tr><td>AATAAAAAAATAAAA</td><td>8</td><td>1.51E-7</td><td>No Hit</td><td></td><td></td></tr><tr><td>AGCTAGCTAGC</td><td>6</td><td>1.47E-7</td><td>No Hit</td><td></td><td></td></tr><tr><td>AGCGAGCGAGC</td><td>4</td><td>6.23E-8</td><td>No Hit</td><td></td><td></td></tr><tr><td>AGCAAGCTAGC</td><td>3</td><td>2.47E-7</td><td>No Hit</td><td></td><td></td></tr></table>
9d6c6b6f03e438ce6060377c2b76125a75a6d839d88a58f98ceb4feb71d1d276.png	simple	<table><tr><td></td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1 year follow up</td><td>66</td><td>81.5</td></tr><tr><td>Lost to follow up</td><td>5</td><td>6</td></tr><tr><td>Deceased at 1 year</td><td>10</td><td>12.3</td></tr><tr><td>Referral done to specialized cardiology center</td><td>37</td><td>45.6</td></tr><tr><td>Underwent Exercise ECG</td><td>22</td><td>27</td></tr><tr><td>Underwent Coronary angiogram</td><td>10</td><td>12.3</td></tr><tr><td>Underwent Revascularization</td><td>7</td><td>7.3</td></tr><tr><td>Re-admitted with Coronary events</td><td>6</td><td>7.4</td></tr></table>
e2f1208ba786b914631177c52ff85fcd9c204f7489633c6035e7ab3eb00f17ae.png	simple	<table><tr><td>Modification</td><td>Hypotheses tested</td></tr><tr><td>Ranking task</td><td>Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses).</td></tr><tr><td>BTD/WTD split</td><td>Separating the BTD and WTD cTTO tasks will reduce the inconsistencies of the valuations and improve the overall data quality (i.e. more WTD responses, higher values for mild heath state and fewer spikes).</td></tr><tr><td>Feedback module</td><td>Presenting respondents with the rank ordering implied by their cTTO valuations will reduce the inconsistencies as they will identify and flag problematic valuations for removal from the data.</td></tr></table>
69f72db68beb2c0a4287ed2b603749d8840a2eedb76b699b5e057fc0a57275d2.png	simple	<table><tr><td>Viroid small RNAs (vd-sRNAs)</td><td>Reference</td></tr><tr><td>vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis</td><td>Di Serio et al., 2009; Navarro et al., 2012a</td></tr><tr><td>Gaining further insights into the genesis and role of vd-RNAs of hop stunt viroid and grapevine yellow speckle viroid 1 in plant–viroid interaction</td><td>Navarro et al., 2009</td></tr><tr><td>vd-sRNAs from PSTVd-infected wild-type and RDR6i <i>Nicotiana benthamiana</i> plants accumulate to levels paralleling their genomic RNA, display similar patterns with prevailing 22- or 21-nt plus-strand species, and adopt strand-specific hot spot profiles</td><td>Di Serio et al., 2010</td></tr><tr><td>The pathway involved in the biogenesis of vd-sRNAs of hop stunt viroid was studied and revealed</td><td>Martinez et al., 2010</td></tr><tr><td>Characterization of vd-sRNA of hop stunt viroid, grapevine yellow speckle 1 and grapevine yellow speckle 2 viroids in grapevine</td><td>Alabi et al., 2012</td></tr><tr><td>vd-sRNAs of peach latent mosaic viroid (PLMVd) were characterized. Similarly to host microRNAs (miRNAs), two PLMVd vd-sRNA derived from the pathogenic determinant of an extreme albinism direct cleavage of a specific host mRNA, strongly suggesting their involvement in symptom expression</td><td>Navarro et al., 2012a</td></tr><tr><td>Based on the observation that viroid-infected plants generate vd-sRNAs 21–24 nt, an approach was developed to utilize several bioinformatic tools for identifying novel and known viroids and viroid-like circular RNAs in sRNA libraries</td><td>Wu et al. (2012)</td></tr><tr><td>vd-sRNAs derived from potato spindle tuber viroid variants inducing different symptoms, may aim at multiple and different host mRNA targets</td><td>Wang et al., 2011; Piernikarczyk et al., 2013</td></tr><tr><td>Computational algorithms as bioinformatic tools were utilized to identify circular RNAs of viroid or satellite sRNAs</td><td>Zhang et al., 2014</td></tr><tr><td>Extending the host range of apple dimple fruit viroid to fig</td><td>Chiumenti et al., 2014</td></tr><tr><td>Inoculation with a single variant of peach latent mosaic viroid generates a highly heterogeneous progeny within a single infected peach seedling. The most distant variants displayed a 17% variation level when compared to the parent sequence</td><td>Glouzon et al., 2014</td></tr><tr><td>vd-sRNAs of potato spindle tuber viroid (PSTVd) and effects of artificial miRNA derived from PSTVd-mild or -severe infected plants were analyzed. Differences in the distribution of vdsRNAs hot spots were observed. Data suggest involvement of vd-sRNAs in symptom expression</td><td>Adkar-Purushothama et al., 2015; Avina-Padilla et al., 2015</td></tr><tr><td>Extending the host range of hop stunt viroid to chickpea</td><td>Pirovano et al., 2015</td></tr></table>
4526840ac44e1c429c75e03afeb2946241b4800bcf5c21c018fdbe4f5af0d75c.png	complex	<table><tr><td rowspan="2">Species</td><td rowspan="2">Specimen voucher</td><td colspan="4"><i>cox</i>1<sup><i>a</i></sup></td><td colspan="4">ITS-2<sup>b</sup></td></tr><tr><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><td>Pairwise difference (%)</td><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><td>Pairwise difference (%)</td></tr><tr><td rowspan="2"><i>I. auritulus</i></td><td>S63</td><td>KY213767</td><td>674</td><td>31.75</td><td rowspan="2">1.1</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S64</td><td>KY213768</td><td>674</td><td>31.75</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="2"><i>I. anatis</i></td><td>S28</td><td>KY213769</td><td>674</td><td>31.90</td><td rowspan="2">1.2</td><td>KY213757</td><td>703</td><td>54.62</td><td>–</td></tr><tr><td>S29</td><td>KY213770</td><td>674</td><td>31.90</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td rowspan="5"><i>I. holocyclus</i></td><td>S1</td><td>KY213782</td><td>674</td><td>32.20</td><td rowspan="5">0.2–0.9</td><td>KY213766</td><td>679</td><td>55.38</td><td rowspan="5">1.4–8.6</td></tr><tr><td>S4</td><td>KY213783</td><td>674</td><td>32.05</td><td>KY213765</td><td>630</td><td>55.70</td></tr><tr><td>S37</td><td>KY213781</td><td>674</td><td>32.34</td><td>KY213756</td><td>684</td><td>55.40</td></tr><tr><td>S17</td><td>KY213779</td><td>674</td><td>32.49</td><td>KY213762</td><td>638</td><td>55.80</td></tr><tr><td>S39</td><td>KY213780</td><td>674</td><td>31.90</td><td>KY213755</td><td>676</td><td>55.47</td></tr><tr><td rowspan="6"><i>I. myrmecobii</i></td><td>S26</td><td>KY213784</td><td>674</td><td>30.86</td><td rowspan="6">0.2–1.1</td><td>KY213758</td><td>649</td><td>53.80</td><td rowspan="6">0.8–3.6</td></tr><tr><td>S46</td><td>KY213785</td><td>674</td><td>31.16</td><td>KY213753</td><td>656</td><td>53.70</td></tr><tr><td>S56</td><td>KY213786</td><td>674</td><td>31.00</td><td>KY213752</td><td>657</td><td>53.60</td></tr><tr><td>S44</td><td>KY213787</td><td>674</td><td>31.00</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S25</td><td>KY213788</td><td>674</td><td>30.70</td><td>KY213759</td><td>668</td><td>53.30</td></tr><tr><td>S42</td><td>KY213789</td><td>674</td><td>30.86</td><td>KY213754</td><td>647</td><td>53.80</td></tr><tr><td rowspan="4"><i>I. cornuatus</i></td><td>S19</td><td>KY213792</td><td>674</td><td>30.42</td><td rowspan="4">0.2–1.2</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S20</td><td>KY213793</td><td>674</td><td>30.12</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S18</td><td>KY213790</td><td>674</td><td>30.12</td><td>KY213761</td><td>654</td><td>53.36</td><td>–</td></tr><tr><td>S41</td><td>KY213791</td><td>674</td><td>30.27</td><td>-</td><td>–</td><td>–</td><td>–</td></tr><tr><td><i>I. dendrolagi</i></td><td>S14</td><td>KY213776</td><td>674</td><td>30.70</td><td>–</td><td>KY213763</td><td>672</td><td>55.20</td><td>–</td></tr><tr><td rowspan="2"><i>I. trichosuri</i></td><td>S23</td><td>KY213777</td><td>674</td><td>31.90</td><td rowspan="2">0.3</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S21</td><td>KY213778</td><td>674</td><td>31.90</td><td>KY213760</td><td>704</td><td>56.39</td><td>–</td></tr><tr><td rowspan="3"><i>I. hirsti</i></td><td>S10</td><td>KY213773</td><td>674</td><td>33.10</td><td rowspan="3">0.2–0.3</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S12</td><td>KY213774</td><td>674</td><td>33.38</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S9</td><td>KY213775</td><td>674</td><td>33.23</td><td>KY213764</td><td>667</td><td>56.97</td><td>–</td></tr><tr><td rowspan="2"><i>I. tasmani</i></td><td>S68</td><td>KY213771</td><td>674</td><td>32.20</td><td rowspan="2">10.9</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td>S69</td><td>KY213772</td><td>674</td><td>32.05</td><td>–</td><td>–</td><td>–</td><td>–</td></tr></table>
c32fcb0e0118c88a3a96412e8581206ba1ef06cb0ff6984f1ea5e7c4c05c7217.png	complex	<table><tr><td>Parameter</td><td colspan="2">Value</td></tr><tr><td></td><td colspan="2">n = 4068</td></tr><tr><td>Age (n,%)</td><td></td><td></td></tr><tr><td> 18-34</td><td>20</td><td>0.5</td></tr><tr><td> 35-44</td><td>108</td><td>2.7</td></tr><tr><td> 45-54</td><td>513</td><td>12.6</td></tr><tr><td> 55-64</td><td>1,481</td><td>36.4</td></tr><tr><td> > = 65</td><td>1,946</td><td>47.8</td></tr><tr><td>Geographic region (n,%)</td><td></td><td></td></tr><tr><td> Northeast</td><td>538</td><td>13.2</td></tr><tr><td> Northcentral</td><td>1,249</td><td>30.7</td></tr><tr><td> South</td><td>2,071</td><td>50.9</td></tr><tr><td> West</td><td>208</td><td>5.1</td></tr><tr><td>Payer type (n,%)</td><td></td><td></td></tr><tr><td> HMO</td><td>81</td><td>2.0</td></tr><tr><td> Indemnity</td><td>1,814</td><td>44.6</td></tr><tr><td> PPO</td><td>1,210</td><td>29.7</td></tr><tr><td> POS</td><td>941</td><td>23.1</td></tr><tr><td> Other</td><td>21</td><td>0.5</td></tr><tr><td>Comorbidities (n,%)</td><td></td><td></td></tr><tr><td> Cerebrovascular Disease</td><td>426</td><td>10.5</td></tr><tr><td> Coronay heart disease</td><td>910</td><td>22.4</td></tr><tr><td> Heart failure</td><td>66</td><td>1.6</td></tr><tr><td> Peripheral arterial disease</td><td>165</td><td>4.1</td></tr><tr><td> Diabetes</td><td>808</td><td>19.9</td></tr><tr><td> Kidney Disease</td><td>60</td><td>1.5</td></tr><tr><td> Liver Disease</td><td>272</td><td>6.7</td></tr><tr><td> Respiratory Disease</td><td>2,384</td><td>58.6</td></tr><tr><td>Health care expenditures prior to index date (mean, SD)</td><td></td><td></td></tr><tr><td> -365 days</td><td>28,562</td><td>31,136</td></tr></table>
344c047d125c8b8fce7adbac1aa7cffe188723c542bbe3dd679b10d8c25321b4.png	complex	<table><tr><td>Combination</td><td colspan="3">Nr of MRSA strains (%) for which combinations gave</td></tr><tr><td></td><td>Synergy</td><td>No interaction</td><td>Antagonism</td></tr><tr><td>LVX + VA (n = 50)</td><td>16 (32)</td><td>34 (68)</td><td>0</td></tr><tr><td>LVX + TEC (n = 50)</td><td>9 (18)</td><td>41 (82)</td><td>0</td></tr><tr><td>CTX + VA (n = 50)</td><td>23 (46)</td><td>27 (54)</td><td>0</td></tr><tr><td>CTX + TEC (n = 50)</td><td>43 (86)</td><td>7 (14)</td><td>0</td></tr><tr><td>LVX + VA + AMK (n = 25)</td><td>5 (20)</td><td>20 (80)</td><td>0</td></tr><tr><td>LVX + TEC + AMK (n = 25)</td><td>10 (40)</td><td>15 (60)</td><td>0</td></tr><tr><td>LVX + VA + CAZ (n = 25)</td><td>15 (60)</td><td>10 (40)</td><td>0</td></tr><tr><td>LVX + TEC + CAZ (n = 25)</td><td>20 (80)</td><td>5 (20)</td><td>0</td></tr><tr><td>LVX + VA + FEP (n = 25)</td><td>10 (40)</td><td>15 (60)</td><td>0</td></tr><tr><td>LVX + TEC + FEP (n = 25)</td><td>10 (40)</td><td>15 (60)</td><td>0</td></tr><tr><td>LVX + VA + IPM (n = 25)</td><td>5 (20)</td><td>20 (80)</td><td>0</td></tr><tr><td>LVX + TEC + IPM (n = 25)</td><td>10 (40)</td><td>15 (60)</td><td>0</td></tr><tr><td>LVX + VA + TZP (n = 25)</td><td>5 (20)</td><td>20 (80)</td><td>0</td></tr><tr><td>LVX + TEC + TZP (n = 25)</td><td>20 (80)</td><td>5 (20)</td><td>0</td></tr></table>
81dc4443e2381ce07b834592708047f19ea47c10afca1ab8ef86a0b99dee720b.png	complex	<table><tr><td></td><td>Attack-free periods Mean ± S.D.</td><td>Control Mean ± S.D.</td><td>P</td></tr><tr><td>IOP, mmHg</td><td><i>14,11 ± 2,88</i></td><td>15,81 ± 0,81</td><td rowspan="2">0,07</td></tr><tr><td>Range</td><td>(11–20)</td><td>(11–20)</td></tr><tr><td>AL, mm</td><td>23,08 ± 1,2</td><td><i>23,3 ± 0,7</i></td><td>0,4</td></tr><tr><td>Pachymetry</td><td></td><td></td><td rowspan="2">0,5</td></tr><tr><td>CCT, μm</td><td>538,13 ± 35,42</td><td>533,20 ± 31,85</td></tr><tr><td>ACD, mm</td><td>3,48 ± 0,23</td><td>3,52 ± 0,25</td><td>0,4</td></tr><tr><td>Keratometry readings</td><td></td><td></td><td></td></tr><tr><td><i>K</i>1, D</td><td>43,11 ± 1,72</td><td>43,23 ± 1,52</td><td>0,7</td></tr><tr><td><i>K</i>2, D</td><td>44,23 ± 2,03</td><td>44,19 ± 1,50</td><td>0,9</td></tr><tr><td>LT, mm</td><td>4,47 ± 3,75</td><td>3,76 ± 0,31</td><td>0,3</td></tr><tr><td>PD, mm</td><td>5,99 ± 0,92</td><td>5,81 ± 1,07</td><td>0,4</td></tr><tr><td>WtW, mm</td><td>12,20 ± 0,44</td><td></td><td>0,112</td></tr></table>
7a3c4d265f40377bac54487b45b714ba7d43d5f8a701f4c4f58c80c61c34c59a.png	simple	<table><tr><td>Gene</td><td>Number of exons</td><td>Number of mutations worldwide*</td><td>Number of homopolymer repeats in CDS</td><td>Function in hearing process</td></tr><tr><td><i>GJB2</i></td><td>2</td><td>> 220</td><td>0</td><td>ion homeostasis</td></tr><tr><td><i>SLC26A4</i></td><td>21</td><td>43</td><td>7</td><td>ion homeostasis</td></tr><tr><td><i>MYO15A</i></td><td>66</td><td>28</td><td>8</td><td>hair bundle, motor protein</td></tr><tr><td><i>OTOF</i></td><td>48</td><td>26</td><td>4</td><td>exocytose at auditory ribbon synapse</td></tr><tr><td><i>CDH23</i></td><td>69</td><td>21</td><td>4</td><td>hair bundle, adhesion protein</td></tr><tr><td><i>TMC1</i></td><td>24</td><td>20</td><td>4</td><td>unknown function</td></tr><tr><td><i>TMPRSS3</i></td><td>13</td><td>16</td><td>3</td><td>unknown function</td></tr><tr><td><i>TECTA</i></td><td>23</td><td>10</td><td>2</td><td>extracellular matrix protein</td></tr><tr><td><i>TRIOBP</i></td><td>24</td><td>9</td><td>7</td><td>hair bundle, cytoskeletal formation</td></tr><tr><td><i>TMIE</i></td><td>4</td><td>8</td><td>0</td><td>unknown function</td></tr><tr><td><i>PJVK</i></td><td>7</td><td>7</td><td>3</td><td>signaling of hair cells and neurons</td></tr><tr><td><i>ESPN</i></td><td>13</td><td>6</td><td>1</td><td>hair bundle, cytoskeletal formation</td></tr><tr><td><i>PCDH15</i></td><td>33</td><td>5</td><td>8</td><td>hair bundle, adhesion protein</td></tr><tr><td><i>ESRRB</i></td><td>12</td><td>5</td><td>1</td><td>transcription factor</td></tr><tr><td><i>MYO7A</i></td><td>49</td><td>5</td><td>5</td><td>hair bundle, motor proteins</td></tr></table>
50da0d33ff7a4b971732535ddf6f227fbf25b07f97e2144f417c740529eda003.png	complex	<table><tr><td rowspan="3">Parameter</td><td colspan="6">Mean value for group ± SE<sup><i>a</i></sup></td></tr><tr><td rowspan="2">NI</td><td rowspan="2">Pretherapy (120 dpi)</td><td colspan="4">Posttherapy (180–200 dpi)</td></tr><tr><td>Veh</td><td>PTX</td><td>Bz</td><td>Bz+PTX</td></tr><tr><td>Parasitemia level (10<sup>4</sup> parasites/ml)</td><td>0</td><td>53 ± 10</td><td>56 ± 45</td><td>23 ± 8.5 #</td><td>9.9 ± 9.9 ##</td><td>5.7 ± 3 ###</td></tr><tr><td>% of mice with arrhythmia</td><td>0</td><td>100 ± 0 *</td><td>100 ± 0 </td><td>100 ± 0 </td><td>100 ± 0 </td><td>48 ± 3 #,§,‡,†</td></tr><tr><td>No. of flutter events/2 min</td><td>0</td><td>0</td><td>41.3 ± 2.6 ,†††</td><td>29.5 ± 0.5 #,†††</td><td>0 ###,§§§</td><td>0 ###,§§§</td></tr><tr><td>% of mice with AVB2</td><td>0</td><td>86 ± 6 </td><td>78 ± 7 </td><td>82 ± 2</td><td>58 ± 1.5 §,†</td><td>41 ± 2 #,§,‡,††</td></tr><tr><td>No. of AVB2 events/2 min</td><td>0</td><td>212 ± 11 </td><td>292 ± 18 *,††</td><td>47 ± 1.5 ###,†††</td><td>50 ± 2.8 ###,†††</td><td>51 ± 1.2 ###,†††</td></tr><tr><td>QRS (ms)</td><td>11 ± 0.14</td><td>13 ± 0.48 </td><td>13.4 ± 0.3 *</td><td>11.8 ± 0.2 ##</td><td>11.9 ± 0.4 #</td><td>10.9 ± 0.3 ###,††</td></tr><tr><td>QTc (ms)</td><td>77 ± 2.5</td><td>89.9 ± 2.4 </td><td>94.2 ± 2.7 ***</td><td>88.3 ± 3.4</td><td>86.9 ± 3.9</td><td>83.2 ± 3.4#</td></tr></table>
609a9bf23144ac74c901d3e0ba1507b6dba7274205e0dd13ba3ea3f27ca6010d.png	complex	<table><tr><td rowspan="2">Parameter</td><td colspan="3">Temperature (K)</td></tr><tr><td>293 </td><td>303 </td><td>313 </td></tr><tr><td>−Δ<i>G</i>° (kJ mol<sup>−1</sup>)</td><td>6.543</td><td>6.063</td><td>5.687</td></tr><tr><td>−Δ<i>H</i>° (kJ mol<sup>−1</sup>)</td><td>16.869</td><td> </td><td> </td></tr><tr><td>−Δ<i>S</i>° (kJ mol<sup>−1</sup> K<sup>−1</sup>)</td><td>0.0353</td><td> </td><td> </td></tr><tr><td><i>E</i><sub><i>a</i></sub> (kJ mol<sup>−1</sup>)</td><td>3.309</td><td> </td><td> </td></tr></table>
a327b8cca8006d6f7c06986145863ba2e641b9cbfdee803a533298b60a004b3f.png	simple	<table><tr><td>Temperature (°C)</td><td>−40</td><td>−20</td><td>0</td><td>+20</td><td>+40</td><td>+60</td></tr><tr><td>Resonant frequency of the upper resonator (Hz)</td><td>31,331.12</td><td>31,379.3</td><td>31,426.16</td><td>31,462.37</td><td>31,496.56</td><td>31,514.02</td></tr><tr><td>Resonant frequency of the lower resonator (Hz)</td><td>31,439.55</td><td>31,486.05</td><td>31,531.33</td><td>31,565.55</td><td>31,598.49</td><td>31,615.11</td></tr><tr><td>Frequency difference (Hz)</td><td>108.43</td><td>106.75</td><td>105.17</td><td>103.18</td><td>101.93</td><td>101.09</td></tr></table>
a6ecd755c552375672789dd1962a36c614adf6104321133a04609f3085c38769.png	simple	<table><tr><td>Participant code</td><td>Sex</td><td>Age (yrs)</td><td>BMI (kg/m<sup>2</sup>)</td><td>Injury level and AIS score</td><td>Years since SCI</td><td>Medications</td><td>Treatment</td></tr><tr><td>1</td><td>M</td><td>46</td><td>32.9</td><td>C5A</td><td>23.3</td><td>Baclofen, Temazepam</td><td>CPAP</td></tr><tr><td>2</td><td>M</td><td>68</td><td>27.7</td><td>C4A</td><td>23.9</td><td>Baclofen </td><td>CPAP</td></tr><tr><td>3</td><td>F</td><td>28</td><td>20.3</td><td>C5A</td><td>4.10</td><td>Baclofen, Diazepam</td><td>—</td></tr><tr><td>4</td><td>M</td><td>42</td><td>20.8</td><td>C6A</td><td>17.10</td><td>Baclofen, Diazepam</td><td>Oral Splint</td></tr><tr><td>5</td><td>M</td><td>26</td><td>18.5</td><td>C6A</td><td>10.10</td><td>Baclofen </td><td>—</td></tr><tr><td>Positive control</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>1</td><td>M</td><td>43</td><td>24.8</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td>2</td><td>F</td><td>31</td><td>20.7</td><td>—</td><td>—</td><td>—</td><td>—</td></tr></table>
65bda91d12487ccb97d2350910e10214894bd133ee6f2e32ba9df100f737e7b8.png	complex	<table><tr><td> </td><td> </td><td colspan="2">Women</td><td colspan="2">Men</td></tr><tr><td> </td><td> </td><td colspan="2">N = 214</td><td colspan="2">N = 154</td></tr><tr><td> </td><td> </td><td>OR</td><td>p</td><td>OR</td><td>p</td></tr><tr><td>Surgical specialties</td><td>Combining work with family</td><td>0.4 (0.3–0.6)</td><td>.000</td><td>0.4 (0.3–0.7)</td><td>.000</td></tr><tr><td> </td><td>Good salary<sup>a</sup></td><td>1.9 (1.2–3.0)</td><td>.004</td><td>0.8 (0.5–1.3)</td><td>NS</td></tr><tr><td> </td><td>In line with technical skills</td><td>1.4 (1.0–1.9)</td><td>.034</td><td>1.9 (1.2–3.0)</td><td>.011</td></tr><tr><td> </td><td>Lots of direct patient contact</td><td>0.9 (0.6–1.3)</td><td>NS</td><td>0.6 (0.4–0.9)</td><td>.018</td></tr><tr><td>Non-surgical specialties</td><td>Research opportunities</td><td>1.4 (1.0–1.9)</td><td>.023</td><td>1.9 (1.3–2.9)</td><td>.001</td></tr><tr><td> </td><td>Good salary</td><td>0.4 (0.2–0.6)</td><td>.000</td><td>0.8 (0.5–1.3)</td><td>NS</td></tr><tr><td> </td><td>Interesting content</td><td>2.4 (1.0–5.5)</td><td>.048</td><td>1.7 (0.8–3.9)</td><td>NS</td></tr><tr><td>Family medicine</td><td>Lots of direct patient contact</td><td>3.7 (1.8–7.9)</td><td>.001</td><td>2.9 (1.4–6.0)</td><td>.005</td></tr><tr><td> </td><td>Career prospects<sup>a</sup></td><td>0.4 (0.2–0.7)</td><td>.002</td><td>0.8 (0.4–1.5)</td><td>NS</td></tr><tr><td> </td><td>Combining work with family</td><td>2.3 (1.3–4.2)</td><td>.004</td><td>1.6 (0.9 –2.9)</td><td>NS</td></tr><tr><td> </td><td>Good salary</td><td>1.9 (1.1–3.3)</td><td>.018</td><td>1.7 (0.9–3.2)</td><td>NS</td></tr><tr><td> </td><td>Interesting content</td><td>0.4 (0.2–0.9)</td><td>.024</td><td>0.8 (0.4–1.9)</td><td>NS</td></tr><tr><td> </td><td>In line with technical skills</td><td>0.6 (0.4–1.0)</td><td>.045</td><td>0.7 (0.5–1.2)</td><td>NS</td></tr><tr><td> </td><td>Research opportunities</td><td>0.8 (0.6–1.3)</td><td>NS</td><td>0.6 (0.4–1.0)</td><td>.031</td></tr><tr><td>Uncertain</td><td>Combining work with family</td><td>2.1 (1.5–3.1)</td><td>.000</td><td>1.8 (1.2–2.7)</td><td>.005</td></tr><tr><td> </td><td>Lots of direct patient contact</td><td>0.6 (0.4–0.8)</td><td>.003</td><td>1.0 (0.7–1.5)</td><td>NS</td></tr></table>
d9f4a228207e26fbd3dd1feac24d3fc15c4f90f4bd3d84754cf1832653aeeeb8.png	simple	<table><tr><td>Characteristics</td><td>THC score mean (SE)</td><td>CH score mean (SE)</td><td>PH score mean (SE)</td><td><i>P</i> value</td></tr><tr><td>First contact and continuity</td><td>95.40 (0.39)</td><td>90.93 (0.52)</td><td>85.23 (0.51)</td><td><0.001</td></tr><tr><td>Comprehensiveness (medical care)</td><td>80.9 (0.99)</td><td>78.05 (1.03)</td><td>80.45 (0.67)</td><td>0.075</td></tr><tr><td>Comprehensiveness (social care)</td><td>90.33 (0.84)</td><td>85.39 (0.73)</td><td>81.91 (0.61)</td><td><0.001</td></tr><tr><td>First contact (access)</td><td>80.16 (1.15)</td><td>69.21 (1.40)</td><td>60.04 (0.86)</td><td><0.001</td></tr><tr><td>Coordination</td><td>91.65 (0.73)</td><td>84.39 (0.91)</td><td>77.65 (0.75)</td><td><0.001</td></tr><tr><td>Family centeredness</td><td>90.34 (0.68)</td><td>87.93 (0.60)</td><td>84.18 (0.53)</td><td><0.001</td></tr><tr><td>Community orientation</td><td>87.98 (0.87)</td><td>80.36 (0.85)</td><td>67.36 (0.78)</td><td><0.001</td></tr><tr><td>Same doctor</td><td>66.42 (1.54)</td><td>70.95 (1.26)</td><td>74.44 (0.95)</td><td><0.001</td></tr><tr><td>Stableness</td><td>45.37 (1.18)</td><td>43.14 (1.04)</td><td>48.75 (0.92)</td><td>0.001</td></tr><tr><td>Total</td><td>86.64 (0.49)</td><td>82.01 (0.50)</td><td>77.42 (0.38)</td><td><0.001</td></tr></table>
64614a2c87183ea4fced537834c7c9e1550ddef18f72a3b13ef598a943c3d59b.png	complex	<table><tr><td>Authors</td><td>Intervention</td><td>Patient Population</td><td>Design</td><td>No. of Patients</td><td>Outcome</td></tr><tr><td rowspan="2">Pizzocarro et al<sup>15</sup></td><td rowspan="2">IFN-α2b <i>v</i> placebo</td><td rowspan="2">Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)</td><td rowspan="2">Multicenter, randomized, controlled trial</td><td rowspan="2">247</td><td>5-year OS: 0.665 (control) <i>v</i> 0.660 (treatment) (HR 1.040; 95% CI, 0.671 - 1.613, <i>P =</i> 0.861)</td></tr><tr><td>5-year DFS: 0.671 (control) <i>v</i> 0.567 (treatment) (HR 1.412; 95% CI, 0.927–2.149, <i>P = .</i>107)</td></tr><tr><td rowspan="3">Messing et al<sup>16</sup></td><td rowspan="3">IFN-α-NL <i>v</i> observation</td><td rowspan="3">pT3–4a and/or node-positive)</td><td rowspan="3">Multicenter, randomized, controlled trial</td><td rowspan="3">283</td><td>At 10.4 years median follow-up:</td></tr><tr><td>Median survival: 7.4 years (control) <i>v</i> 5.1 years (treatment) (<i>P = .</i>09).</td></tr><tr><td>DFS: 3.0 years (control) <i>v</i> 2.2years (treatment) (<i>P = .</i>33)</td></tr><tr><td rowspan="2">Clark et al<sup>17</sup></td><td rowspan="2">IL-2 <i>v</i> observation</td><td rowspan="2">T3b-4 or N1–3 (LA) or M1</td><td rowspan="2">Multicenter, randomized, controlled trial</td><td rowspan="2">69 total; 44 LA, 25 M1 disease</td><td>2-year DFS: 48% (control in LA patients) <i>v</i> 53% (treatment in LA patients) (<i>P =</i> 0.73)</td></tr><tr><td>2-year OS: 77% (control in LA patients) <i>v</i> 86% (treatment in LA patients) (<i>P = .</i>38)</td></tr><tr><td rowspan="2">Passalacqua et al<sup>18</sup></td><td rowspan="2">IL-2 and IFN-α <i>v</i> observation</td><td rowspan="2">pT<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub> a-b-c; pN0-pN3, M0</td><td rowspan="2">Multicenter, randomized, controlled trial</td><td rowspan="2">310</td><td>5-year DFS: 0.73 (control) <i>v</i> 0.73 (treatment)</td></tr><tr><td>10-year DFS: 0.60 (control) <i>v</i> 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, <i>P =</i> 0.47)</td></tr><tr><td rowspan="7">Atzpodien et al<sup>19</sup></td><td rowspan="7">IL-2 and IFN-α2a and intravenous 5 <i>v</i> fluorouracil</td><td rowspan="7">pT3b/c pN0 or pT4pN0), pN, complete resection of tumor relapse or solitary metastasis (R0)</td><td rowspan="7">Multicenter, randomized, controlled trial</td><td rowspan="7">203</td><td>At median follow-up of 4.3 years:</td></tr><tr><td>2-year OS: 91% (control) <i>v</i> 81% (treatment)</td></tr><tr><td>5-year OS: 76% (control) <i>v</i> 58% (treatment)</td></tr><tr><td>8-year OS: 66% (control) <i>v</i> 58% (treatment) (<i>P =</i> 0.0278)</td></tr><tr><td>2-year DFS: 62% (control) <i>v</i> 54% (treatment)</td></tr><tr><td>5-year DFS: 49% (control) <i>v</i> 42% (treatment)</td></tr><tr><td>8-year DFS: 49% (control) <i>v</i> 39% (treatment) (<i>P =</i> 0.2398)</td></tr><tr><td rowspan="2">Aitchison et al<sup>22</sup></td><td rowspan="2">IL-2 and IFN-α2a and intravenous 5-fluorouracil</td><td rowspan="2">T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion</td><td rowspan="2">Multicenter, randomized, controlled trial</td><td rowspan="2">309</td><td>3-year DFS: 50% (control) <i>v</i> 60% (treatment) (HR 0.87; 95% CI, 0.63-1.20)</td></tr><tr><td>5 year OS: 60% (control) <i>v</i> 68% (treatment) (HR 0.91; 95% CI, 0.60–1.38)</td></tr><tr><td rowspan="3">Galligioni et al<sup>24</sup></td><td rowspan="3">Autologous irradiated tumor cells & BCG <i>v</i> observation</td><td rowspan="3">Stages I, II, and III</td><td rowspan="3">Prospective, randomized, controlled trial</td><td rowspan="3">120</td><td>At 61 months median follow-up:</td></tr><tr><td>5-year OS: 78% (control) <i>v</i> 69% (treatment)</td></tr><tr><td>5-year DFS: 72% (control) <i>v</i> 63% (treatment)</td></tr><tr><td rowspan="2">Adler et al<sup>25</sup></td><td rowspan="2">Autologous irradiated tumor cells & BCG & hormone <i>v</i> hormone</td><td rowspan="2">All stages</td><td rowspan="2">Prospective, randomized, controlled trial</td><td rowspan="2">43</td><td>Trend for prolongation of DFS for stage I, II, and III</td></tr><tr><td>(<i>P</i><.1)</td></tr><tr><td rowspan="3">Wood et al<sup>26</sup></td><td rowspan="3">Autologous, tumor-derived heat-shock protein (glycoprotein 96)–peptide complex (HSPPC-96; vitespen) <i>v</i> observation</td><td rowspan="3">cT1b–T4 N0 M0, or cT any N1-2 M0</td><td rowspan="3">Multicenter, randomized, controlled trial</td><td rowspan="3">819</td><td>At 1.9 years median follow-up:</td></tr><tr><td>Recurrence: 39.8% (control) <i>v</i> 37.7% (treatment) (HR 0·923; 95% CI, 0·729–1·169, <i>P =</i> .506)</td></tr><tr><td>OS not mature</td></tr><tr><td rowspan="4">Jocham et al<sup>27</sup></td><td rowspan="4">Autologous renal tumor cells (Reniale)</td><td rowspan="4">pT2–3b pN0–3 M0</td><td rowspan="4">Multicenter, randomized, controlled trial</td><td rowspan="4">558</td><td>At 5-year follow-up:</td></tr><tr><td>DFS: 67.8% (control) <i>v</i>77.4% (treatment) (<i>P</i> = .0204) At 70-month follow-up:</td></tr><tr><td>DFS: 59.3% (control) <i>v</i> 72% (treatment)</td></tr><tr><td>HR for tumor progression: 1.58 (95% CI 1.05–2.37) and 1.59 (1.07–2.36) (<i>P = .</i>0204)</td></tr></table>
9cbc7db15d5507d810ead300e7144942aa102881844e8f20a080dc57f636df25.png	simple	<table><tr><td>Species</td><td>Fu’s <i>FS</i></td><td>Tajima’s <i>D</i></td><td>SSD</td><td><i>rg</i></td></tr><tr><td><i>H. bovis</i></td><td>−12.795*</td><td>−2.031 </td><td>0.001</td><td>0.035</td></tr><tr><td><i>H. sinense</i></td><td>−19.809*</td><td>−2.320</td><td>0.001</td><td>0.033</td></tr></table>
e759968a4778e9d325a31ea72e252f0fff40ad908fe50b8e268222cb0bf1f2bf.png	simple	<table><tr><td>Primary</td><td>Definition</td></tr><tr><td>Tumor (T)</td><td></td></tr><tr><td>Tx</td><td>Primary tumor cannot be assessed</td></tr><tr><td>T0</td><td>No evidence of primary tumor</td></tr><tr><td>Tis</td><td>Carcinoma in situ</td></tr><tr><td>T1</td><td>Tumor 2 cm or less in greatest dimension and no medullary bone invasion</td></tr><tr><td>T2</td><td>Tumor more than 2 cm but not more than 4 cm in greatest dimension and no bone invasion or tumor 2 cm or less in greatest dimension with medullary bone invasion</td></tr><tr><td>T3</td><td>Tumor more than 4 cm in greatest dimension and no medullary bone invasion or tumor more than 2 cm but not more than 4 cm with medullary bone invasion</td></tr><tr><td>T4a</td><td>Tumor more than 4 cm in greatest dimension with medullary bone invasion or tumor invades into mandibular canal, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face</td></tr><tr><td>T4b</td><td>Tumor invades masticator space, pterygoid plates, or skull base; or encases internal carotid artery</td></tr></table>
bbdfd8defba185c77201196f24d50efe0e442122d3fe069b818ede18902d2920.png	simple	<table><tr><td>Location of study village</td><td>Types of prevention practices reported</td><td>Frequency & motivation for bed net use</td><td>Influences on preventative health behaviours</td><td>Community suggestions for participation in malaria elimination</td></tr><tr><td>North Tanna</td><td>Use of bed netsClean home/personalhygieneProtective clothingTidy village/sourceInsect spray</td><td>Some reported seasonal use others reported year round use (varies at household & individual levels)Motivation to nets for both mosquito nuisance and protection from malariaNet rarely used whentravelling</td><td>Health officers most influential (VHW, nurse)Church leaders, chiefs &Village eldersTeachersMothers most influentialon health behaviours ofchildrenRisk perceptionAcceptability andPractical issues</td><td>Take advice of village leadersSet example for othersTidy village/sourcereducton activitiesUse bed netsMosquito sprayand coilsUse fire/smoke for protection outsideImprove roads to Lenakel/closer clinics for treatment</td></tr><tr><td>Middle Bush</td><td>Use of bed netsClean homeTidy village/sourcereductionDrinking clean waterBlanket for protectionwhen sleeping duringtravel</td><td>Mostly seasonal use of bed netsPrimary motivation ismosquito nuiscanceNet rarely used whentravelling</td><td>Doctors & health officersCheif & church leadersTeachersHousehold heads influencefamily practicesMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues</td><td>Village leaders to spread messagesLeaders to set example for othersTidy village/sourcereduction activitiesUse bed netsImprove access to earlyand effectivetreatment</td></tr><tr><td>South Tanna</td><td>Use of bed netsClean home/personalhygieneTidy village/sourcereductionFire/smoke as repellentBlanket for protectionwhen travelling</td><td>Some reported seasonal use others year round use (varies at household &individual levels)Motivation to use nets forboth mosquito nuiscanceand protection frommalariaNet rarely used whentravelling</td><td>Health officers Church leaders, chief and village eldersHousehold heads influencefamilyMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues</td><td>Village leaders to encourage participationTidy village/sourcereduction activitiesUse bed netsSupport IRS</td></tr><tr><td>Homogeneity/ Heterogeneity of responses</td><td>Homogeneity in types of protection methods used across the 3 villages</td><td>Heterogeneity between the Middle Bush village and other 2 villages due to absence of malaria</td><td>Homogeneity in influences on health behaviours across the 3 villages</td><td>Homogeneity in ideas for participation in malaria prevention across the 3 villages</td></tr></table>
bd3dea0d9151d634f3d2bc7fc2f5ad94f2b893e81fa845f640953d3c22e1b094.png	complex	<table><tr><td rowspan="3">Sex and variable</td><td colspan="4">Blood pressure category</td><td rowspan="3"><i>P</i> for difference<sup>b</sup></td></tr><tr><td>Normal</td><td>Pre-</td><td>Stage 1</td><td>Stage 2<sup>a</sup></td></tr><tr><td>Men</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No. of participants</td><td>3309</td><td>5866</td><td>2874</td><td>4120</td><td> </td></tr><tr><td> Age, years</td><td>56.5 ± 8.4</td><td>58.6 ± 7.9</td><td>60.1 ± 7.4</td><td>62.2 ± 6.2</td><td><0.0001</td></tr><tr><td> Blood pressure, mm Hg</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Systolic</td><td>109.6 ± 6.8</td><td>127.7 ± 6.5</td><td>143.5 ± 7.5</td><td>144.7 ± 16.3</td><td><0.0001</td></tr><tr><td>Diastolic</td><td>67.9 ± 6.2</td><td>77.4 ± 6.5</td><td>85.7 ± 7.6</td><td>85.4 ± 11.0</td><td><0.0001</td></tr><tr><td> Body mass index, kg/m<sup>2</sup></td><td>22.9 ± 2.7</td><td>23.7 ± 2.8</td><td>24.3 ± 2.9</td><td>24.7 ± 2.9</td><td><0.0001</td></tr><tr><td> Total cholesterol, mmol/L</td><td>5.3 ± 0.9</td><td>5.3 ± 0.9</td><td>5.3 ± 0.9</td><td>5.3 ± 0.9</td><td>0.0168</td></tr><tr><td> HDL-cholesterol, mmol/L</td><td>1.4 ± 0.4</td><td>1.4 ± 0.3</td><td>1.4 ± 0.4</td><td>1.4 ± 0.4</td><td>0.2994</td></tr><tr><td> Triglycerides, mmol/L</td><td>1.5 ± 1.0</td><td>1.8 ± 1.2</td><td>1.9 ± 1.4</td><td>1.8 ± 1.2</td><td><0.0001</td></tr><tr><td> History of diabetes, %</td><td>7.1</td><td>9.3</td><td>10.9</td><td>13.6</td><td><0.0001</td></tr><tr><td> Smoking status, %</td><td> </td><td> </td><td> </td><td> </td><td><0.0001</td></tr><tr><td>Never</td><td>21.2</td><td>22.3</td><td>21.5</td><td>23.5</td><td> </td></tr><tr><td>Former</td><td>27.3</td><td>32.3</td><td>36.4</td><td>39.7</td><td> </td></tr><tr><td>Current</td><td>51.4</td><td>45.4</td><td>42.1</td><td>36.8</td><td> </td></tr><tr><td> Drinking habit, %</td><td> </td><td> </td><td> </td><td> </td><td><0.0001</td></tr><tr><td>None</td><td>31.7</td><td>25.0</td><td>21.0</td><td>19.0</td><td> </td></tr><tr><td>Sometimes</td><td>27.1</td><td>22.2</td><td>19.6</td><td>18.3</td><td> </td></tr><tr><td>Daily</td><td>41.3</td><td>52.8</td><td>59.4</td><td>62.7</td><td> </td></tr><tr><td colspan="6"> </td></tr><tr><td>Women</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No. of participants</td><td>7480</td><td>9371</td><td>3307</td><td>6099</td><td> </td></tr><tr><td> Age, years</td><td>56.4 ± 7.8</td><td>59.4 ± 7.1</td><td>60.8 ± 6.5</td><td>62.3 ± 5.6</td><td><0.0001</td></tr><tr><td> Blood pressure, mm Hg</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Systolic</td><td>108.1 ± 7.4</td><td>127.9 ± 6.2</td><td>144.8 ± 6.4</td><td>142.6 ± 16.5</td><td><0.0001</td></tr><tr><td>Diastolic</td><td>66.0 ± 6.4</td><td>75.5 ± 6.7</td><td>83.2 ± 7.7</td><td>81.8 ± 10.3</td><td><0.0001</td></tr><tr><td> Body mass index, kg/m<sup>2</sup></td><td>22.2 ± 2.8</td><td>23.2 ± 3.0</td><td>23.9 ± 3.2</td><td>24.6 ± 3.4</td><td><0.0001</td></tr><tr><td> Total cholesterol, mmol/L</td><td>5.5 ± 0.9</td><td>5.7 ± 0.9</td><td>5.8 ± 0.9</td><td>5.7 ± 0.8</td><td><0.0001</td></tr><tr><td> HDL-cholesterol, mmol/L</td><td>1.6 ± 0.4</td><td>1.6 ± 0.4</td><td>1.6 ± 0.4</td><td>1.5 ± 0.4</td><td><0.0001</td></tr><tr><td> Triglycerides, mmol/L</td><td>1.2 ± 0.7</td><td>1.4 ± 0.9</td><td>1.5 ± 0.9</td><td>1.5 ± 0.9</td><td><0.0001</td></tr><tr><td> History of diabetes, %</td><td>2.7</td><td>4.2</td><td>5.5</td><td>9.0</td><td><0.0001</td></tr><tr><td> Smoking status, %</td><td> </td><td> </td><td> </td><td> </td><td><0.0001</td></tr><tr><td>Never</td><td>87.9</td><td>92.3</td><td>92.6</td><td>93.1</td><td> </td></tr><tr><td>Former</td><td>2.3</td><td>1.7</td><td>1.5</td><td>1.7</td><td> </td></tr><tr><td>Current</td><td>9.8</td><td>6.0</td><td>5.9</td><td>5.2</td><td> </td></tr><tr><td> Drinking habit, %</td><td> </td><td> </td><td> </td><td> </td><td><0.0001</td></tr><tr><td>None</td><td>74.0</td><td>76.6</td><td>77.5</td><td>79.8</td><td> </td></tr><tr><td>Sometimes</td><td>20.0</td><td>17.9</td><td>16.8</td><td>14.9</td><td> </td></tr><tr><td>Daily</td><td>6.0</td><td>5.5</td><td>5.7</td><td>5.3</td><td> </td></tr></table>
49b9650bad8a1b535d0e9feebfa90eae15e67eb5ef3d3a95237d7ccf441ba6c3.png	complex	<table><tr><td>Exon</td><td>Primers (3′-5′)</td><td>Annealing temperature (°C)</td><td>Buffer pH</td><td>MgCl<sub>2</sub> (mM)</td><td>% DMSO</td><td>Fragment (bp)</td></tr><tr><td rowspan="2">1</td><td>F: GCAGATTTAAAGCAACACCACC</td><td rowspan="2">60</td><td rowspan="2">8.4</td><td rowspan="2">1</td><td rowspan="2">0</td><td rowspan="2">242</td></tr><tr><td>R: CCCCTTCAAATTATCCTCAGC</td></tr><tr><td rowspan="2">2</td><td>F: CTAGTGATTCATCGATGTAGCTC</td><td rowspan="2">52</td><td rowspan="2">8.4</td><td rowspan="2">1</td><td rowspan="2">10</td><td rowspan="2">370</td></tr><tr><td>R: TTTCCAGCTCCTCTGGTCATTGC</td></tr><tr><td rowspan="2">3</td><td>F: TGATGTCAGTTTTCAAAGTTTTCC</td><td rowspan="2">54</td><td rowspan="2">8.4</td><td rowspan="2">1</td><td rowspan="2">0</td><td rowspan="2">313</td></tr><tr><td>R: TAATTAGCAAAACTGAGAGAGTGG</td></tr><tr><td rowspan="2">4</td><td>F: GCACACATTAAATTTGTTTCTGCA</td><td rowspan="2">54</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">345</td></tr><tr><td>R: TACCACTTTGTCAGATTATAGATG</td></tr><tr><td rowspan="2">5</td><td>F: TAGTAACTCCACATTTTTCTATAC</td><td rowspan="2">50</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">301</td></tr><tr><td>R: TAAGTGCAAAGTAATAGTAACTGT</td></tr><tr><td rowspan="2">6</td><td>F: AATATTTTCAGAGTAAGCACTCAT</td><td rowspan="2">50</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">288</td></tr><tr><td>R: ACACTTTATACAATCCCAATCAAA</td></tr><tr><td rowspan="2">7</td><td>F: GTGATGTTGCTTAAAAGCATCAAAC</td><td rowspan="2">54</td><td rowspan="2">8.6</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">325</td></tr><tr><td>R: CTTGTAAAGAAGCAACAAGATCAAC</td></tr><tr><td rowspan="2">8</td><td>F: CCATTTTCCTGAAACACTACCCTA</td><td rowspan="2">52</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">377</td></tr><tr><td>R: TTGGGGTACAGTGCAACAGATTAG</td></tr><tr><td rowspan="2">9</td><td>F: AATTATTTGAATTTCCAGACACCT</td><td rowspan="2">50</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">375</td></tr><tr><td>R: GGGTTATTCTATGAAATTAGTCCA</td></tr><tr><td rowspan="2">10</td><td>F: GCAATTTCACTATTCTATGAAAGG</td><td rowspan="2">52</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">348</td></tr><tr><td>R: ACAGAATTGGCTACATAATGGCT</td></tr></table>
051f8ed7ad1e8f47a83c3eaa9357b3b585f044ec69007aff2db1708be6091c72.png	complex	<table><tr><td></td><td colspan="7"><i>r</i>/<i>P</i></td></tr><tr><td></td><td>sIL-6</td><td>sVEGF</td><td>pVEGF</td><td>D-D</td><td>Platelets</td><td>Fibrinogen</td><td>sVEGF/pl</td></tr><tr><td>sIL-6</td><td></td><td>0.25/0.03</td><td>0.33/0.005</td><td>0.41/0.006</td><td></td><td>0.23/0.06</td><td>0.22/0.06</td></tr><tr><td>sVEGF</td><td></td><td></td><td>0.48/<0.001</td><td>0.25/0.04</td><td>0.22/0.06</td><td></td><td>0.88/<0.0001</td></tr><tr><td>pVEGF</td><td></td><td></td><td></td><td>0.38/0.0019</td><td>0.23/0.05</td><td>0.26/0.0339</td><td>0.38/0.001</td></tr><tr><td>D-D</td><td></td><td></td><td></td><td></td><td></td><td>0.26/0.03</td><td>0.34/0.0061</td></tr></table>
3b739a09abcdf520c305a4db641011f63646101ff8e0c41ff7bc36a3025ebcb3.png	complex	<table><tr><td colspan="2">Variable</td><td colspan="2">CTX only</td><td colspan="2">Trastuzumab + CTX</td><td colspan="2">Total</td><td><i>P</i>-value</td></tr><tr><td colspan="2">Number of patients</td><td colspan="2">45</td><td colspan="2">70</td><td colspan="2">115</td><td></td></tr><tr><td colspan="2">Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Male</td><td>34</td><td>75.6%</td><td>52</td><td>74.3%</td><td>86</td><td>74.8%</td><td>0.878</td></tr><tr><td></td><td>Female</td><td>11</td><td>24.4%</td><td>18</td><td>25.7%</td><td>29</td><td>25.2%</td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Median age, years (range)</td><td colspan="2">58 (37–72)</td><td colspan="2">59 (30–80)</td><td colspan="2">58 (30–80)</td><td>0.884</td></tr><tr><td>BMI</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Median, kg/m<sup>2</sup> (range)</td><td colspan="2">22.7 (16.7–35.0)</td><td colspan="2">21.4 (13.8–32.5)</td><td colspan="2">21.9 (13.8–35.0)</td><td>0.059</td></tr><tr><td colspan="2">Baseline LVEF</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Median, % (range)</td><td colspan="2">66 (57–75)</td><td colspan="2">65 (57–75)</td><td colspan="2">66 (57–75)</td><td>0.307</td></tr><tr><td colspan="6">Maximally decreased LVEF from baseline LVEF</td><td></td><td></td><td></td></tr><tr><td></td><td>Median, % (range)</td><td colspan="2">6 (1–12)</td><td colspan="2">7 (1–21)</td><td colspan="2">6 (1–21)</td><td>0.279</td></tr><tr><td colspan="6">Total treatment cycles</td><td></td><td></td><td></td></tr><tr><td></td><td>Median, number (range)</td><td colspan="2">8 (2–92)</td><td colspan="2">9 (1–62)</td><td colspan="2">8 (1–92)</td><td>0.827*</td></tr><tr><td colspan="2">Hypertension</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>12</td><td>26.7%</td><td>18</td><td>25.7%</td><td>30</td><td>26.1%</td><td>0.910</td></tr><tr><td></td><td>No</td><td>33</td><td>73.3%</td><td>52</td><td>74.3%</td><td>85</td><td>73.9%</td><td></td></tr><tr><td colspan="2">Underlying cardiac disease</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>1</td><td>2.2%</td><td>3</td><td>4.3%</td><td>4</td><td>3.5%</td><td>>0.99†</td></tr><tr><td></td><td>No</td><td>44</td><td>97.8%</td><td>67</td><td>95.7%</td><td>111</td><td>96.5%</td><td></td></tr><tr><td colspan="2">Diabetes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>5</td><td>11.1%</td><td>8</td><td>11.4%</td><td>13</td><td>11.3%</td><td>>0.99†</td></tr><tr><td></td><td>No</td><td>40</td><td>88.9%</td><td>62</td><td>88.6%</td><td>102</td><td>88.7%</td><td></td></tr><tr><td colspan="2">Hyperlipidemia</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>0</td><td>0.0%</td><td>2</td><td>2.8%</td><td>2</td><td>1.7%</td><td>0.519†</td></tr><tr><td></td><td>No</td><td>45</td><td>100%</td><td>68</td><td>97.2%</td><td>113</td><td>98.3%</td><td></td></tr><tr><td colspan="2">Cerebrovascular disease</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Yes</td><td>1</td><td>2.2%</td><td>3</td><td>4.3%</td><td>4</td><td>3.5%</td><td>>0.99†</td></tr><tr><td></td><td>No</td><td>44</td><td>97.8%</td><td>67</td><td>95.7%</td><td>111</td><td>96.5%</td><td></td></tr><tr><td colspan="2">Smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Current</td><td>15</td><td>33.3%</td><td>20</td><td>28.6%</td><td>35</td><td>30.4%</td><td>0.862</td></tr><tr><td></td><td>Former</td><td>11</td><td>24.4%</td><td>18</td><td>25.7%</td><td>29</td><td>25.2%</td><td></td></tr><tr><td></td><td>Never</td><td>19</td><td>42.3%</td><td>32</td><td>45.7%</td><td>51</td><td>44.4%</td><td></td></tr></table>
43abd7ea9aa2958cb9c4c38f65bebf34e0d5086d9807b3466cc5c933a970d44f.png	simple	<table><tr><td>Factors</td><td>β</td><td>S.E.</td><td>aOR (95% CI)</td></tr><tr><td>Residence (rural vs. urban)</td><td>0.79</td><td>0.36</td><td>2.03 (1.30–4.25)</td></tr><tr><td>Parental history of T1DM (positive history vs. negative)</td><td>3.90</td><td>2.54</td><td>9.03 (1.02–85.32)</td></tr><tr><td>Mod Of Delivery (cesarean vs. vaginal)</td><td>0.75</td><td>0.43</td><td>2.13 (1.09–5.03)</td></tr><tr><td>Breast feeding (>6 months vs. <6 months)</td><td>−1.46</td><td>0.39</td><td>0.23 (0.11–0.50)</td></tr><tr><td>Introduction of cows milk in first year of life (positive vs. negative)</td><td>2.99</td><td>0.42</td><td>19.94 (8.73–45.53)</td></tr><tr><td>Vitamin D Supplementation in first year of life (positive vs. negative)</td><td>−2.16</td><td>0.37</td><td>0.11 (0.05–0.24)</td></tr><tr><td>Physical Activity (high vs. low)</td><td>−2.90</td><td>0.44</td><td>0.05 (0.02–0.12)</td></tr></table>
49045c228e57731c1c31b291eb285e94b24e524689c2ba5caf4ae261560c570e.png	simple	<table><tr><td>Sample sizes</td><td>N</td><td>Alternative</td><td>Power</td><td>Correct classif. rate</td></tr><tr><td>200/200/200/200</td><td>800</td><td>.05/.05/.05/.10</td><td>.682</td><td>.935</td></tr><tr><td>540/200/40/20</td><td>800</td><td>.05/.05/.05/.10</td><td><i>.251</i></td><td>.758</td></tr><tr><td>200/200/200/200</td><td>800</td><td>.05/.05/.10/.10</td><td>.792</td><td>.831</td></tr><tr><td>540/200/40/20</td><td>800</td><td>.05/.05/.10/.10</td><td><i>.425</i></td><td>.687</td></tr><tr><td>200/200/200/200</td><td>800</td><td>.05/.10/.10/.10</td><td>.603</td><td>.783</td></tr><tr><td>540/200/40/20</td><td>800</td><td>.05/.10/.10/.10</td><td>.755</td><td>.854</td></tr><tr><td>400/400/400/400</td><td>1600</td><td>.05/.05/.05/.10</td><td>.915</td><td>.971</td></tr><tr><td>1340/200/40/20</td><td>1600</td><td>.05/.05/.05/.10</td><td><i>.266</i></td><td>.749</td></tr><tr><td>400/400/400/400</td><td>1600</td><td>.05/.05/.10/.10</td><td>.968</td><td>.916</td></tr><tr><td>1340/200/40/20</td><td>1600</td><td>.05/.05/.10/.10</td><td><i>.438</i></td><td>.667</td></tr><tr><td>400/400/400/400</td><td>1600</td><td>.05/.10/.10/.10</td><td>.903</td><td>.904</td></tr><tr><td>1340/200/40/20</td><td>1600</td><td>.05/.10/.10/.10</td><td>.832</td><td>.883</td></tr><tr><td>9740/200/40/20</td><td>10000</td><td>.05/.05/.05/.10</td><td><i>.252</i></td><td>.702</td></tr></table>
c17e26922501fa200748fe4a2fa0c28a05c9e57fac77e472e589420f038b0f2a.png	simple	<table><tr><td>Substance</td><td>Reported Usage</td><td>Percent of Survey Participants</td></tr><tr><td>Opioid Pharmaceuticals</td><td>18</td><td>5.95%</td></tr><tr><td>Hallucinogens</td><td>11</td><td>3.63%</td></tr><tr><td>MDMA/Ecstasy</td><td>10</td><td>3.30%</td></tr><tr><td>Cocaine/Crack Cocaine</td><td>7</td><td>2.31%</td></tr><tr><td>Benzodiazepine Pharmaceuticals</td><td>6</td><td>1.98%</td></tr><tr><td>Other Substances</td><td>5</td><td>1.65%</td></tr><tr><td>Stimulant Pharmaceuticals</td><td>3</td><td>0.99%</td></tr><tr><td>Methamphetamine</td><td>2</td><td>0.66%</td></tr><tr><td>Heroin</td><td>0</td><td>0.00%</td></tr></table>
e4f94af152f9d28f7c7e4179400ba99cfceb42842d9bef13d2a362e34fcd6c20.png	complex	<table><tr><td>Variables</td><td>Lean</td><td>Overweight</td><td>Obese</td><td><i>p</i> for heterogeneity</td></tr><tr><td>BMI (kg/m<sup>2</sup>)(mean)</td><td>18.5–24.9922.7 ± 1.7</td><td>25–29.9927.1 ± 1.6</td><td>≥3033.5 ± 3.8</td><td></td></tr><tr><td>No. of subjects (%)</td><td>246 (51)</td><td>150 (31)</td><td>77 (18)</td><td></td></tr><tr><td colspan="5">Sociodemographic variables</td></tr><tr><td> Age (years)</td><td>48 ± 16</td><td>57 ± 17</td><td>61 ± 16</td><td><0.0001</td></tr><tr><td> Female/male</td><td>122/124</td><td>66/84</td><td>49/28</td><td><0.0001</td></tr><tr><td> University degree or higher</td><td>180</td><td>89</td><td>33</td><td><0.0001</td></tr><tr><td> Household income (above median)</td><td>149</td><td>84</td><td>38</td><td>0.1</td></tr><tr><td colspan="5">Health behaviors</td></tr><tr><td> Current smoking (%)</td><td>16</td><td>11</td><td>6</td><td>0.9</td></tr><tr><td> Physical activity (kJ/d/Kg)</td><td>47 ± 20</td><td>47 ± 22</td><td>43 ± 23</td><td>0.44</td></tr><tr><td colspan="5">Health measures</td></tr><tr><td> Systolic blood pressure (BP) (mm Hg)</td><td>116 ± 15</td><td>123 ± 16</td><td>126 ± 19</td><td><0.0001</td></tr><tr><td> Diastolic BP (mm Hg)</td><td>71 ± 10</td><td>75 ± 11</td><td>77 ± 11</td><td><0.0001</td></tr><tr><td colspan="5">Disease diagnosis</td></tr><tr><td> Myocardial infarction</td><td>1</td><td>3</td><td>1</td><td>0.3</td></tr><tr><td> Cancer</td><td>11</td><td>6</td><td>9</td><td>0.03</td></tr><tr><td> Diabetes</td><td>3</td><td>6</td><td>9</td><td><0.0001</td></tr><tr><td> Stroke</td><td>4</td><td>0</td><td>1</td><td>0.3</td></tr><tr><td> High cholesterol</td><td>21</td><td>17</td><td>17</td><td><0.01</td></tr><tr><td> High BP</td><td>19</td><td>30</td><td>29</td><td><0.001</td></tr></table>
513e2705eb476525540ba7d2362d3caebe6c5db6dda6115897e9f5d1bb1797eb.png	simple	<table><tr><td>Time since quitting</td><td>Beneficial health changes that take place</td></tr><tr><td>24 h</td><td>Lungs start to clear out mucus and other smoking debris</td></tr><tr><td>48 h</td><td>Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved</td></tr><tr><td>72 h</td><td>Breathing becomes easier. Bronchial tubes begin to relax and energy levels increase</td></tr><tr><td>2–12 weeks</td><td>Circulation improves</td></tr><tr><td>3–9 months</td><td>Coughs, wheezing and breathing problems improve as lung function is increased by up to 10%</td></tr><tr><td>1 year</td><td>Risk of a heart attack falls to about half that of a smoker</td></tr><tr><td>10 years</td><td>Risk of lung cancer falls to half that of a smoker</td></tr><tr><td>15 years</td><td>Risk of heart attack falls to the same as someone who has never smoked</td></tr></table>
2b728e94b64c77e8c57028284c2154b77100046446a0aa03874716903639008a.png	simple	<table><tr><td><i>Characteristic</i></td><td><i>N</i></td><td><i>%</i></td></tr><tr><td>Pre-pregnancy nutritional status (BMI)</td><td></td><td></td></tr><tr><td>Underweight (<18.5 kg/m<sup>2</sup>)</td><td>84</td><td>10.9</td></tr><tr><td>Normal weight (18.5 – 24.99 kg/m<sup>2</sup>)</td><td>494</td><td>63.8</td></tr><tr><td>Overweight (25.0 – 29.99 kg/m<sup>2</sup>)</td><td>131</td><td>16.9</td></tr><tr><td>Obese (≥30.0 kg/m<sup>2</sup>)</td><td>65</td><td>8.4</td></tr><tr><td>Total weight gain</td><td></td><td></td></tr><tr><td>Low</td><td>209</td><td>26.9</td></tr><tr><td>Intermediate</td><td>298</td><td>38.4</td></tr><tr><td>High</td><td>270</td><td>34.7</td></tr><tr><td>Mode of delivery</td><td></td><td></td></tr><tr><td>Normal</td><td>288</td><td>49.6</td></tr><tr><td>Forceps</td><td>22</td><td>3.8</td></tr><tr><td>Cesarean section</td><td>270</td><td>46.6</td></tr><tr><td>Gestational age at birth</td><td></td><td></td></tr><tr><td>Preterm (<37 weeks)</td><td>26</td><td>4.7</td></tr><tr><td>Term (≥37 weeks)</td><td>527</td><td>95.3</td></tr><tr><td>Weight at birth</td><td></td><td></td></tr><tr><td>Low (<2500 g)</td><td>33</td><td>4.3</td></tr><tr><td>Normal (2500 g - 3999 g)</td><td>695</td><td>91.1</td></tr><tr><td>High (≥4000 g)</td><td>35</td><td>4.6</td></tr><tr><td>Pregnancy complications</td><td></td><td></td></tr><tr><td>None</td><td>455</td><td>54.9</td></tr><tr><td>Other</td><td>347</td><td>41.9</td></tr><tr><td>Gestational diabetes mellitus</td><td>27</td><td>3.3</td></tr></table>
7cab41ad43ea6d49f724014d02eab406d283381d41fc557db2e634517e5d3a7b.png	simple	<table><tr><td>Analysis</td><td>Number of plants assayed</td><td>Number of tolerant plants</td><td>Transformation frequency</td></tr><tr><td>Basta leaf paint</td><td>78</td><td>70</td><td>89.73%</td></tr><tr><td>Kanamycin/paromomycin Leaf bleach</td><td>34</td><td>32</td><td>94.12%</td></tr></table>
9041d001108cdf6f3abad0897d6840b9c7e47351597d5b03df2850fa28544111.png	simple	<table><tr><td>Plant specie</td><td> Aa length</td><td>PTS1</td><td>pI</td><td>Molecular Mass (kDa)</td><td>Accession number</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>486</td><td>-SKI</td><td>7.02 </td><td>53.6</td><td>AEE73797.1</td></tr><tr><td><i>Cleome spinosa</i></td><td>485</td><td>-SMI</td><td>5.80</td><td>53.6</td><td>ABD96861.1</td></tr><tr><td><i>Medicago sativa</i></td><td>486</td><td>-SRI</td><td>5.33</td><td>53.7</td><td>AAB41553.1</td></tr><tr><td><i>Oryza sativa</i></td><td>480</td><td>-AKM</td><td>5.85</td><td>52.7</td><td>AJB98434.1</td></tr><tr><td><i>Pinus sylvestris</i></td><td>483</td><td>-SKI</td><td>6.31</td><td>53.3</td><td>ADP03057.1</td></tr><tr><td><i>Pinus pinaster</i></td><td>483</td><td>-SKI</td><td>6.74</td><td>53.2</td><td>ADP03318.1</td></tr><tr><td><i>Spinacia oleracea</i></td><td>483</td><td>-SKI</td><td>6.04</td><td>53.2</td><td>AAK51690.1</td></tr><tr><td><i>Vitis vinifera</i></td><td>438</td><td>-SKI</td><td>8.13</td><td>48.3 </td><td>CAN67602.1</td></tr><tr><td><i>Zea mays</i></td><td>480</td><td>-SKI</td><td>6.09</td><td>52.7</td><td>ACN35899.1</td></tr></table>
70d62af37847142c49bb710b344006c1ac1f791da70b43ed69c15e35ee9b85ab.png	complex	<table><tr><td>Oil</td><td>Isothermal T (°C)</td><td>t<sub>0</sub> (min)</td><td>t<sub>max</sub>(min)</td><td>Regression equation<sub>a</sub></td><td>R<sup>2</sup><sub>b</sub></td><td>Reported t<sub>0</sub> or shelf life at 20 °C (d)</td></tr><tr><td colspan="7">Linola</td></tr><tr><td></td><td>100</td><td>170.7</td><td>287.1</td><td rowspan="3">Log (k) = 0.0211 T-4.3479</td><td rowspan="3">0.9987</td><td rowspan="3">5.9</td></tr><tr><td></td><td>110</td><td>108.3</td><td>183.7</td></tr><tr><td></td><td>120</td><td>64.6</td><td>114.5</td></tr><tr><td colspan="7">GT</td></tr><tr><td></td><td>100</td><td>162.5</td><td>229.9</td><td rowspan="3">Log (k) = 0.0237 T – 4.5500</td><td rowspan="3">0.9633</td><td rowspan="3">8.3</td></tr><tr><td></td><td>110</td><td>78.4</td><td>128.4</td></tr><tr><td></td><td>120</td><td>54.6</td><td>88.4</td></tr><tr><td colspan="7">W 92</td></tr><tr><td></td><td>100</td><td>200.1</td><td>424.3</td><td rowspan="3">Log (k) = 0.0240 T – 4.7354</td><td rowspan="3">0.9574</td><td rowspan="3">12.5</td></tr><tr><td></td><td>110</td><td>140.8</td><td>297.9</td></tr><tr><td></td><td>120</td><td>66.1</td><td>210.5</td></tr><tr><td colspan="7">W 86</td></tr><tr><td></td><td>100</td><td>118.5</td><td>270.8</td><td rowspan="3">Log (k) = 0.0277 T – 4.8907</td><td rowspan="3">0.9346</td><td rowspan="3">15.1</td></tr><tr><td></td><td>110</td><td>83.9</td><td>186.7</td></tr><tr><td></td><td>120</td><td>33.0</td><td>120.5</td></tr></table>
bfd119c0b6be480ddb5b805cebdf7ac9bb286ca5b70f3b62c8c2139a08db1fff.png	simple	<table><tr><td>Resource</td><td>Brief description</td><td>Included information</td></tr><tr><td>Facilitator manual</td><td>Comprehensive train-the-trainer manual detailing all information required for the delivery of the program</td><td>* Introduction* Successful facilitating* Background to the research* Session guides</td></tr><tr><td>Manual for Dads</td><td>Handbook for fathers that includes a summary of the information from the face-to-face sessions and additional background information</td><td>* Session 1: Weight loss fundamentals for men* Session 2: Raising children in an inactive world* Session 3: Ready to rumble with dad* Session 4: Healthy eating for families - dads matter* Session 5: Fun, fitness and fundamental movement skills* Session 6: Sustaining healthy lifestyles* Session 7: Weight loss is a journey not a destination</td></tr><tr><td>Dad's log book</td><td>Handbook that dads use as a working document</td><td>* Program activities: Energy calculations; sedentary behaviors; goal setting; eating habits* Homework activities: Children's screen time; family fitness activity; family cooking; children's food intake; cue words; family activity* Monitoring procedures: Pedometer chart; weight loss chart; goal recording</td></tr><tr><td>Website user guide</td><td>Handbook to guide fathers through the setup and use of the dietary and physical activity monitoring website</td><td>* Setting up a profile* Food and exercise diary* Check in diary* Charts and reports</td></tr><tr><td>Kid's Handbook</td><td>Includes tasks for children to complete each week with their dads that must be signed off with their dads (space to receive a sticker from facilitators if completed)</td><td>* Kids homework activities* Recipes to cook with dad</td></tr><tr><td>Green slips</td><td>Homework activity slips given to fathers at the end of each session</td><td>* Activities are designed to align with the principles presented at the intervention session and any activities detailed in the Dad's log book and Kid's handbook (e.g. cooking meals with kids, family fundamental movement skills circuit, rough and tumble games with dad)</td></tr></table>
67c8cf325ee2bc68262aa7b706ce6888a914cb6ccbc32573867218eda4a3a3fd.png	simple	<table><tr><td></td><td>F0-1</td><td>F2-4</td><td>P value</td><td>F0-2</td><td>F3-4</td><td>P value</td><td>F0-3</td><td>F4</td><td>P value</td></tr><tr><td>HBeAg (+)</td><td>4.60 (4.38-4.78)</td><td>4.12 (3.98-4.30)</td><td><0.001</td><td>4.51 (4.28-4.74)</td><td>4.03 (3.89-4.25)</td><td><0.001</td><td>4.48 (4.26-4.71)</td><td>3.95 (3.74-4.10)</td><td><0.001</td></tr><tr><td>HBeAg (-)</td><td>3.20 (2.77-3.62)</td><td>3.42 (2.84-3.83)</td><td>0.084</td><td>3.32 (2.82-3.82)</td><td>3.24 (2.78-3.65)</td><td>0.349</td><td>3.23 (2.77-3.68)</td><td>3.37 (3.02-3.92)</td><td>0.178</td></tr></table>
4e880de69aab207044031f62ef14f6d0d4c16c6e6daac698ab85bced4f24f56e.png	complex	<table><tr><td></td><td></td><td colspan="3">Echium Oil</td><td colspan="3">Fish Oil</td><td colspan="3">Significant Effect</td></tr><tr><td>Fatty Acids</td><td>Control</td><td>EO-1</td><td>EO-3</td><td>EO-5</td><td>FO-1</td><td>FO-3</td><td>FO-5</td><td>Oil</td><td>Dose</td><td>Oil × Dose</td></tr><tr><td>C16:0</td><td>19.4 ± 0.90</td><td>20.1 ± 0.91</td><td>18.77 ± 0.84</td><td>18.36 ± 0.66</td><td>19.12 ± 0.43</td><td>20.24 ± 0.38</td><td>20.37 ± 0.92</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C16:1<i>n</i>-9</td><td>1.9 ± 0.40 <sup>b</sup></td><td>1.1 ± 0.13 <sup>a</sup></td><td>1.2 ± 0.28 <sup>a</sup></td><td>1.0 ± 0.18 <sup>a</sup></td><td>1.4 ± 0.15 <sup>a</sup></td><td>1.7 ± 0.14 <sup>b</sup></td><td>1.90.13 <sup>b</sup></td><td>0.003</td><td>ns</td><td>ns</td></tr><tr><td>C18:0</td><td>14.8 ± 0.60 <sup>b</sup></td><td>12.5 ± 0.57 <sup>a</sup></td><td>12.1 ± 1.04 <sup>a</sup></td><td>13.3 ± 1.09 <sup>a</sup></td><td>14.9 ± 0.71 <sup>b</sup></td><td>14.6 ± 0.87 <sup>b</sup></td><td>15.1 ± 0.72 <sup>b</sup></td><td>0.012</td><td>ns</td><td>ns</td></tr><tr><td>C18:1<i>n</i>-9</td><td>17.2 ± 0.77</td><td>18.5 ± 0.29</td><td>18.0 ± 1.16</td><td>17.6 ± 0.56</td><td>18.6 ± 0.44</td><td>18.6 ± 0.57</td><td>16.9 ± 0.56</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C18:1<i>n</i>-7</td><td>5.6 ± 0.37 <sup>b</sup></td><td>4.2 ± 0.71 <sup>a</sup></td><td>3.2 ± 0.43 <sup>a</sup></td><td>3.3 ± 0.18 <sup>a</sup></td><td>5.3 ± 0.24 <sup>a,b</sup></td><td>5.1 ± 0.39 <sup>b</sup></td><td>4.7 ± 0.27 <sup>a,b</sup></td><td><0.001</td><td>ns</td><td>ns</td></tr><tr><td>C18:2<i>n</i>-6 (LA)</td><td>20.4 ± 0.71 <sup>a,b</sup></td><td>21.0 ± 0.14 <sup>a,b</sup></td><td>20.0 ± 0.62 <sup>a,b</sup></td><td>19.2 ± 1.09 <sup>a</sup></td><td>21.7 ± 0.54 <sup>b</sup></td><td>19.5 ± 0.48 <sup>a,b</sup></td><td>18.3 ± 0.42 <sup>a</sup></td><td>ns</td><td>0.018</td><td>ns</td></tr><tr><td>C18:3<i>n</i>-3 (ALA)</td><td>0.0 ± 0.00 <sup>a</sup></td><td>1.3 ± 0.29 <sup>b</sup></td><td>2.6 ± 0.57 <sup>b,c</sup></td><td>3.1 ± 0.41 <sup>c</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td><0.001</td><td>ns</td><td>ns</td></tr><tr><td>C18:4<i>n</i>-3 (SDA)</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td></td><td></td><td></td></tr><tr><td>C20:0</td><td>2.5 ± 0.36</td><td>1.9 ± 0.82</td><td>2.1 ± 0.64</td><td>2.7 ± 0.57</td><td>1.9 ± 0.33</td><td>2.0 ± 0.40</td><td>2.5 ± 0.38</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C20:2<i>n</i>-6</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td></td><td></td><td></td></tr><tr><td>C20:3<i>n</i>-6</td><td>0.7 ± 0.06</td><td>0.7 ± 0.02</td><td>1.0 ± 0.07</td><td>0.9 ± 0.10</td><td>0.7 ± 0.08</td><td>0.8 ± 0.09</td><td>0.6 ± 0.07</td><td>ns</td><td>ns</td><td>ns</td></tr><tr><td>C20:4<i>n</i>-6 (ARA)</td><td>16.2 ± 1.66 <sup>a,b</sup></td><td>16.0 ± 2.16 <sup>a,b</sup></td><td>17.6 ± 2.66 <sup>a,b</sup></td><td>17.3 ± 1.12 <sup>b</sup></td><td>13.1 ± 0.84 <sup>a,b</sup></td><td>11.1 ± 0.39 <sup>a</sup></td><td>11.8 ± 1.20 <sup>a,b</sup></td><td>0.027</td><td>ns</td><td>ns</td></tr><tr><td>C20:5<i>n</i>-3 (EPA)</td><td>0.2 ± 0.13 <sup>a</sup></td><td>0.7 ± 0.06 <sup>a,b</sup></td><td>1.3 ± 0.06 <sup>b</sup></td><td>1.3 ± 0.07 <sup>b</sup></td><td>0.8 ± 0.03 <sup>b</sup></td><td>2.0 ± 0.23 <sup>c</sup></td><td>2.7 ± 0.08 <sup>d</sup></td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td>C24:0</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td></td><td></td><td></td></tr><tr><td>C22:5<i>n</i>-3 (DPA)</td><td>0.0 ± 0.00 <sup>a</sup></td><td>0.5 ± 0.13 <sup>b</sup></td><td>0.9 ± 0.13 <sup>b</sup></td><td>0.8 ± 0.12 <sup>b</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td>0.0 ± 0.00 <sup>a</sup></td><td><0.001</td><td>ns</td><td>ns</td></tr><tr><td>C22:6<i>n</i>-3 (DHA)</td><td>1.1 ± 0.09 <sup>a</sup></td><td>1.4 ± 0.28 <sup>a,b</sup></td><td>1.4 ± 0.11 <sup>a</sup></td><td>1.1 ± 0.15 <sup>a</sup></td><td>2.6 ± 0.28 <sup>b</sup></td><td>4.5 ± 0.26 <sup>c</sup></td><td>5.2 ± 0.53 <sup>c</sup></td><td><0.001</td><td>0.001</td><td><0.001</td></tr><tr><td>Total <i>n</i>-3 PUFA</td><td>1.3 ± 0.10 <sup>a</sup></td><td>2.7 ± 0.60 <sup>a,b</sup></td><td>3.6 ± 0.22 <sup>b</sup></td><td>3.2 ± 0.30 <sup>b</sup></td><td>3.4 ± 0.29 <sup>b</sup></td><td>6.5 ± 0.48 <sup>c</sup></td><td>7.9 ± 0.52 <sup>c</sup></td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td>Total <i>n</i>-6 PUFA</td><td>37.3 ± 2.02 <sup>c</sup></td><td>18.0 ± 1.92 <sup>a</sup></td><td>21.2 ± 2.20 <sup>a</sup></td><td>21.2 ± 0.95 <sup>a</sup></td><td>35.4 ± 0.52 <sup>b</sup></td><td>31.4 ± 1.50 <sup>b</sup></td><td>30.7 ± 1.36 <sup>b</sup></td><td><0.001</td><td>ns</td><td>0.012</td></tr><tr><td>EPA + DHA</td><td>1.3 ± 0.10 <sup>a</sup></td><td>2.1 ± 0.33 <sup>a,b</sup></td><td>2.7 ± 0.09 <sup>b</sup></td><td>2.4 ± 0.21 <sup>b</sup></td><td>3.4 ± 0.29 <sup>b</sup></td><td>6.5 ± 0.48 <sup>c</sup></td><td>7.9 ± 0.52 <sup>d</sup></td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td>Total SFA</td><td>36.7 ± 0.64 <sup>b</sup></td><td>34.6 ± 1.22 <sup>a,b</sup></td><td>32.9 ± 1.25 <sup>a</sup></td><td>34.4 ± 1.38 <sup>a,b</sup></td><td>35.9 ± 0.60 <sup>b</sup></td><td>36.9 ± 1.23 <sup>b</sup></td><td>37.9 ± 1.98 <sup>b</sup></td><td>0.014</td><td>ns</td><td>ns</td></tr><tr><td>Total MUFA</td><td>24.7 ± 1.48 <sup>b</sup></td><td>23.8 ± 1.00 <sup>a</sup></td><td>22.4 ± 1.62 <sup>a</sup></td><td>22.0 ± 0.78 <sup>a</sup></td><td>25.2 ± 0.71 <sup>b</sup></td><td>25.3 ± 0.80 <sup>b</sup></td><td>23.5 ± 0.27 <sup>a,b</sup></td><td>0.027</td><td>ns</td><td>ns</td></tr><tr><td>Total PUFA</td><td>38.7 ± 2.00 <sup>a,b</sup></td><td>41.6 ± 2.21 <sup>a,b</sup></td><td>44.7 ± 1.91 <sup>b</sup></td><td>43.7 ± 1.25 <sup>a,b</sup></td><td>38.8 ± 0.58 <sup>a,b</sup></td><td>37.9 ± 0.97 <sup>a</sup></td><td>38.6 ± 1.86 <sup>a,b</sup></td><td>0.001</td><td>ns</td><td>ns</td></tr></table>
77b0561c4a86b6b8f1da0143197e99c6f158f8c5267f351916f894f198c2cfe4.png	complex	<table><tr><td rowspan="2">Stimulus/Cytokine</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>OR (95%CI)</td><td>OR (95%CI)</td><td>OR (95%CI)</td></tr><tr><td>Spontaneous production</td><td></td><td></td><td></td></tr><tr><td> IL-5 (n = 418)</td><td>1.42 (0.93;2.15)</td><td>1.00 (0.52;1.92)</td><td>0.95 (0.48;1.87)</td></tr><tr><td> IL-13 (n = 418)</td><td>1.54 (1.01;2.37)</td><td>0.67 (0.34;1.32)</td><td>0.53 (0.26;1.07)</td></tr><tr><td> IFN-γ (n = 417)</td><td>1.88 (1.19;2.98)</td><td>1.67 (0.83;3.37)</td><td>1.50 (0.72;3.10)</td></tr><tr><td> IL-10 (n = 415)</td><td>1.86 (1.05;3.32)</td><td>2.64 (1.12;6.22)</td><td>2.56 (1.05;6.24)</td></tr><tr><td> IL-17 (n = 416)</td><td>0.83 (0.37;1.84)</td><td>2.13 (0.66;6.84)</td><td>1.61 (0.48;5.42)</td></tr><tr><td><i>Ascaris lumbricoides</i></td><td></td><td></td><td></td></tr><tr><td> IL-5 (n = 418)</td><td>0.75 (0.48;1.15)</td><td>1.50 (0.75;3.00)</td><td>1.53 (0.74;3.15)</td></tr><tr><td> IL-13 (n = 418)</td><td>0.66 (0.44;1.01)</td><td>1.14 (0.59;2.22)</td><td>1.29 (0.65;2.57)</td></tr><tr><td> IFN-γ (n = 417)</td><td>1.35 (0.78;2.33)</td><td>1.73 (0.72;4.12)</td><td>1.67 (0.67;4.14)</td></tr><tr><td> IL-10 (n = 416)</td><td>1.83 (1.08;3.11)</td><td>2.43 (1.09;5.38)</td><td>2.51 (1.09;5.79)</td></tr><tr><td> IL-17 (n = 416)</td><td>0.69 (0.33;1.47)</td><td>0.79 (0.27;2.34)</td><td>0.61 (0.19;1.95)</td></tr><tr><td>House dust mite</td><td></td><td></td><td></td></tr><tr><td> IL-5 (n = 418)</td><td>1.73 (1.06;2.82)</td><td>2.06 (0.98;4.29)</td><td>2.09 (0.97;4.52)</td></tr><tr><td> IL-13 (n = 418)</td><td>0.89 (0.58;1.35)</td><td>1.54 (0.80;2.99)</td><td>1.48 (0.74;2.94)</td></tr><tr><td> IFN-γ (n = 417)</td><td>1.45 (0.85;2.46)</td><td>1.63 (0.68;3.92)</td><td>1.57 (0.64;3.87)</td></tr><tr><td> IL-10 (n = 416)</td><td>2.42 (1.54;3.78)</td><td>1.83 (0.91;3.68)</td><td>2.24 (1.07;4.70)</td></tr><tr><td> IL-17 (n = 411)</td><td>1.22 (0.57;2.61)</td><td>1.63 (0.61;4.38)</td><td>1.63 (0.57;4.67)</td></tr></table>
b196ffaa06b07e309127b22edb8bbaca8e6ff96d22e08a94ba25beffbb1d77e7.png	complex	<table><tr><td> </td><td>Kindergarten</td><td>Elementary school</td><td>Junior high school</td><td rowspan="3"><i>P</i>-value<sup>b</sup></td></tr><tr><td> </td><td><i>n</i> (%)</td><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td colspan="4">Feeling upon awakening</td><td> </td></tr><tr><td> good</td><td>213 (86.2)</td><td>877 (76.5)</td><td>389 (61.6)</td><td> </td></tr><tr><td> bad</td><td>34 (13.8)</td><td>270 (23.5)</td><td>243 (38.5)</td><td> </td></tr><tr><td> total</td><td>247</td><td>1147</td><td>632</td><td><0.01</td></tr><tr><td colspan="4">Time of awakening</td><td> </td></tr><tr><td> <6:30</td><td>40 (16.2)</td><td>414 (36.3)</td><td>168 (26.6)</td><td> </td></tr><tr><td> ≥6:30</td><td>207 (83.8)</td><td>726 (63.7)</td><td>464 (73.4)</td><td> </td></tr><tr><td> total</td><td>247</td><td>1140</td><td>632</td><td><0.01</td></tr><tr><td>Bedtime</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <22:00</td><td>232 (93.9)</td><td>816 (71.1)</td><td>60 (9.5)</td><td> </td></tr><tr><td> ≥22:00</td><td>15 (6.1)</td><td>331 (28.9)</td><td>572 (90.5)</td><td> </td></tr><tr><td> total</td><td>247</td><td>1147</td><td>632</td><td><0.01</td></tr><tr><td>Sleep duration</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ≥8 h</td><td>244 (98.8)</td><td>432 (76.5)</td><td>177 (28.0)</td><td> </td></tr><tr><td> <8 h</td><td>3 (1.2)</td><td>133 (23.5)</td><td>455 (72.0)</td><td> </td></tr><tr><td> total</td><td>247</td><td>565</td><td>632</td><td><0.01</td></tr><tr><td>Television</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <2 h</td><td>166 (67.2)</td><td>786 (68.6)</td><td>292 (46.2)</td><td> </td></tr><tr><td> ≥2 h</td><td>81 (32.8)</td><td>360 (31.4)</td><td>340 (53.8)</td><td> </td></tr><tr><td> total</td><td>247</td><td>1146</td><td>632</td><td><0.01</td></tr><tr><td>Video games</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <30 min</td><td>221 (89.5)</td><td>731 (64.1)</td><td>411 (65.0)</td><td> </td></tr><tr><td> ≥30 min</td><td>26 (10.5)</td><td>409 (35.9)</td><td>221 (35.0)</td><td> </td></tr><tr><td> total</td><td>247</td><td>1140</td><td>632</td><td><0.01</td></tr><tr><td colspan="4">Personal computer<sup>a</sup></td><td> </td></tr><tr><td> <30 min</td><td>—</td><td>1007 (88.0)</td><td>437 (69.2)</td><td> </td></tr><tr><td> ≥30 min</td><td>—</td><td>138 (12.1)</td><td>195 (30.9)</td><td> </td></tr><tr><td> total</td><td>—</td><td>1145</td><td>632</td><td><0.01</td></tr><tr><td>Cellular phone<sup>a</sup></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <30 min</td><td>—</td><td>1096 (95.6)</td><td>526 (83.2)</td><td> </td></tr><tr><td> ≥30 min</td><td>—</td><td>51 (4.5)</td><td>106 (16.8)</td><td> </td></tr><tr><td> total</td><td>—</td><td>1147</td><td>632</td><td><0.01</td></tr></table>
355f5bf7dc943e1f4e693e5e9b39195b3269526e70386ed6dfbf1946f4380d5e.png	complex	<table><tr><td>Instrument</td><td>Countries</td></tr><tr><td colspan="2">Supply side regulation: in patent drugs</td></tr><tr><td>Price controls: administrative or statutory pricing</td><td>All EU Member States except Germany, UK and, to a certain extent, Sweden</td></tr><tr><td>External reference pricing</td><td>All EU Member States except UK, Germany, Sweden</td></tr><tr><td>Rate of return regulation</td><td>UK</td></tr><tr><td>Negotiations and price-volume agreements</td><td>France, Italy, Austria</td></tr><tr><td>Direct expenditure controls: payback</td><td>France, Portugal, Austria</td></tr><tr><td>Direct expenditure controls: price volume agreements</td><td>France</td></tr><tr><td>Cost-plus pricing</td><td>Spain</td></tr><tr><td colspan="2">Supply side regulation: off patent drugs</td></tr><tr><td>Tendering for generics pharmaceuticals in primary care</td><td>Netherlands, Germany</td></tr><tr><td>Price capping for generics and linking these to the originator price</td><td>Italy, Greece, France</td></tr><tr><td colspan="2">Supply side regulation: reimbursement methods</td></tr><tr><td>Positive and negative formularies</td><td>All EU Member States</td></tr><tr><td>Internal reference pricing</td><td>Germany, Netherlands, Czech Republic, Italy, Spain, France, Hungary</td></tr><tr><td>Health Technology Assessments (HTA)</td><td>UK, Sweden, Netherlands, Hungary, Poland, Finland, Estonia, Latvia, Lithuania. In France only assessment of clinical benefit</td></tr><tr><td>Innovative pricing and reimbursement schemes</td><td>Italy, Germany, UK, Finland</td></tr><tr><td colspan="2">Demand side regulation: policies towards physicians</td></tr><tr><td>Clinical practice guidelines</td><td>All EU Member States</td></tr><tr><td>Compulsory generic prescribing</td><td>UK, Denmark, Estonia</td></tr><tr><td>Financial incentives</td><td>France, UK</td></tr><tr><td>Prescription monitoring and audit</td><td>Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia</td></tr><tr><td colspan="2">Demand side regulation: policies towards pharmacies</td></tr><tr><td>Control of remuneration (e.g. margins, fees) including contractual arrangements</td><td>All Member States</td></tr><tr><td>Generic substitution</td><td>France, Italy, Spain, Sweden</td></tr><tr><td colspan="2">Demand side regulation: policies towards patients</td></tr><tr><td>Cost-sharing</td><td>All EU Member States</td></tr><tr><td>Encouraging use of over-the counter medicines and “de-listing”</td><td>UK, Germany, Sweden, Netherlands</td></tr></table>
994e7fed73a981166042137eb1ceb3ccf34538781ff06c62ab1192a1de65d163.png	complex	<table><tr><td> </td><td colspan="3">Baseline</td><td colspan="3">12 months</td><td colspan="3">18 months</td></tr><tr><td> </td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td></tr><tr><td> </td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td></tr><tr><td>Variables</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>W.Vs. C(P)</td><td>W.Vs. C(P)</td><td>W.Vs. W(P)</td><td>W.Vs. C(P)</td><td>W.Vs. C(P)</td><td>W.Vs. W(P)</td></tr><tr><td>Coping</td><td>79</td><td>69</td><td>73</td><td>44</td><td>44</td><td>40</td><td>44</td><td>41</td><td>36</td></tr><tr><td>With</td><td>1.069±794</td><td>1.126±0.775</td><td>1.013±0.946</td><td>0.864±0.771</td><td>1.239±0.730</td><td>1.192±0.835</td><td>1.064±0.952</td><td>1.388±0.856</td><td>1.342±1.127</td></tr><tr><td>Symptoms</td><td> </td><td> </td><td> </td><td>(0.091)</td><td>(0.858)</td><td>(0.057)</td><td>(0.190)</td><td>(0.793)</td><td>(0.286)</td></tr><tr><td>Confidence</td><td>79</td><td>69</td><td>73</td><td>44</td><td>44</td><td>39</td><td>43</td><td>41</td><td>36</td></tr><tr><td>About</td><td>7.406±1.719</td><td>7.827±1.488</td><td>7.858±1.512</td><td>7.826±1.551</td><td>7.682±1.785</td><td>8.064±1.575</td><td>7.690±1.920</td><td>7.546±1.848</td><td>8.015±1.476</td></tr><tr><td>Doing Things</td><td> </td><td> </td><td> </td><td>(0.433)</td><td>(0.297)</td><td>(0.060)</td><td>(0.235)</td><td>(0.422)</td><td>*(0.041)</td></tr></table>
aabae43c2e062a4e91f4301d8d7608f69ad4601a63e5ee4647388d35db29c119.png	complex	<table><tr><td></td><td></td><td colspan="4">Male</td><td colspan="4">Female</td></tr><tr><td></td><td></td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td></tr><tr><td>Age groups</td><td>Standard Population</td><td>Death rate %</td><td>Expected # death</td><td>Death rate %</td><td>Expected # death</td><td>Death rate %</td><td>Expected # death</td><td>Death rate %</td><td>Expected # death</td></tr><tr><td>All ages</td><td>4859</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18–54</td><td>1223</td><td>0.53</td><td>6.5</td><td>0.97</td><td>11.9</td><td>1.10</td><td>13.5</td><td>2.70</td><td>33.0</td></tr><tr><td>55–65</td><td>1245</td><td>1.78</td><td>22.2</td><td>1.84</td><td>22.9</td><td>1.72</td><td>21.4</td><td>1.52</td><td>18.9</td></tr><tr><td>66–78</td><td>1289</td><td>2.77</td><td>35.7</td><td>3.65</td><td>47.0</td><td>2.95</td><td>38.0</td><td>3.97</td><td>51.2</td></tr><tr><td>79 +</td><td>1102</td><td>5.80</td><td>63.9</td><td>6.67</td><td>73.5</td><td>7.08</td><td>78.0</td><td>12.03</td><td>132.6</td></tr><tr><td colspan="2">Total number of deaths expected</td><td></td><td>128</td><td></td><td>155</td><td></td><td>151</td><td></td><td>236</td></tr><tr><td colspan="2">Crude rates</td><td colspan="2">2.1 %</td><td colspan="2">3.5 %</td><td colspan="2">3.3 %</td><td colspan="2">7.8 %</td></tr><tr><td colspan="2">Age adjusted rates</td><td colspan="2">128/4859 = 2.6 %</td><td colspan="2">155/4859 = 3.2 %</td><td colspan="2">151/4859 = 3.1 %</td><td colspan="2">236/4859 = 4.9 %</td></tr></table>
7cb6bcd64c0d923dbf16dab46e8843b522d327754a546daa30e819ec78c1dc58.png	simple	<table><tr><td>ATC Code</td><td>Drug classification</td><td>No. of visits </td><td>%</td></tr><tr><td>G01A</td><td>Anti-infectives</td><td>5402</td><td>15.1%</td></tr><tr><td>M01A</td><td>Anti-inflammatory, non-steroids</td><td>3754 </td><td>10.5%</td></tr><tr><td>N02B</td><td>Other analgesics and anti-pyretics</td><td>2884 </td><td>8.1%</td></tr><tr><td>G03D</td><td>Progestogens</td><td>2871 </td><td>8.0%</td></tr><tr><td>A02A</td><td>Antacids</td><td>2683</td><td>7.5%</td></tr><tr><td>D07C</td><td>Corticosteroids, combinations with antibiotics</td><td>2090 </td><td>5.9%</td></tr><tr><td>R06A</td><td>Antihistamines for systemic use</td><td>1932 </td><td>5.4%</td></tr><tr><td>A03A</td><td>Drugs for functional bowel disorders</td><td>1866 </td><td>5.2%</td></tr><tr><td>J01D</td><td>Other beta-lactam anti-bacterials</td><td>1863 </td><td>5.5%</td></tr><tr><td>G03C</td><td>Estrogens</td><td>1837 </td><td>5.1%</td></tr></table>
d359cf6779ec4a62b83fef499338d02626981798ccde74e4b76d13b1e95d4aa0.png	simple	<table><tr><td>Variables</td><td>Number</td><td>Percentage </td></tr><tr><td>Acute or chronic inflammation</td><td>36</td><td>30</td></tr><tr><td>Rheumatism </td><td>33</td><td>26.6</td></tr><tr><td>Degeneration of valves</td><td>49</td><td>40.8</td></tr><tr><td>Endocarditic </td><td>2</td><td>1.6</td></tr></table>
894cd54dc033248001c560a56c6dbc378e474eaf04bd682ad11adf166f34a660.png	complex	<table><tr><td></td><td></td><td colspan="3">Pairwise correlation at age 7 year</td></tr><tr><td>Compound</td><td>PFAS concentration, ng/mL, median (IQR<sup>a</sup>)</td><td>PFOS</td><td>PFOA</td><td>PFHxS</td></tr><tr><td>Age 5 year</td><td></td><td></td><td></td><td></td></tr><tr><td>PFOS</td><td>17.3 (14.2,21.3)</td><td>0.77</td><td>0.06</td><td>0.43</td></tr><tr><td>PFOA</td><td>4.1 (3.3, 5.0)</td><td>0.34</td><td>0.61</td><td>0.39</td></tr><tr><td>PFHxS</td><td>0.6 (5.0, 0.9)</td><td>0.40</td><td>0.27</td><td>0.85</td></tr><tr><td>Age 7 year</td><td></td><td></td><td></td><td></td></tr><tr><td>PFOS</td><td>15.5 (12.8, 19.2)</td><td>1</td><td></td><td></td></tr><tr><td>PFOA</td><td>4.4 (3.5, 5.7)</td><td>0.29</td><td>1</td><td></td></tr><tr><td>PFHxS</td><td>0.5 (0.4,0.7)</td><td>0.50</td><td>0.34</td><td>1</td></tr></table>
5b13e3946e7db79e1ab6827d2ac096aacf3582858a3e6d3728afedd2692bf47e.png	simple	<table><tr><td>Analyses</td><td>Nanoemulsion</td><td>Curcumin-nanoemulsion</td></tr><tr><td>Size (nm)</td><td>200 ± 9.9</td><td>199 ± 0.2</td></tr><tr><td>Zeta potential (mV)</td><td>−40.2</td><td>−46.3</td></tr><tr><td>Polydispersity index (PdI)</td><td>0.248</td><td>0.179</td></tr></table>
cd1cfe32c43d6206340212aecb87519938e1fdb3931f5763bebc34979ab86378.png	simple	<table><tr><td></td><td>BMD (g/cm<sup>2)</sup></td><td>BMC (g)</td><td>Area (cm<sup>2)</sup></td></tr><tr><td>Lumbar Vertebra</td><td></td><td></td><td></td></tr><tr><td> Baseline (n = 8)</td><td>0.237 ± 0.018</td><td>0.502 ± 0.073</td><td>2.124 ± 0.287</td></tr><tr><td> Control (n = 12)</td><td>0.259 ± 0.026</td><td>0.609 ± 0.107</td><td>2.343 ± 0.297</td></tr><tr><td> 1.5 mg CsA (n = 11)</td><td>0.204 ± 0.030</td><td>0.473 ± 0.091</td><td>2.325 ± 0.260</td></tr><tr><td> 7.5 mg CsA (n = 9)</td><td>0.201 ± 0.015</td><td>0.462 ± 0.073 </td><td>2.291 ± 0.462</td></tr><tr><td>Proximal Femur</td><td></td><td></td><td></td></tr><tr><td> Baseline (n = 8)</td><td>0.245 ± 0.038</td><td>0.126 ± 0.022</td><td>0.513 ± 0.028</td></tr><tr><td> Control (n = 12)</td><td>0.258 ± 0.046</td><td>0.139 ± 0.029</td><td>0.536 ± 0.029</td></tr><tr><td> 1.5 mg CsA (n = 11)</td><td>0.181 ± 0.036</td><td>0.099 ± 0.017</td><td>0.542 ± 0.037</td></tr><tr><td> 7.5 mg CsA (n = 9)</td><td>0.171 ± 0.039</td><td>0.092 ± 0.025*</td><td>0.530 ± 0.027</td></tr><tr><td>Middle Femur</td><td></td><td></td><td></td></tr><tr><td> Baseline (n = 8)</td><td>0.298 ± 0.075</td><td>0.228 ± 0.058</td><td>0.762 ± 0.021</td></tr><tr><td> Control (n = 12)</td><td>0.323 ± 0.068</td><td>0.258 ± 0.052</td><td>0.794 ± 0.058</td></tr><tr><td> 1.5 mg CsA (n = 11)</td><td>0.311 ± 0.066</td><td>0.241 ± 0.058</td><td>0.771 ± 0.052</td></tr><tr><td> 7.5 mg CsA (n = 9)</td><td>0.317 ± 0.058</td><td>0.243 ± 0.045</td><td>0.767 ± 0.065</td></tr></table>
7eb352bb9b7058be31025a521a60981a1412827629c03d651783f2e2ada4a3ae.png	simple	<table><tr><td>Indicators</td><td>Value</td></tr><tr><td>White blood cell</td><td>5200/<i>μ</i>L</td></tr><tr><td>Hemoglobin</td><td>11.3 g/dL</td></tr><tr><td>Platelet</td><td>103 × 10<sup>3</sup>/<i>μ</i>L</td></tr><tr><td>Prothrombin time</td><td>96%</td></tr><tr><td>Activated partial thromboplastin time</td><td>22.6 s</td></tr><tr><td>Aspartate aminotransferase</td><td>26 U/L</td></tr><tr><td>Alanine aminotransferase</td><td>20 U/L</td></tr><tr><td>Lactate dehydrogenase</td><td>244 U/L</td></tr><tr><td>Alkaline phosphatase</td><td>280 U/L</td></tr><tr><td>Total bilirubin</td><td>0.7 mg/dL</td></tr><tr><td>Total protein</td><td>6.9 g/dL</td></tr><tr><td>Albumin</td><td>3.9 g/dL</td></tr><tr><td>Blood urea nitrogen</td><td>25.6 mg/dL</td></tr><tr><td>Creatinine</td><td>1.05 mg/dL</td></tr><tr><td>Uric acid</td><td>7.3 mg/dL</td></tr><tr><td>Na</td><td>139 mEq/L</td></tr><tr><td>K</td><td>6.9 mEq/L</td></tr><tr><td>Cl</td><td>104 mEq/L</td></tr><tr><td>Total cholesterol</td><td>169 mg/dL</td></tr><tr><td>C-reactive protein</td><td>0.11 mg/dL</td></tr><tr><td>Protein induced by vitamin K absence II</td><td>61 mAU/mL</td></tr><tr><td><i>α</i>-Fetoprotein</td><td>384 ng/mL</td></tr></table>
dcfd7677c0181f651175ed12a59de2c5588fb07ac1d7698028648e1ebe019ccc.png	complex	<table><tr><td>H-reflex parameters</td><td>Ankle Positions</td><td colspan="6">Muscle and posture</td></tr><tr><td></td><td></td><td colspan="2">Sol</td><td colspan="2">MG</td><td colspan="2">LG</td></tr><tr><td></td><td></td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td></tr><tr><td>Amplitude</td><td>N</td><td>7.25†(3.35)</td><td>4.28§‡(2.03)</td><td>2.06†(1.20)</td><td>1.38§‡(0.85)</td><td>1.50†(0.70)</td><td>1.15§‡(0.67)</td></tr><tr><td></td><td>DF</td><td>2.47†(2.63)</td><td>1.96§(2.18)</td><td>0.60†(0.39)</td><td>0.53§(0.60)</td><td>0.47†(0.34)</td><td>0.49§(0.51)</td></tr><tr><td></td><td>PF</td><td>5.95(3.37)</td><td>6.40‡(2.88)</td><td>1.76(1.19)</td><td>2.65‡(1.52)</td><td>1.38(0.89)</td><td>1.81‡(0.97)</td></tr><tr><td>H/M</td><td>N</td><td>0.51†(0.17)</td><td>0.38§‡(0.19)</td><td>0.42†(0.30)</td><td>0.20§‡(0.11)</td><td>0.28†(0.13)</td><td>0.18§‡(0.08)</td></tr><tr><td></td><td>DF</td><td>0.22†(0.18)</td><td>0.19§(0.18)</td><td>0.17†(0.14)</td><td>0.08§(0.08)</td><td>0.18†(0.04)</td><td>0.11§(0.12)</td></tr><tr><td></td><td>PF</td><td>0.40(0.24)</td><td>0.60‡(0.27)</td><td>0.32(0.25)</td><td>0.39‡(0.15)</td><td>0.22(0.09)</td><td>0.32‡(0.14)</td></tr><tr><td>Latency</td><td>N</td><td>30.2(2.3)</td><td>30.6(2.3)</td><td>29.3(2.2)</td><td>29.3(2.3)</td><td>29.1(2.1)</td><td>28.9(2.4)</td></tr><tr><td></td><td>DF</td><td>30.4(2.5)</td><td>30.9(2.3)</td><td>29.3(2.3)</td><td>29.3(2.3)</td><td>29.0(2.3)</td><td>29.0(2.6)</td></tr><tr><td></td><td>PF</td><td>30.5(2.3)</td><td>30.8(2.3)</td><td>29.1(2.2)</td><td>29.1(2.4)</td><td>28.8(2.4)</td><td>28.7(2.1)</td></tr></table>
76dc40985f8fc0941018d5f09099dafb577510518ae4bf7e6a49aa41dfa726b9.png	simple	<table><tr><td>Groups</td><td>LDH</td><td>CK-MB</td><td>CK</td><td>CTN-I</td><td>MB</td></tr><tr><td>C</td><td>0.92 ± 0.04</td><td>2.11 ± 0.18</td><td>11.70 ± 0.46</td><td>144.61 ± 12.71</td><td>3.32 ± 0.49</td></tr><tr><td>EE</td><td>1.08 ± 0.09<sup><i>∗</i></sup></td><td>3.23 ± 0.19<sup><i>∗</i></sup></td><td>16.93 ± 0.41<sup><i>∗</i></sup></td><td>172.00 ± 12.83<sup><i>∗</i></sup></td><td>4.90 ± 0.41<sup><i>∗</i></sup></td></tr><tr><td>LS</td><td>1.04 ± 0.06<sup>#</sup></td><td>3.14 ± 0.24</td><td>14.56 ± 0.53<sup>#</sup></td><td>157.18 ± 16.95</td><td>4.22 ± 0.43<sup>#</sup></td></tr><tr><td>HS</td><td>1.02 ± 0.10<sup>#</sup></td><td>2.57 ± 0.21<sup>#Δ</sup></td><td>13.19 ± 1.91<sup>#Δ</sup></td><td>159.26 ± 8.93</td><td>3.98 ± 0.54<sup>#Δ</sup></td></tr></table>
8516d483d2d2f11c25f4d5844c3722e908cbdd4b0fca508607e268a5769ec1a1.png	complex	<table><tr><td>Genotypes</td><td colspan="3">No. identified proteins</td><td colspan="3">ρ-Value<sup>a</sup>/FPR<sup>b</sup>(%)</td><td>No. proteins</td></tr><tr><td></td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td></td></tr><tr><td>Resistant<sup>c</sup></td><td>3297</td><td>3302</td><td>3602</td><td>93/0.71</td><td>92/0.70</td><td>93/0.70</td><td>2002</td></tr><tr><td>Susceptible<sup>c</sup></td><td>3228</td><td>3187</td><td>3153</td><td>93/0.71</td><td>93/0.67</td><td>93/0.70</td><td>1859</td></tr></table>
c55dcde3a3f959f6751fc1b756a3190eccdfee801a430c12daf31b820acb6806.png	simple	<table><tr><td>Key actor</td><td>Moura-Barrancos</td><td>Guadiana</td><td>Malcata</td><td>Total</td></tr><tr><td>Land owners (including livestock breeders)</td><td>9</td><td>9</td><td>5</td><td>23</td></tr><tr><td>Local council representatives</td><td>8</td><td>8</td><td>8</td><td>24</td></tr><tr><td>Local nature conservation technicians (administration, NGOs, fiscalization)</td><td>6</td><td>7</td><td>7</td><td>20</td></tr><tr><td>Land and hunting managers</td><td>6</td><td>8</td><td>2</td><td>16</td></tr><tr><td>Hunting guards</td><td>8</td><td>3</td><td>3</td><td>14</td></tr><tr><td>Nature activity users and promoters (tourism, collectors, leisure)</td><td>6</td><td>7</td><td>5</td><td>18</td></tr><tr><td>Lynx observers</td><td>9</td><td>-</td><td>7</td><td>16</td></tr><tr><td>Total</td><td>52</td><td>42</td><td>37</td><td><i>131</i></td></tr><tr><td>Hunter</td><td>26</td><td>19</td><td>15</td><td>60</td></tr><tr><td>Non-hunter</td><td>26</td><td>23</td><td>22</td><td>71</td></tr></table>
8967f96dbb8410715325620c49fc323a70de9fa327f43c2946d050080c4d7b76.png	complex	<table><tr><td> </td><td colspan="2"> Participants</td><td colspan="2">GPS routes</td></tr><tr><td> </td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Total/All</td><td>175</td><td> </td><td>1191</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Girl</td><td>89</td><td>50.86%</td><td>614</td><td>51.55%</td></tr><tr><td> Boy</td><td>86</td><td>49.14%</td><td>577</td><td>48.45%</td></tr><tr><td>How do you usually travel to school?</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> By car</td><td>41</td><td>23.43%</td><td>262</td><td>22.00%</td></tr><tr><td> By bus or train</td><td>68</td><td>38.86%</td><td>475</td><td>39.88%</td></tr><tr><td> By bicycle</td><td>8</td><td>4.57%</td><td>62</td><td>5.21%</td></tr><tr><td> On foot</td><td>58</td><td>33.14%</td><td>392</td><td>32.91%</td></tr><tr><td>Home location</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Urban</td><td>57</td><td>32.57%</td><td>367</td><td>30.81%</td></tr><tr><td> Town & Fringe</td><td>44</td><td>25.14%</td><td>300</td><td>25.19%</td></tr><tr><td> Village, Hamlet & Isolated Dwelling</td><td>74</td><td>42.29%</td><td>524</td><td>44.00%</td></tr><tr><td colspan="2">What is your annual household pre-tax income?</td><td> </td><td> </td><td> </td></tr><tr><td> Up to £10,000</td><td>17</td><td>9.71%</td><td>96</td><td>8.06%</td></tr><tr><td> Over £10,000 to £30,000</td><td>40</td><td>22.86%</td><td>284</td><td>23.85%</td></tr><tr><td> Over £30,000 to £50,000</td><td>49</td><td>28.00%</td><td>341</td><td>28.63%</td></tr><tr><td> Over £50,000 to £70,000</td><td>30</td><td>17.14%</td><td>184</td><td>15.45%</td></tr><tr><td> Over £70,000</td><td>10</td><td>5.71%</td><td>78</td><td>6.55%</td></tr><tr><td> I do not wish to share this information</td><td>28</td><td>16.00%</td><td>203</td><td>17.04%</td></tr></table>
3674f0e61e6f81351688d6d71fd17c478cef1b0f98477b6af47c3a61abc0e49c.png	complex	<table><tr><td rowspan="2">Measurement day</td><td rowspan="2">Dosage</td><td colspan="2">ucOC (ng/mL)</td><td colspan="2">Gla-OC (ng/mL)</td><td colspan="2">UGR</td><td colspan="2">Dietary vitamin K intake (μg/week)</td></tr><tr><td>Median</td><td>Range</td><td>Median</td><td>Range</td><td>Median</td><td>Range</td><td>Median</td><td>Range</td></tr><tr><td>Day 1</td><td>Baseline</td><td>5.03</td><td>(2.20-23.03)</td><td>18.41</td><td>(10.62-26.60)</td><td>0.32</td><td>(0.13-1.70)</td><td>-</td><td>-</td></tr><tr><td>Day 8</td><td>0 μg/day</td><td>5.81</td><td>(2.63-26.65)</td><td>18.71</td><td>(8.62-24.36)</td><td>0.36</td><td>(0.12-1.88)</td><td>40.18</td><td>(0.00-540.27)</td></tr><tr><td>Day 15</td><td>300 μg/day</td><td>6.77</td><td>(1.89-14.52)</td><td>21.27</td><td>(10.57-26.91)</td><td>0.35</td><td>(0.18-0.54)</td><td>17.40</td><td>(0.00-638.76)</td></tr><tr><td>Day 22</td><td>600 μg/day</td><td>4.82</td><td>(1.84-8.73)</td><td>25.33</td><td>(12.29-33.04)</td><td>0.22</td><td>(0.14-0.31)</td><td>31.68</td><td>(0.00-389.40)</td></tr><tr><td>Day 29</td><td>900 μg/day</td><td>2.98</td><td>(1.27-6.90)</td><td>22.75</td><td>(12.38-38.10)</td><td>0.15</td><td>(0.10-0.23)*</td><td>9.60</td><td>(0.00-196.94)</td></tr><tr><td>Day 36</td><td>1500 μg/day</td><td>3.92</td><td>(1.88-7.52)</td><td>23.33</td><td>(13.97-45.49)</td><td>0.15</td><td>(0.13-0.21)</td><td>7.50</td><td>(0.00-167.58)</td></tr></table>
cb284a639c0aeed84de90a360cfbe35af8509436da56f951aa5115cae125acd4.png	simple	<table><tr><td>Topic</td><td>Reference</td><td>Question</td><td>Summary of the results</td></tr><tr><td>Knowledge</td><td>(26–42)</td><td>Differences in knowledge</td><td>Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: educational level, disadvantaged groups, etc</td></tr><tr><td></td><td>(43–48)</td><td>Effective tools to improve knowledge and reduce inequalities</td><td>Differences tend to diminish after any kind intervention to inform women. Results about written material are inconclusive; short counseling showed to be effective</td></tr><tr><td>Coverage</td><td>(16, 49–51)</td><td>Longer screening intervals can increase the coverage for hard-to-reach population</td><td>No data are available</td></tr><tr><td></td><td>(9, 52)</td><td>Access to opportunistic HPV testing could be limited by the high cost of the test in private laboratories</td><td>No data are available</td></tr><tr><td></td><td>(49, 53, 54)</td><td>Self-sampling device could be used to reduce sampling costs, but could affect coverage</td><td>Only one trial conducted in Mexico. A lower coverage was achieved, but it was due to women not found at home and to whom the self-sampling was not mailed</td></tr><tr><td>Participation</td><td>(9, 13, 16, 17, 21, 26, 32, 50, 52, 53, 55–57)</td><td>The proposal of a new test may change the participation</td><td>Several observational studies and one trial found a small increase in participation when invited for a HPV test compared to Pap test. No data on how it will impact on inequalities</td></tr><tr><td></td><td></td><td>Longer intervals could disrupt the habits, thereby of women reducing participation</td><td>No data are available</td></tr><tr><td></td><td>(14, 22, 49, 53–55, 58–75)</td><td>Self-sampling device could be used to participation in screening program</td><td>Nine studies showed a positive effect of self-sampling in under-screened population. Some studies showed that the device is acceptable also among disadvantage women, even in some case to a minor extent</td></tr><tr><td>Compliance to screening protocols</td><td>(41)</td><td>Longer intervals could increase opportunistic over-screening</td><td>No data are available</td></tr><tr><td></td><td>(9, 21, 35, 36, 57)</td><td>Referral to early rescreen after HPV positive cytology-negative test could increase use of unnecessary ascertainment</td><td>No data are available</td></tr><tr><td></td><td>(17, 21, 76, 77)</td><td>Referral to early rescreen after HPV positive cytology-negative test could result in substantial loss to follow up</td><td>The compliance to early rescreen in this group of women varied among studies, showing that correct communication can reduce loss to follow up. No data about differences in socio-economic status are available</td></tr><tr><td>Communication of positive results</td><td>(2, 9, 78–81)</td><td>Communication of HPV positivity can induce anxiety</td><td>Several studies showed anxiety after the communication of Pap test and/or HPV positivity. Women with higher educational level are advantaged in understanding the gynecologist’s and midwife’s recommendations and explanations</td></tr><tr><td></td><td>(32, 40, 79, 80, 82–84)</td><td>Communication of HPV positivity can induce changes in sexual habits</td><td>Some studies showed concern about the sexual transmission of the virus. These concerns were stronger in women of lower educational level and disadvantaged ethnic groups</td></tr><tr><td></td><td>(31, 36, 84–91)</td><td>Effective ways to reduce anxiety and other adverse effects</td><td>Face-to-face counseling was preferred by women, but cannot be used only for positive results because of the anxiety caused by the understanding that the test was positive and the need to wait for the counseling. Short phone counseling only for positive was also appreciated</td></tr><tr><td>Interaction vaccine and screening</td><td>(38, 92–98)</td><td>Negative effect of vaccine on future screening</td><td>Only one studies reported a small proportion of girls referring that vaccination would change their attitude to screening</td></tr><tr><td></td><td>(56, 99–103)</td><td>Association between vaccine and screening attitudes</td><td>Several studies showed an association between vaccine and screening attitude or between vaccination and screening coverage in mothers. Results are heterogeneous</td></tr></table>
797e12826203697a09d4590807cc41abe01757656ed803f9f0ac5bd84da080e4.png	simple	<table><tr><td><i>Cytogenetic abnormality</i></td><td><i>Frequency</i></td><td>ASXL1 <i>mutational frequency</i></td><td>SETBP1 <i>mutational frequency</i></td><td>SRSF2 <i>mutational frequency</i></td><td>U2AF1 <i>mutational frequency</i></td><td>SF3B1 <i>mutational frequency</i></td><td><i>Spanish cytogenetic risk stratification</i></td><td><i>Mayo–French cytogenetic risk stratification</i></td></tr><tr><td><i>+8</i></td><td>~23%</td><td>~24%</td><td>0%</td><td>~27%</td><td>0%</td><td>0%</td><td>High risk</td><td>Intermediate risk</td></tr><tr><td><i>-Y</i></td><td>~20%</td><td>~12% (SS)</td><td>~40%</td><td>~16%</td><td>0%</td><td>~9%</td><td>Low risk</td><td>Low risk</td></tr><tr><td><i>-7/7q-</i></td><td>~14%</td><td>~14%</td><td>~40%</td><td>~11%</td><td>40%</td><td>0%</td><td>High risk</td><td>Intermediate risk</td></tr><tr><td><i>20q-</i></td><td>~8%</td><td>~10%</td><td>0%</td><td>~11%</td><td>0%</td><td>0%</td><td>Intermediate risk</td><td>Intermediate risk</td></tr><tr><td><i>der(3q)</i></td><td>~8%</td><td>~2% (SS)</td><td>0%</td><td>~3%</td><td>20%</td><td>45% (SS)</td><td>Intermediate risk</td><td>Low risk</td></tr><tr><td><i>+21</i></td><td>~8%</td><td>~10%</td><td>0%</td><td>~5%</td><td>20%</td><td>0%</td><td>Intermediate risk</td><td>Intermediate risk</td></tr><tr><td><i>Complex and monosomal karyotypes (MK)</i></td><td>~10%</td><td>~4%</td><td>~20%</td><td>~8%</td><td>~40% (SS)</td><td>0%</td><td>Complex high risk. MK not included in stratification</td><td>High risk</td></tr></table>
02cb4251e0872e38a50aefba503cdeb163749621e5fc64bbd52c82912fee4424.png	simple	<table><tr><td>Risk factor</td><td>Changes in capillary morphology or blood rheology</td></tr><tr><td>Aging</td><td>Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30]</td></tr><tr><td>Hypertension</td><td>Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericytes [33, 34]</td></tr><tr><td>Diabetes</td><td>Human: Thickened basement membranes [35, 36]. Hyperviscosity and reduced erythrocyte deformability in proportion to microvascular complications [37]Animal models: Pericyte loss and thickening of capillary basement membrane [31, 38, 39]. Glycocalyx degradation by oxidative stress, oxidized lipoproteins, and hyperglycemia [40–42]In vitro: Hyperglycemia-induced oxidative stress in the pericytic mitochondria causes pericyte apoptosis [43]</td></tr><tr><td>Alzheimer’s diseaseAPOE ε4 genotype</td><td>Human brain: Pericyte degeneration, pericapillary fibrosis [44]In vitro: Cultured human pericytes undergo degeneration when exposed to certain subtypes of Aβ [45]. Pericytes express Aβ receptors involved in amyloid internalization and pericyte death [46]</td></tr><tr><td>Nicotine use (including smoking)</td><td>Nicotine upregulates the expression of adhesion molecules in the capillary endothelium [47] and increases leukocyte rolling [48]</td></tr></table>
315ef80ab1b1dbdf332c36eaea4dc76b86ad03cfdb50fbeec50af2b62493fcc1.png	simple	<table><tr><td>Authors</td><td>Contrast</td></tr><tr><td><sup></sup>Aichorn et al., 2009</td><td>False belief > photo (question)</td></tr><tr><td><sup></sup>Abraham et al., 2010</td><td>Belief-questions > control-questions and desire-questions > control-questions</td></tr><tr><td><sup></sup>Bahnemann et al., 2010</td><td>ToM judgments minus appearance judgments</td></tr><tr><td><sup></sup>Bruneau et al., 2012</td><td>ToM localizer</td></tr><tr><td><sup></sup>Dohnel et al., 2012</td><td>Sally Anne task (true and false ToM minus reality)</td></tr><tr><td>Fletcher et al., 1995</td><td>ToM stories vs. Physical stories</td></tr><tr><td>Gallagher et al., 2000</td><td>ToM vs. non-ToM stories</td></tr><tr><td>Gobbini et al., 2007</td><td>False belief stories vs. physical belief stories</td></tr><tr><td><sup></sup>Hartwright et al., 2012</td><td>False belief minus false photograph</td></tr><tr><td>Hynes et al., 2005</td><td>Cognitive PT minus Control</td></tr><tr><td><sup></sup>Jenkins and Mitchell, 2010</td><td>Mentalizing scenarios > non-social scenarios</td></tr><tr><td><sup></sup>Kobayashi et al., 2008</td><td>ToM > physical (both japanese and english language groups)</td></tr><tr><td><sup></sup>Kobayashi et al., 2006</td><td>ToM compared with non-ToM-conjunction among language groups</td></tr><tr><td><sup></sup>van der Meer et al., 2011</td><td>ToM high inhibition minus fixation</td></tr><tr><td>Mitchell, 2007</td><td>Tom minus attention cueing task</td></tr><tr><td>Perner et al., 2006</td><td>False belief vignettes minus photo vignettes</td></tr><tr><td><sup></sup>Rabin et al., 2009</td><td>ToM photo minus autobiographical memory photo</td></tr><tr><td>Ruby and Decety, 2003</td><td>3rd person minus 1st person</td></tr><tr><td><sup></sup>Samson et al., 2008</td><td>ToM cartoons minus non-ToM cartoons</td></tr><tr><td>Saxe and Kanwisher, 2003</td><td>ToM inference minus mechanical inference</td></tr><tr><td>Saxe and Powell, 2006</td><td>False belief minus false photograph</td></tr><tr><td>Saxe et al., 2006</td><td>ToM reference experiment</td></tr><tr><td><sup></sup>Veroude et al., 2012</td><td>Others vs. self (females only)</td></tr><tr><td>Vollm et al., 2006</td><td>ToM minus physical causality one character</td></tr><tr><td><sup></sup>Wolf et al., 2010</td><td>Social minus physical inference (multiple choice and silent)</td></tr><tr><td>Young et al., 2007</td><td>Belief minus photo</td></tr><tr><td><sup></sup>Young et al., 2010</td><td>Mental > physical sentences</td></tr><tr><td><sup></sup>Zaitchik et al., 2010</td><td>Belief sentences > control sentences</td></tr></table>
be693d037d5728952e751e13b54dd2c0a5e1b8b2bafd1a39f86113577f51fa39.png	complex	<table><tr><td></td><td colspan="2">With seizures<sup>§</sup></td><td></td><td rowspan="2">Without seizures</td></tr><tr><td></td><td>Early seizures</td><td>Late seizures</td><td><i>p</i>value</td></tr><tr><td></td><td>n = 13 (%)</td><td>n = 15 (%)</td><td></td><td>n = 152 (%)</td></tr><tr><td>Mean age, years</td><td>47.3 ± 17.3</td><td>52.1 ± 25.0</td><td>0.32</td><td>53.2 ± 17.9</td></tr><tr><td>Sex (male/female)</td><td>7/6</td><td>9/6</td><td>0.74</td><td>92/60</td></tr><tr><td>Mean GCS on presentation</td><td>11.5 ± 3.9</td><td>12.1 ± 4.4</td><td>0.71</td><td>13.1 ± 3.1</td></tr><tr><td>Clinical features</td><td></td><td></td><td></td><td></td></tr><tr><td>Fever/chills</td><td>8 (61.5)</td><td>13 (86.6)</td><td>0.20</td><td>89 (58.5)</td></tr><tr><td>Headache</td><td>9 (69.2)</td><td>9 (60)</td><td>0.71</td><td>69 (45.3)</td></tr><tr><td>Disturbed consciousness</td><td>8 (61.5)</td><td>8 (53.3)</td><td>0.66</td><td>61 (40.1)</td></tr><tr><td>Visual disturbance</td><td>2 (15.3)</td><td>5(33.3)</td><td>0.61</td><td>26 (17.1)</td></tr><tr><td>Hearing impairment</td><td>1 (7.6)</td><td>1 (6.6)</td><td>1.0</td><td>4 (2.6)</td></tr><tr><td>Hyponatremia</td><td>3 (23.1)</td><td>2 (13.3)</td><td>0.64</td><td>21 (13.8)</td></tr><tr><td>Outcome</td><td></td><td></td><td></td><td></td></tr><tr><td>Death</td><td>5 (38.4)</td><td>10 (66.6)</td><td>0.14</td><td>42 (27.6)</td></tr><tr><td>Mean length of hospitalization (days)</td><td>58.0 ± 38.9</td><td>89.3 ± 62.6</td><td>0.08</td><td>56.9 ± 49.3</td></tr></table>
1f5f3846e2a14069c1532f4d685538471eb0babafe5d5bdfaf4330777fbf9caf.png	complex	<table><tr><td>Scale</td><td>Whole sample</td><td colspan="3">Gender</td><td colspan="3">Presence of symptoms</td></tr><tr><td></td><td>N = 446</td><td>Boys N = 207</td><td>Girls N = 239</td><td>p-value (ANOVA)</td><td>No symptoms N = 197</td><td>At least one symptom once a week N = 199</td><td>p-value (ANOVA)</td></tr><tr><td>PsyWB</td><td>69.4 ± 20.6</td><td>75.4 ± 18.6</td><td>64.2 ± 0.7</td><td>p < 0.001</td><td>76.5 ± 18.1</td><td>62.8 ± 21.3</td><td>p < 0.001</td></tr><tr><td>PhyWB</td><td>64.4 ± 18.7</td><td>69.4 ± 17.9</td><td>60.0 ± 8.3</td><td>p < 0.001</td><td>72.0 ± 15.1</td><td>56.1 ± 18.2</td><td>p < 0.001</td></tr><tr><td>VIT</td><td>66.3 ± 22.2</td><td>70.1 ± 21.0</td><td>62.9 ± 22.5</td><td>p < 0.001</td><td>71.5 ± 20</td><td>61.4 ± 22.9</td><td>p < 0.001</td></tr><tr><td>RT</td><td>49.4 ± 24.4</td><td>48.9 ± 23.3</td><td>49.9 ± 25.2</td><td>0.68</td><td>51.9 ± 2.3</td><td>47.2 ± 26.0</td><td>p < 0.05</td></tr><tr><td>SP</td><td>48.8 ± 26.2</td><td>48.3 ± 26.4</td><td>49.1 ± 25.9</td><td>0.75</td><td>51.6 ± 24.5</td><td>47.6 ± 27.1</td><td>0.12</td></tr><tr><td>RF</td><td>61.4 ± 20.7</td><td>54.9 ± 18.8</td><td>67.0 ± 20.8</td><td>p < 0.001</td><td>61.2 ± 20.7</td><td>62.8 ± 20.9</td><td>0.4</td></tr><tr><td>RP</td><td>53.0 ± 26.2</td><td>55.4 ± 24.9</td><td>51.0 ± 27.2</td><td>0.80</td><td>55.4 ± 25.1</td><td>50.7 ± 27.4</td><td>0.8</td></tr><tr><td>BI</td><td>61.6 ± 28.1</td><td>65.0 ± 25.2</td><td>58.8 ±30.0</td><td>0.023</td><td>66.2 ± 26.9</td><td>59.2 ± 27.8</td><td>p < 0.05</td></tr><tr><td>LA</td><td>53.6 ± 20.8</td><td>57.7 ± 19.5</td><td>50.0 ± 1.3</td><td>p < 0.001</td><td>56.1 ± 19.7</td><td>50.3 ± 21.9</td><td>p < 0.001</td></tr><tr><td>SSL</td><td>59.6 ± 32.4</td><td>59.3 ± 30.7</td><td>59.9 ± 4.2</td><td>0.87</td><td>57.7 ± 32.1</td><td>61.8 ± 33.1</td><td>0.26</td></tr><tr><td>Index</td><td>58.6 ± 13.0</td><td>60.7 ± 12.1</td><td>56.3 ± 3.5</td><td>p < 0.01</td><td>62.3 ± 11.7</td><td>55.3 ± 13.5</td><td>p < 0.001</td></tr></table>
0e888c0c3a134a6d66cf0fae547c4e6c4746c4858a0da3c82e1efddd086dba72.png	complex	<table><tr><td rowspan="2">Maternal health service use indicator</td><td rowspan="2">Overall (<i>n</i> = 1457)</td><td colspan="2">District</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Jhelum (<i>n</i> = 747)</td><td>Layyah (<i>n</i> = 710)</td></tr><tr><td>Sought at least one antenatal care (ANC) visit</td><td>96.6</td><td>97.8</td><td>95.3</td><td>0.01</td></tr><tr><td>Type of ANC provider</td><td></td><td></td><td></td><td></td></tr><tr><td> Community Midwife (CMW)</td><td>8.3</td><td>13.8</td><td>2.4</td><td>0.00</td></tr><tr><td> Doctor</td><td>57.5</td><td>57.2</td><td>57.8</td><td>0.83</td></tr><tr><td> Skilled birth attendant</td><td>27.2</td><td>24.3</td><td>30.4</td><td>0.02</td></tr><tr><td> <i>Dai</i></td><td>4.6</td><td>2.6</td><td>6.7</td><td>0.00</td></tr><tr><td>Type of childbirth attendant</td><td></td><td></td><td></td><td></td></tr><tr><td> CMW</td><td>7.9</td><td>12.4</td><td>3.2</td><td>0.00</td></tr><tr><td> Doctor</td><td>36.1</td><td>47.6</td><td>24</td><td>0.00</td></tr><tr><td> Non-physician skilled birth attendant</td><td>25.5</td><td>26.3</td><td>24.6</td><td>0.49</td></tr><tr><td> <i>Dai</i>/traditional birth attendant</td><td>30.5</td><td>13.7</td><td>48.2</td><td>0.00</td></tr><tr><td>Place of delivery</td><td></td><td></td><td></td><td></td></tr><tr><td> Home (home and <i>dai</i> home)</td><td>41.2</td><td>29.3</td><td>54</td><td>0.00</td></tr><tr><td> CMW clinic/home</td><td>1.1</td><td>3.1</td><td>0.7</td><td>0.01</td></tr><tr><td> Government</td><td>21.6</td><td>27.1</td><td>15.9</td><td>0.00</td></tr><tr><td> Private</td><td>35.1</td><td>40.5</td><td>29.4</td><td>0.00</td></tr><tr><td>Satisfaction with CMW care</td><td></td><td></td><td></td><td></td></tr><tr><td>For ANC (n = 245)</td><td></td><td></td><td></td><td>0.05</td></tr><tr><td> Very satisfied</td><td>39.5</td><td>44.2</td><td>12.9</td><td></td></tr><tr><td> Satisfied</td><td>53.7</td><td>50.0</td><td>74.2</td><td></td></tr><tr><td> Somewhat satisfied</td><td>2.9</td><td>1.8</td><td>9.6</td><td></td></tr><tr><td> Somewhat dissatisfied/dissatisfied</td><td>4.0</td><td>4.0</td><td>3.3</td><td></td></tr><tr><td>For delivery (competency) (n = 109)</td><td></td><td></td><td></td><td>0.00</td></tr><tr><td> Very satisfied</td><td>68.1</td><td>75.2</td><td>39.3</td><td></td></tr><tr><td> Satisfied</td><td>28.5</td><td>21.1</td><td>58.5</td><td></td></tr><tr><td> Somewhat satisfied</td><td>1.7</td><td>1.6</td><td>2.2</td><td></td></tr><tr><td> Somewhat dissatisfied/dissatisfied</td><td>1.7</td><td>2.2</td><td>0.0</td><td></td></tr></table>
c3e974bb607779f0afb2364ee61779faae83478577d625acbcd39e270a9edd14.png	complex	<table><tr><td></td><td>High-energy probe</td><td>Low-energy probe</td><td>Units</td></tr><tr><td>Source used</td><td><sup>22</sup>Na</td><td><sup>99m</sup>Tc</td><td></td></tr><tr><td>Photon energy</td><td>511</td><td>142</td><td>keV</td></tr><tr><td>Sensitivity</td><td>10</td><td>12</td><td>cps/kBq</td></tr><tr><td colspan="4">Spatial resolution</td></tr><tr><td> @ 1 cm in air</td><td>15</td><td>10</td><td>mm</td></tr><tr><td> @ 5 cm in air</td><td>47</td><td>35</td><td>mm</td></tr><tr><td>Count rate range</td><td>1–50</td><td>1–100</td><td>kcps</td></tr><tr><td>Count rate loss</td><td>< 10%</td><td>< 10%</td><td></td></tr><tr><td>Shielding</td><td>n.a.</td><td>1</td><td>mmPb</td></tr><tr><td>Weight</td><td>500</td><td>650</td><td>g</td></tr></table>
0efed21407dc158d6bacdffaf89c5d686bf718d59d8541202955ae59566ae7e7.png	simple	<table><tr><td>Data</td><td>Feature</td><td>Vector</td><td>Algorithm</td><td>F1</td><td>AUC</td><td><i>p</i>-value</td></tr><tr><td>iDASH</td><td>Bag-of-words + UMLS (5SG)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.932</td><td>0.957</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.931</td><td>0.957</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (15ST)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.930</td><td>0.957</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf-idf</td><td>SVM-Lin-SGD</td><td>0.928</td><td>0.955</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.927</td><td>0.955</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words</td><td>Tf</td><td>NB</td><td>0.893</td><td>0.935</td><td>Baseline</td></tr><tr><td>MGH</td><td>Bag-of-words + UMLS (5SG)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.934</td><td>0.964</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (15ST)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.931</td><td>0.962</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.930</td><td>0.962</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.924</td><td>0.958</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (5SG)</td><td>Tf</td><td>LR-L1</td><td>0.915</td><td>0.953</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words</td><td>Tf</td><td>NB</td><td>0.755</td><td>0.867</td><td>Baseline</td></tr></table>
5e50bc49272936126da507bd36c013e5598e511b1fb8409f05bda246871a8094.png	simple	<table><tr><td>Characteristic</td><td>Number (N = 1,568)</td><td>Percent (%)</td></tr><tr><td>Sex</td><td>915</td><td>58.4</td></tr><tr><td>Female</td><td>653</td><td>41.6</td></tr><tr><td>Male</td><td></td><td></td></tr><tr><td>Age group (in years)</td><td></td><td></td></tr><tr><td>15 – 24</td><td>410</td><td>26.1</td></tr><tr><td>25 – 34</td><td>595</td><td>37.9</td></tr><tr><td>35 – 49</td><td>563</td><td>35.9</td></tr><tr><td>Educational level</td><td></td><td></td></tr><tr><td>No formal education</td><td>142</td><td>9.1</td></tr><tr><td>Primary Education</td><td>1,308</td><td>83.4</td></tr><tr><td>Secondary Education and above</td><td>118</td><td>7.5</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>Married/cohabiting</td><td>969</td><td>62.2</td></tr><tr><td>Single</td><td>444</td><td>27.7</td></tr><tr><td>Divorced/separated/widowed</td><td>155</td><td>10.1</td></tr><tr><td>Occupation</td><td></td><td></td></tr><tr><td>Student</td><td>56</td><td>3.6</td></tr><tr><td>Salaried employed</td><td>36</td><td>2.3</td></tr><tr><td>Self-employed</td><td>76</td><td>4.8</td></tr><tr><td>Peasant/farmer</td><td>1,370</td><td>87.4</td></tr><tr><td>Others</td><td>30</td><td>1.9</td></tr><tr><td>Radio ownership</td><td></td><td></td></tr><tr><td>Yes</td><td>1,211</td><td>77.2</td></tr><tr><td>No</td><td>357</td><td>22.8</td></tr></table>
8a318e331bf48e4ad384729ef1c099fbd6a49adca7d9c91fe703a82d7bebce58.png	simple	<table><tr><td></td><td>CHF absent (n = 66)</td><td>CHF present (n = 29)</td><td>p</td></tr><tr><td>Age (years)</td><td>54.9 ± 10.2</td><td>65.8 ± 14.2</td><td>< 0.001</td></tr><tr><td>Systemic Hypertension</td><td>32 (49%)</td><td>18 (62%)</td><td>0.22</td></tr><tr><td>Diabetes Mellitus</td><td>12 (18%)</td><td>5 (17%)</td><td>0.91</td></tr><tr><td>Site of infarction</td><td></td><td></td><td></td></tr><tr><td> Anterior</td><td>35 (53%)</td><td>19 (66%)</td><td>0.26</td></tr><tr><td> Inferior</td><td>31 (47%)</td><td>10 (34%)</td><td></td></tr><tr><td>Treatment</td><td></td><td></td><td></td></tr><tr><td> PTI</td><td>26 (39%)</td><td>10 (35%)</td><td></td></tr><tr><td> Trombolysis</td><td>30 (46%)</td><td>10 (34.5%)</td><td></td></tr><tr><td> Conservative</td><td>10 (15%)</td><td>9 (31%)</td><td>0.19</td></tr><tr><td>CKMB peak (iu/l)</td><td>205 ± 138</td><td>346 ± 239</td><td>0.004</td></tr><tr><td>Angiography</td><td></td><td></td><td></td></tr><tr><td> Non obstructive</td><td>5 (8%)</td><td>1 (3%)</td><td></td></tr><tr><td> One vessel disease</td><td>34 (51%)</td><td>10 (35%)</td><td></td></tr><tr><td> Multivessel disease</td><td>22 (33%)</td><td>15 (52%)</td><td></td></tr><tr><td> Not done</td><td>5 (8%)</td><td>3 (10%)</td><td>0.31</td></tr></table>
382d0f83cddca8d51367bea9320581212c4de242a27d726968f292b97fcd5fa7.png	complex	<table><tr><td></td><td colspan="2">No. of children</td><td>Cumulative incidence</td></tr><tr><td>Year</td><td>Born alive</td><td>With clubfoot</td><td>per thousand (95% CI)</td></tr><tr><td>1991</td><td>62,189</td><td>70</td><td>1.12 (0.9–1.3)</td></tr><tr><td>1992</td><td>68,996</td><td>64</td><td>0.93 (0.8–1.2)</td></tr><tr><td>1993</td><td>64,873</td><td>73</td><td>1.12 (0.8–1.4)</td></tr><tr><td>1994</td><td>61,000</td><td>51</td><td>0.84 (0.6–1.2)</td></tr><tr><td>1995</td><td>58,063</td><td>55</td><td>0.95 (0.8–1.2)</td></tr><tr><td>1996</td><td>58,479</td><td>57</td><td>0.97 (0.8–1.2)</td></tr><tr><td>1997</td><td>57,629</td><td>70</td><td>1.20 (0.9–1.3)</td></tr><tr><td>1998</td><td>55,313</td><td>59</td><td>1.07 (1.0–1.3)</td></tr><tr><td>1999</td><td>54,879</td><td>58</td><td>1.05 (0.9–1.2)</td></tr><tr><td>2000</td><td>53,152</td><td>63</td><td>1.19 (1.0–1.3)</td></tr><tr><td>2001</td><td>51,890</td><td>51</td><td>0.98 (0.8–1.2)</td></tr><tr><td>2002</td><td>51,234</td><td>51</td><td>1.00 (0.8–1.2)</td></tr><tr><td>2003</td><td>51,899</td><td>53</td><td>1.02 (0.8–1.2)</td></tr><tr><td>2004</td><td>51,728</td><td>52</td><td>1.01 (0.8–1.3)</td></tr><tr><td>Total</td><td>801,324</td><td>827</td><td>1.03 (0.8–1.2)</td></tr></table>
1f6fcff36fc7c307f8b2dbac5250fd8470136387a2ceb8edfb8b7c840de8d2a7.png	complex	<table><tr><td colspan="4">Group session topics</td></tr><tr><td>Session #</td><td>Physical activity</td><td>Nutrition</td><td>Educational incentive</td></tr><tr><td>1</td><td>Overview of healthy nutrition</td><td>Overview of exercise</td><td>Pedometer</td></tr><tr><td>2</td><td>Eating healthy on a budget</td><td>Being active at home</td><td>Fruit and vegetable guide</td></tr><tr><td>3</td><td>Eating out and fast food</td><td>Local exercise resources</td><td>Water bottle</td></tr><tr><td>4</td><td>Portion control and measuring</td><td>Hidden times for exercise</td><td>Measuring cups</td></tr><tr><td>5</td><td>Label reading and breakfast</td><td>Injury prevention and treatment</td><td>Massage tool</td></tr><tr><td>6</td><td>Healthy drinks</td><td>Building strong muscles</td><td>Healthy drink ingredients</td></tr><tr><td>7</td><td>Mindful eating and lunch</td><td>Take a deep breath and relax</td><td>Muscle relaxation CD</td></tr><tr><td>8</td><td>Healthy fast food and dinner</td><td>Exercise with friends and family</td><td>Whole grain pasta</td></tr><tr><td>9</td><td>Eating at social events and holidays</td><td>Mini holidays for exercise</td><td>Food pamphlet</td></tr><tr><td>10</td><td>Healthier traditions and review</td><td>Review and social dancing</td><td>Recipe with ingredients</td></tr><tr><td>11</td><td>Relapse response</td><td>Review and relay games</td><td>Motivational letter</td></tr><tr><td>12-15</td><td colspan="2">Review relapse response, problem solving, and goal setting</td><td>Social support cards and displayable health guides</td></tr><tr><td colspan="4"><underline>Community health worker support session topics</underline></td></tr><tr><td colspan="4"><underline>Nutrition</underline></td></tr><tr><td colspan="4"> Beverage inventory, evaluation of milk and water consumption, and goal for healthy beverages</td></tr><tr><td colspan="4"> Evaluation of fat in cooking and goal for cooking with less fat (steaming, baking, etc.)</td></tr><tr><td colspan="4"> Evaluation of fruit and vegetable consumption and goal for consuming more fruits and vegetables</td></tr><tr><td colspan="4"> Evaluation of high calorie foods and goals for reduction of high calorie food or snacking</td></tr><tr><td colspan="4"> Decision-making for shopping and meal planning</td></tr><tr><td colspan="4"><underline>Physical activity</underline></td></tr><tr><td colspan="4"> Chart and practice walking route (at first environmental support session)</td></tr><tr><td colspan="4"> Identify support network of friends and family members for exercise</td></tr><tr><td colspan="4"> Identify exercise locations in and around home</td></tr><tr><td colspan="4"> Select physical activity goal</td></tr><tr><td colspan="4"> Identify new physical activities to try</td></tr><tr><td colspan="4">Topics may be covered in any order, but must be during the intensive intervention phase.</td></tr></table>
215591d858d895cb393c51918d08f39927cdb042eccfca7e42da767f53131aa2.png	simple	<table><tr><td>Feature</td><td><i>P. fici</i></td></tr><tr><td>Assembly size (Mb)</td><td>52</td></tr><tr><td>Scaffold N50 (Mb)</td><td>4</td></tr><tr><td>Coverage (fold)</td><td>24.5</td></tr><tr><td>GC content (%)</td><td>48.73</td></tr><tr><td>GC exon (%)</td><td>53.56</td></tr><tr><td>GC intron (%)</td><td>44.18</td></tr><tr><td>Repeat content (%)</td><td>2.97</td></tr><tr><td>Protein-coding genes</td><td>15,413</td></tr><tr><td>Gene density (genes per Mb)</td><td>296.9</td></tr><tr><td>Exons per gene</td><td>2.76</td></tr><tr><td>tRNA genes</td><td>258</td></tr><tr><td>rRNA genes</td><td>52</td></tr><tr><td>Pseudogenes</td><td>494</td></tr><tr><td>Transposable elements (%)</td><td>1.54</td></tr></table>
eabdc044914cfe983f9c954720c16bca7f7f6b63b311d69ba81b953f7e950fd7.png	simple	<table><tr><td></td><td>Controls (<i>N</i> = 39) (%)</td><td>Cases (<i>N</i> = 123) %</td></tr><tr><td>Stage I</td><td>22 (56)</td><td>55 (45)</td></tr><tr><td>Stage II</td><td>14 (36)</td><td>54 (44)</td></tr><tr><td>Stage III</td><td>3 (8)</td><td>14 (11)</td></tr><tr><td>ER or PR positive/HER2 negative</td><td>33 (85)</td><td>104 (85)</td></tr><tr><td>ER or PR positive/HER2 positive</td><td>6 (15)</td><td>19 (15)</td></tr></table>
df6ed866700eb51da72a81a4283cc6462915686e607fb619c7089e337ded4ce5.png	simple	<table><tr><td>Mutation model</td><td>Sign test</td><td>Standardized differences test</td><td>Wilcoxon test</td></tr><tr><td>IAM</td><td>Hee = 20.49</td><td>T<sub>2 </sub>= 13.196</td><td>P (one tail for H deficiency) 1.000</td></tr><tr><td></td><td>Hd = 0</td><td>P = 0.000</td><td>P (one tail for H excess) 0.000</td></tr><tr><td></td><td>He = 40</td><td></td><td>P (two tails for H excess and deficiency) 0.000</td></tr><tr><td></td><td>P = 0.000</td><td></td><td></td></tr><tr><td>SMM</td><td>Hee = 22.40</td><td>T<sub>2 </sub>= 11.518</td><td>P (one tail for H deficiency) 1.000</td></tr><tr><td></td><td>Hd = 0</td><td>P = 0.000</td><td>P (one tail for H excess) 0.000</td></tr><tr><td></td><td>He = 40</td><td></td><td>P (two tails for H excess and deficiency) 0.000</td></tr><tr><td></td><td>P = 0.000</td><td></td><td></td></tr></table>

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.